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Abstract  
Several modulatory molecules interact at the trophoblast-endometrial 
interface to generate a favourable environment for blastocyst implantation. 
Successful implantation requires a delicate balance between the tissue 
inhibitor matrix metalloproteinases (TIMPs) and activators of matrix 
metalloproteinases (MMPs) which are involved in the synthesis and 
degradation of extracellular matrix. The tissue hormone relaxin (RLX) has 
been reported to stimulate MMPs activity in various species including human, 
pig and rat. In this study we hypothesised that trophoblast-endometrial 
interactions are influenced by the functional expression of MMPs, TIMPs and 
human RLX during early implantation. The aims of the study are to determine 
whether RLX-2, MMPs and TIMPs levels would be clinically useful predictive 
markers of impending pregnancy loss, or other adverse pregnancy 
outcomes, and to explore the trophoblast-endometrial interactions under the 
influence of altered expression levels of RLX-2, MMP-2 and TIMP-2. 
We conducted both in vivo and in vitro studies. In vivo: Four cohorts of 
pregnant women were recruited. These were a) pregnant women with a 
viable pregnancy and a history of recurrent miscarriage (RM), b) pregnant 
women, matched for gestational age with no history of RM (as controls), c) 
women seen in early pregnancy presenting with threatened miscarriage and 
d) healthy controls also matched for gestational age. Serum RLX-2, MMP-2, 
MMP-9 and TIMP-2 levels were determined in each of these cohorts by 
ELISA and compared for corresponding study gestations.     
In vitro: studies involved co-incubation of T-HESCs and JAR cell lines with 
increasing concentrations of RLX-2, TIMP-2 and Batimastat to the cultures, 
Production of MMP-2 in the supernatant was evaluated by ELISA. In vitro 2D 
and 3D endometrial models, and JAR spheroids were developed and 
employed to study attachment and invasion stages of implantation and 
determine how these processes were affected by MMP-2, MMP-9, TIMP-2 
and RLX-2.     
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Results: In vivo study: There was a significant increase in the serum 
expression of TIMP-2, and a significant decreased in the serum expression 
of MMP-2, MMP-2/TIMP-2 complex and RLX-2 hormone in RM compared to 
their controls with no history of RM.  
In vitro study: Stimulation of T-HESCs with RLX-2 hormone showed 
increased secretion of TIMP-2. The data also showed that RLX-2 increased 
MMP-2 expression by JAR trophoblast cells in a dose-dependent manner, 
with significant differences being observed compared to unstimulated cells.  
Cultured T-HESCs and JAR with TIMP-2 showed a biphasic effect. Both 
showed decreased levels of MMP-2 in the medium after 48h in comparison 
to unstimulated controls, this was followed by increase in MMP-2 levels 
compared to the day before. While the effect Batimastat on the levels of 
secreted MMP-2 by both T-HESCs and JAR cells showed a dramatic decline 
in secreted MMP-2 levels in both a time- and dose-dependent manner. 
The kinetics of attachment between endometrial epithelial and/or endometrial 
stromal monolayers with the JAR spheroids under the effect of RLX-2, MMP-
2, MMP-9 and TIMP-2 co-incubation indicated that TIMP-2 significantly 
decreased the attachment rate of JAR spheroids to endometrial stromal cell 
line in a time-dependent manner of co-incubation. The expansion of the 
trophoblast cells over the endometrial stromal cells was promoted mainly by 
MMP-2 and inhibited by a Batimastat inhibitor. It was surprising that the 
Batimastat inhibitor showed a significant decrease in expansion whereas 
recombinant TIMP-2 did not. 
In conclusion, it appears that MMP-2, TIMP-2 and RLX-2 hormone among 
other proteins play a key role in early human embryo implantation stages. 
The in vivo data suggest that any dysregulation of any of these proteins may 
play a role in the pathogenesis of implantation and recurrent pregnancy loss. 
The in vitro data also suggests that MMP-2 and TIMP-2 appear to be 
implicated in this process. However, there is a need to optimise a cell culture 
model to promote and assist in understanding the potential mechanism and 
the signalling pathways of trophoblast attachment and invasion during 
implantation. Such a model could provide a platform for further studies to 
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reduce implantation failure and recurrent pregnancy, thereby improving 
pregnancy success rate following both spontaneous and assisted 
conception. 
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1.1. Anatomy of the female reproductive system 
The anatomy of the female reproductive system undergoes considerable 
growth and development from intrauterine life to menopause. The female 
reproductive system includes external genitalia and internal genitalia. The 
anatomy of the female reproductive is reviewed extensively in (Stevens and 
Lowe, 2005, Campbell and Monga, 2006, Patton and Thibodeau, 2010). 
1.1.1. External genitalia 
The external female genitalia is called the vulva. It includes the mons pubis, 
labia minora, labia majora, and the vestibule that includes the clitoris, vaginal 
orifice, urethral orifice. The size and shape of the vulva depend on the age, 
race, and gravidity. 
1.1.1.1. Mons pubis  
This is the triangular area overlying the symphysis pubis, and includes the 
pad of fatty tissue underlying the skin. At the onset of sexual maturity, the 
mons pubis is covered with coarse and curly pubic hair arising from hair 
follicles. 
1.1.1.2. Labia majora 
The labia majora are the extensions of the mons pubis on the posterior-
lateral side of the vaginal introitus forming the outer lips of the valve. They 
contain subcutaneous fat and smooth muscle. The labia majora are rich in 
sebaceous glands and apocrine glands. The outer skin of the labia majora is 
pigmented and characterised by the appearance of coarse hair while the 
inner surface is smooth and without hair. 
1.1.1.3. Labia minora 
Labia minora are two thin, hairless skin flaps just medial to the labia majora. 
The labia minora is divided into two parts to enclose the clitoris anteriorly, 
uniting to form the fourchette posteriorly. The vestibule is the area between 
the two labia minora. 
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1.1.1.4. Clitoris 
The clitoris is an erectile vascular organ. It is covered by a thin epidermis that 
is rich in sensory nerves and receptors. The clitoris is situated below the 
mons pubis behind the junction of the labia minora. It contains two corpora 
cavernosa running side-by-side covered by a fibrocollagenous sheath and 
two corpora spongiosum. 
1.1.2. Internal genitalia 
The internal female genitalia includes the vagina, ovaries, fallopian tubes and 
uterus as illustrated in figure 1.1. 
1.1.2.1. Vagina 
The vagina is a distensible muscular canal that extends from the introitus to 
the cervix. The vagina has anterior and posterior walls; both walls are in 
apposition. The anterior wall is around 7 cm long while the posterior wall is 
about 9 cm long. The vaginal wall is formed of three layers; the inner layer is 
the mucosal layer lined with stratified squamous non-keratinised epithelium. 
The middle layer is the muscular layer that contains an inner circular smooth 
muscle and an outer longitudinal smooth muscle. Finally, the outer layer is 
adventitia that is formed of fibrocollagenous tissue. 
1.1.2.2. Ovaries 
The paired ovaries are situated on the right and the left side of the uterus. 
The size of the ovary varies with age and function. In women of reproductive 
age, it is approximately 30 mm x15 mm x10 mm. The microscopic structure 
of the ovary includes medulla, cortex and outer tunica albuginea. 
The medulla is the internal part of the ovary that contains supportive 
fibromuscular tissue, blood vessels, nerves and lymphatics. The cortex 
contains a supporting stroma and the functional part of the ovarian cortex 
that is the ovarian follicles in varying phases of development. The outermost 
layer is the tunica albuginea that surrounds the ovarian cortex. The two main 
functions of the ovaries are the formation of mature ova (oogenesis) and 
production of steroid hormones including oestrogen and progesterone. The 
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hormones play an essential role in the regulation of the reproductive function 
in women. 
1.1.2.3. Fallopian tubes 
The human fallopian tubes are seromuscular structure attached to the lateral 
aspects of the uterine fundus and end close to the ovary from the lateral 
side. Each fallopian tube is 10-12 cm long and is divided into four portions 
termed, from medial to lateral, the intramural part, the isthmus, the ampulla 
and the infundibulum. 
The intramural or interstitial segments lie within the uterine myometrium wall 
of the uterus and opens into the cavity of the uterus, this part is the 
narrowest part of the tube. The isthmus is characterised by a thick muscular 
wall and narrow lumen. The ampulla is the widest and longest segment of 
the oviduct. The distal part is the infundibulum from where the fimbria arise 
giving it a funnel-shaped appearance with finger-like projections. 
1.1.2.4. Uterus 
The uterus is a pear-shaped muscular organ. In a woman who has no history 
of pregnancy it measures approxiamtely 75 mm x 50 mm x 30 mm, and 
weighs about 70 gm. The normal uterus is anteverted and anteflexed. The 
uterus is located in the pelvic cavity posterior to the urinary bladder and 
anterior to the rectum. The uterus has four main parts: the fundus, the 
corpus, the isthmus and the cervix. The fundus is the upper end of the 
uterus, to which both fallopian tubes are attached laterally in a portion called 
the cornu. The corpus or body is the middle part of the uterus, and the lower 
part is the cervix. 
The uterine wall is made up of three layers: the outermost layer is the serous 
layer (peritoneum). The middle layer is the muscular layer (myometrium), it is 
a thick layer and contains three smooth muscle layers. The layers extend in 
different directions, oblique, transverse and longitudinal. The muscular layer 
is thick at the fundus and thin at the cervix. The third layer is the innermost 
layer of the uterus, the endometrium.  
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Figure 1.1. The anatomy of the internal female reproductive tract 
Adopted from http://www.gynreform.com/ 
 
6 
 
1.1.2.5. The endometrium 
The endometrium lines the inner uterine cavity and contains three layers. 
The stratum compactum is the thin surface layer of partially ciliated simple 
columnar epithelium. The stratum spongiosum is the middle layer of loose 
connective tissue and the stratum basale is the deep layer that overlies 
underlying myometrium. The stratum compactum and the stratum 
spongiosum slough off after delivery and during menstruation. 
The endometrium is a dynamic structure considered an endocrine organ 
secreting numerous hormones, cytokines and growth factors. The key role of 
the endometrium is to allow a viable embryo to implant during the time of 
receptivity by providing an appropriate local environment for the 
establishment of a successful pregnancy (Johnson, 2000). 
In response to a cyclic variation in the expression of progesterone and 
oestrogen, the endometrium undergoes repeated proliferation, differentiation 
and tissue breakdown during the menstrual cycle (Salamonsen et al., 2003). 
The principal function of the endometrium is to orchestrate the processes 
that result in fertilization, embryo implantation and pregnancy. 
1.1.2.6. The cervix  
The cervix is the narrowest part of the uterus, it is about 3 cm long. The 
vaginal part of the cervix projects into the vagina to form the fornices. The 
upper two-thirds of the cervix is lined by columnar epithelium, whilst the 
lower third comprises stratified squamous epithelium. The junction between 
the columnar and stratified epithelium is known as the transformation zone. 
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Figure 1.2. Histological structure of the endometrium 
Adopted from (Richard and Kristin, 2006 ) 
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1.1.3. Cyclic changes of the endometrium (endometrial cycle) 
Unlike other endometrial mucosal surfaces, the human endometrium 
undergoes cyclic changes during the reproductive phase, in response to 
steroid hormones, locally expressed growth factors and cytokines, to prepare 
the endometrium to host the embryo (Lass et al., 2001, Salamonsen et al., 
2002). 
1.1.3.1. Menstrual phase 
During this phase, and in the absence of fertilisation, shedding of the 
superficial layer of the endometrium results in menstruation. The secretion of 
progesterone and oestrogen decline due to the corpus luteum degeneration 
(Salamonsen et al., 2002). There are a molecular and cellular alterations 
including release of matrix metalloproteinases, cytokines and chemokines. 
1.1.3.2. The proliferative phase 
The proliferative phase begins immediately after the menstrual phase and 
lasts till ovulation. This phase is characterised by proliferation and 
angiogenesis of the endometrium (Strowitzki et al., 2006). After the 
menstruation period, the thickness of the endometrium is about 1-2 mm.  
Ovarian oestradiol is the main hormone which promotes growth and 
proliferation of the endometrium. The proliferative changes include the 
elongation of endometrial glands, the stromal cells acquire spindle shape 
and the epithelial cells become columnar with basal nuclei (Palter and Olive, 
2002, Loke et al., 1995). Moreover, the stroma become dense compact 
layer, the basal layer spiral blood vessels become elongated and form a 
network of loose capillary (Gambino et al., 2002). In the early proliferative 
phase these vessels are uncoiled and unbranched. There is extensive 
proliferation of the glands, endothelial cells and stromal cells by day 8-10 of 
the cycle. During this phase the height of the endometrium increases to 3.5-5 
mm (Speroff and Fritz, 2005).   
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1.1.3.3. Secretory phase  
This phase is after the period of ovulation, from day 14 to day 28 of the cycle. 
The endometrium is mainly under the effect of progesterone and oestrogen 
hormone secreted by corpus luteum (Palter and Olive, 2002). During the 
secretory phase, all endometrial cells are differentiated and infiltration of a 
variety of immune cells into the endometrium (Strowitzki et al., 2006). During 
the time of implantation, the thickness of the endometrium is approximately 
10-14 mm, the endometrial stroma become oedematous (Gambino et al., 
2002). 
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1.2. Implantation 
1.2.1. Physiology of implantation 
The implantation process is considered as a very critical step during 
pregnancy and involves a complicated chain of events (Makrigiannakis et al., 
2006, Kennedy, 1997). For many years, implantation physiology has been 
studied extensively but ethical limitations have hampered human studies 
such that most studies report animal implantation (Kennedy, 1997). Much of 
the mechanism of implantation remains ill-understood. An outline is provided 
here of the processes involved in implantation. 
1.2.2. Preimplantation and Decidualisation  
Decidualisation is defined as “the process of transformation of the 
endometrium into the morphologically and functionally distinct decidual 
tissue, involving the differentiation of endometrial cells and infiltration by 
large numbers of lymphoid cells” (Salamonsen et al., 2003). For successful 
implantation, the endometrium has to convert to decidua. Decidual cells play 
an essential role in implantation and provide the optimum nutritional 
environment for the embryo, it produces factors that appear to key roles in 
regulating trophoblast invasion whilst also protecting the embryo from 
“immune rejection” (Fazleabas and Strakova, 2002). Unlike in other species, 
the decidualisation process in humans starts in the late secretory phase and 
is not dependent on the presence of the blastocyst (Lunghi et al., 2007) 
(King, 2000).  
At the time of uterine receptivity, cellular morphological changes occur, 
involving endometrial stromal cells that change to decidual cells and assume 
large and round appearances. Furthermore, the secretory endometrial 
glands undergo active growth transformation (Dekel et al., 2010). 
Decidua development continues throughout pregnancy, and appears to 
regulate trophoblast invasion and placental development by modifying the 
expression of regulatory molecules including MMPs, surface integrins, major 
histocompatibility complex molecules and cytokines (Lunghi et al., 2007).  
Proteolysis is crucial for decidua remodelling, migration of cells and 
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vascularisation during human embryo implantation. This involves several 
matrix metalloproteinases whose activity is modulated by growth factors, 
steroid hormones and cytokines (Plaisier, 2011).  
Decidua, as a specialised tissue, is thought to provide an environment to 
control and regulate trophoblast invasion. If embryo implantation occures, the 
decidua form three regions. The first layer lies beneath the placenta called 
decidua basalis, formed of both maternal tissue and extravillous trophbalsts. 
The seconed layer overlayes the embryo called decidua capsularis and the 
last layer lines the uterus away from the area of implantation site and known 
as decidua parietalis (Loke et al., 1995). As a result, if implantation occurs in 
extrauterine sites or where there is a deficiency in decidua development, for 
example, a fallopian tube or a previous Caesarean scar, there is a more 
significant degree of trophoblast invasion than usual (Loke et al., 1995).  
1.2.3. Embryo-endometrial synchronization 
The implantation process is an interaction between the embryonic 
trophoblast and the endometrium (Dimitriadis et al., 2010). This requires 
synchronization of the processes involved in embryo development and the 
molecular and cellular events that occur in the endometrium of the uterus. It 
is regulated by paracrine and autocrine hormonal mechanisms (Staun-Ram 
and Shalev, 2005). The interaction takes place at specific time-points called 
the “window of receptivity” which depends on a number of complex 
molecules including cytokines, hormones and growth factors (Nikas, 1999, 
Singh et al., 2011). In humans, the window of receptivity is between days 20-
24 of the menstrual cycle (Lunghi et al., 2007). The synchronization process 
is regulated by steroid hormones and facilitated by molecular events and 
secretions from both the embryo and reproductive tissue (Vigano et al., 
2003) as illustrated in figure 1.3. Any dysregulation in the window of natural 
embryo selection or the embryo quality may lead to miscarriage (Teklenburg 
et al., 2010). 
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In human, the monthly fecundity rate (MFR) is defined as the probability of 
achieving a pregnancy within one menstrual cycle, it is about 20%–30%. In 
contrast, other mammalian species, the MFR is as high as 90% in rabbits 
and 80% in baboons. It has been estimated that human conceptions failure 
to progress to an ongoing pregnancy is approximately 50%. However, about 
15% of clinically recognized pregnancies are ended by miscarry. The theory 
of the discerning endometrium and the high rate of embryo implantation 
failure that characterizes reproduction of the human is thought to be due to 
two key features of human embryos: their high incidence of chromosomal 
abnormalities and their intrinsic invasiveness (Macklon and Brosens, 2014). 
1.2.4. Implantation stages 
The human embryo implantation process involves four phases: hatching, 
apposition, adhesion and invasion (Achache and Revel, 2006). However, two 
factors are essential for successful implantation, the quality of the embryo 
and endometrial receptivity (Cavagna and Mantese, 2003). 
1.2.4.1. Hatching stage 
Before implantation the blastocyst need to hatch out of the zona pellucida 
(acellular glycoprotein coat). Blastocyst hatching begins with formation of a 
nick in the zona pellucida, as a result of hydrostatic pressure exerted the 
increase of the blastocyst expansion. Blastocyst hatching is a crucial step in 
implantation phenomena and any dysregulation in the process results in 
embryo implantation failure.  
Hatching stage is regulated by both cellular and molecular factors, the exact 
process is still ill-understood. However, from the perspective of cellular 
biology aspect trophoectodermal projections (TEPs) are thought to play an 
essential role in hatching. On the other hand, the molecular regulators 
including cytokines, proteases and transcription factors are fundamental for 
blastocyst hatching (Seshagiri et al., 2009).  
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1.2.4.2. Apposition stage 
Orientation or apposition of the blastocyst inside the uterine cavity begins at 
day 6 after the mid-cycle luteinizing hormone surge (day LH+6) (Lim, 2003). 
In this phase, the blastocyst comes in close contact with the epithelial cells of 
the endometrium (Bischof and Campana, 1996). Apposition is also 
considered as an unstable linkage between the blastocyst and the receptive 
epithelial endometrium (Cakmak and Taylor, 2010) through the micro 
protrusions located on the top of epithelium identified as pinopodes (Singh et 
al., 2011). The early signals of the blastocyst and uterine epithelium during 
this stage are illustrated in figure 1.3. 
1.2.4.3. Adhesion stage 
This stage is characterized by a precise transient adhesive molecular 
interaction between the trophoblast and uterine epithelium (van Mourik et al., 
2009). The molecular events engaged in cell adhesion activate cytoplasmic 
signals that play a significant role in the next step (Kimber and Spanswick, 
2000). This stage is regulated by cell adhesion molecules such as (integrins, 
cadherins, selectins and kisspeptins), cytokines and immune cells (van 
Mourik et al., 2009). 
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Figure 1.3. Early signals of blastocyst and receptive endometrium before the stage of 
adhesion 
The figure represents the integrins, integrin receptors and formation of the pinopodes. 
Adapted from (Staun-Ram and Shalev, 2005). 
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1.2.4.4. Invasion phase 
The last stage is the invasion phase, within a few hours of adhesion, the 
embryo penetrate the endometrial epithelium to invade the stroma thereby 
creating a vascular network between the embryo and the mother (Singh et 
al., 2011). The invasion process is the longest phase of implantation. It 
begins with degradation of the basement membrane and the extracellular 
matrix (ECM) where the matrix metalloproteinases (MMPs) play a vital role in 
the control of the tissue inhibitors of matrix metalloproteinases (TIMPs) to 
prevent under or over activity of invasion (Lim, 2003). The cellular, hormonal 
and molecular interactions are illustrated in figure 1.4. This stage is critical 
although it is not explicitly defined (Helige et al., 2008), it is under tight 
regulation (Lala and Graham, 1990), and any imbalance may lead to 
pathological conditions. Excessive trophoblast invasion may lead to placenta 
increta, percreta and accreta, while inadequate invasion may lead to 
intrauterine growth restriction, preeclampsia and miscarriage (Lim, 2003). 
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Figure 1.4. The blastocyst-endometrium interaction including cellular and 
molecular event during invasion phase 
Adapted from (Staun-Ram and Shalev, 2005) 
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1.3. Placenta 
The placenta is a fetal organ that acts as a transporter and secretory unit 
throughout all its development stages (Huppertz, 2008). The placenta and its 
vascular development are crucial to the development and growth of the fetus 
(Reynolds et al., 2010). The importance of sufficient blood flow and vascular 
development of the placenta have been reviewed by many investigators. A 
recent report has emphasized that angiogenesis in the placenta is a critical 
determinant of placental blood flow and consequently affects fetal growth 
(Reynolds et al., 2010). Co-ordination between the development of the 
embryo and placenta is essential, as dysregulated processes can result in 
pregnancy complications such as miscarriage, intrauterine growth 
retardation, preeclampsia and stillbirth (Chaddha et al., 2004). 
1.3.1. Placenta development 
After the blastocyst attaches to the uterine endometrium, it penetrates its 
epithelium cell layer, the basement membrane and the stroma. These events 
are under hormonal (Aplin, 1991) and molecular influence, involving 
angiogenic growth factors, cytokines, adhesion molecules, growth factors 
and proteinases (Regnault et al., 2002). The phases of early placental 
development have been described as follows and illustrated in figure 1.5. 
1.3.1.1. Preimplantation phase  
During days 6 to 7 after conception, blastocyst need to hatch out of the zona 
pellucida, this is followed by the attachment of the blastocyst to the epithelial 
layer of the uterus, this step is considered as the first step in placenta 
development. After the morula stage and before the stage of the blastocyst, 
the first cell type to differentiate is the trophoblast. The inner cell mass of the 
trophoblast is covered with one layer of mononucleated trophoblast. This 
layer surrounds the embryoblast, blastocoel and blastocyst cavity (Huppertz, 
2008). The placenta and the fetal membrane are derived from the 
trophoblast layer while the embryo, placental mesenchyma and the umbilical 
cord are derived from the inner cell mass. 
18 
 
1.3.1.2. Prelacunar phase 
The inner cell mass is the part that is covered with trophoblast cells and 
forms the polarity of the blastocyst, and trophoblast cells that covered this 
part are the cells that attach the uterine epithelium (Huppertz, 2008). 
Following the attachment of the blastocyst to the uterine epithelium, 
differentiation of the polar trophoblast to cytotrophoblast and 
syncytiotrophoblast takes place (Enders and Blankenship, 1999). 
Cytotrophoblast cells are comprised of mononucleated cells while the 
syncytiotrophoblast consists of  multinucleated cells (Huppertz, 2008).  
During the prelacunar stage, the cytotrophoblast divides rapidly and fuse with 
the syncytiotrophoblast resulting in development and expansion of 
syncytiotrophoblast. The syncytiotrophoblast cells act as an invasive 
phenotype to the uterine epithelium, which are the only cells to make contact 
with the maternal cells directly. Any defect in the attachment of the polar part 
of the trophoblast due to rotary motion of the blastocyst during this period 
may lead to implantation failure or umbilical cord placing defect (Huppertz, 
2008). 
1.3.1.3. Lacunar phase 
During this phase (8 days after conception) the syncytiotrophoblast develops 
fluid-filled spaces called lacunae. The tissue masses around these lacunae 
are called trabeculae. The trabeculae play a significant role in the 
development of the placental villus tree. The syncytiotrophoblast invades and 
penetrates the endometrium where it makes contact with maternal capillaries 
as well as the endometrial superficial venous plexuses. It is at this point that 
the first maternal blood cells appear in the syncytiotrophoblast lacunae 
(Huppertz, 2008). 
At day 12 post conception, the cytotrophoblast cells start to invade and 
penetrate the syncytiotrophoblastic mass, this makes contact with the 
placenta from the maternal side by day 15 post conception (Frost and Moore, 
2010, Huppertz, 2008). The cytotrophoblast cells differentiate into the extra 
villus cytotrophoblast (Gude et al., 2004) which penetrates the stroma of the 
endometrium (Chaddha et al., 2004) between capillaries and glands. It 
19 
 
invades the spiral artery wall and ends in the vessel cavities (Huppertz, 
2008).   
1.3.1.4. Villous phase 
The development of this stage is illustrated in figure 1.5. Throughout this 
phase, the trabeculae develop branches, with central cytotrophoblast 
enclosed by the syncytiotrophoblast, these branches are the primary villi. 
The cells of the extraembryonic mesoderm infiltrate into the trabeculae but 
do not make contact with the maternal tissue, forming trophoblastic cell 
columns (Huppertz, 2008). Next, the primary villi are invaded by the 
mesodermal cells to form a mesenchymal core. These structures are called 
secondary villi (Chaddha et al., 2004) or chorionic villi (Mihu et al., 2009). 
However, the tertiary villi are formed when the first placental vessels develop 
(Huppertz, 2008). 
 
 
 
  
20 
 
 
 
 
 
 
Figure 1.5. Phases of early placental development 
(A) From days 12–15 post-conception formation of primary villi from cytotrophoblast cells in 
the core and enveloped by a layer of syncytiotrophoblast cells. (B) From days 15–21 post-
conception the extra-embryonic mesenchyma penetrate the trophoblast column leads to 
development of secondary villi (C) From day 18 post-conception until term, formation of 
tertiary villi by formation of the placental blood vessels. The tertiary villi lead to the formation 
of the placenta villus trees. Adapted from (Chaddha et al., 2004). 
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1.4. Role of hormones in implantation 
The hormonal endocrine system plays a fundamental role in the human 
implantation process. Hormones are involved in the expression, stimulation 
and inhibition of different cytokines, growth factors, cell adhesion factors and 
decidual proteins (Sunder and Lenton, 2000) during implantation. The 
precise role and the exact mechanism are still poorly understood, although 
numerous studies have shown that disturbance in any hormonal function 
may result in impaired embryo implantation (Makrigiannakis et al., 2006). 
However, understanding the molecular and hormonal background of embryo 
implantation can help to diagnose pregnancy loss or subfertility precisely and 
may enable better clinical management (Makrigiannakis et al., 2006). The 
hormones that appear to have functional roles in implantation include 
steroids, human chorionic gonadotropin (HCG) and corticotrophin-releasing 
hormone (CRH). 
1.4.1. Steroids 
It is accepted that the uterine endometrial cells are under the direct control of 
ovarian steroids and the indirect control of different growth factors and 
cytokines (Makrigiannakis et al., 2006). Ovarian progesterone and oestrogen 
regulate several modulatory molecules to enhance uterine receptivity for 
successful embryo implantation (Singh et al., 2011). The progesterone 
concentration increases during the luteal phase of the menstrual cycle and is 
crucial for the secretory differentiation changes in the uterine endometrium to 
facilitate blastocyst attachment (Sengupta and Ghosh, 2000). 
Progesterone plays an essential role in the decidualisation process, with 
cAMP being the principal intracellular mediator (van Mourik et al., 2009). It 
has been suggested that progesterone is a potent stimulator of calcitonin 
mRNA induction in the uterine glandular epithelial cell during the implantation 
window (uterine receptivity). It is also considered as an important 
suppressant factor of leukaemia inhibitory factor (LIF) in endometrium cells 
(Sunder and Lenton, 2000). 
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The role of the oestrogen hormone in the implantation process is to promote 
and express progesterone receptors on endometrial cells. With 
progesterone, it acts to prepare the blastocyst for implantation by promoting 
endometrial cell differentiation (Aplin and Kimber, 2004). However, both 
ovarian steroids are the dominant modulators and play a pivotal role in 
endometrial development, they prepare endometrium with an appropriate 
functional and morphological state to facilitate the blastocyst attachment 
(Singh et al., 2011). Therefore, progesterone deficiency during the luteal 
phase is a recognized association with female infertility (Sengupta and 
Ghosh, 2000).  
1.4.2. Human chorionic gonadotropin (hCG) 
Human chorionic gonadotropin plays a role in the decidualisation process 
and modulates the expression of growth factors and cytokines during embryo 
implantation. It maintains corpus luteum progesterone function until the 
placenta is developed and able to take over (Kodaman and Taylor, 2004).  
During pregnancy, the invading embryo produces hCG and prevents 
menstruation by rescuing the corpus luteum that continue to secret 
progesterone (Fritz and Speroff, 2011). At 10 weeks of gestation, hCG 
reaches its peak and is continued to be secreted throughout pregnancy, but 
its role in progesterone secretion only lasts for the first 3-4 weeks after 
embryo implantation (Cole, 2010).  
1.4.3. Corticotrophin releasing hormone (CRH) 
The corticotrophin-releasing hormone is a glycoprotein hormone that is 
synthesized by the decidua and trophoblast of the placenta (Staun-Ram and 
Shalev, 2005). Recent studies have described the role of corticotrophin-
releasing hormone in the implantation phenomena. They suggested that 
CRH promotes decidualisation and acts as a stimulatory factor for 
progesterone. They also demonstrated its role in decidualisation by 
regulating the local modulators, such as stimulation of inhibitor interleukin-1 
(IL-1), inducer interleukin-6 (IL-6) and the inhibition of enhancer 
prostaglandin E2 (Makrigiannakis et al., 2006). 
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1.5. Molecular and cellular biology of implantation  
Numerous studies have attempted to explain the molecular biology of 
implantation. However, it is still not well defined (Singh and Aplin, 2009). The 
implantation process involves a complex sequence of events starting with 
changes in the uterine epithelial cells organization (Heneweer et al., 2005) 
and endometrial components, these include endometrial glands, stromal 
cells and vessels and the ECM to prepare and drive changes in the 
endometrium for successful embryo implantation (Duc-Goiran et al., 1999). 
Nevertheless, dysregulation in the molecular and cellular events at different 
stages of the implantation process including pre-implantation, implantation 
and post-implantation may lead to an increase in the rate of implantation 
failure (Dey et al., 2004). Successful implantation and placentation involves 
factors which act on the endometrium to make it receptive to the embryo and 
other factors which render the endometrium resistant to implantation. The 
implantation window relies on a critical balance between these two opposing 
series of events (Tabibzadeh, 1998). 
1.5.1. Pinopodes  
Pinopodes are cellular organelles which appear as protrusions located on the 
surface epithelium of the endometrium. They are considered to be 
progesterone-dependent, their life span is about forty-eight hours. Their 
appearance is from day 19  to 21 of the menstrual cycle, corresponding to 
the time of the implantation window (Sunder and Lenton, 2000). Even though 
this has not been confirmed in vivo it seems that the presence of endometrial 
pinopodes throughout the mid-secretory phase may be considered as a 
useful marker of endometrial receptivity to enhance the rate of implantation 
(Achache and Revel, 2006).  
There is a controversy in the literature about the physiological role of 
pinopodes as well as their function and timing. Whilst they are thought by 
many to be markers of implantation (Quinn and Casper, 2009), a recent 
review has queried this assumption, highlighting the lack of evidence in 
humans as well as mice (Quinn and Casper, 2009). Although the function of 
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pinopodes is not clearly defined, it seems that blastocyst attachment at the 
stage of embryo endometrial interactions has more tendency to occur in the 
area of pinopodes, suggesting that their surface may contain receptors that 
are necessary for blastocyst attachment (Achache and Revel, 2006).  
1.5.2. MUC-1  
MUC-1 is a complex glycoprotein layer (Staun-Ram and Shalev, 2005) with 
high molecular weight more than 250 kDa (Meseguer et al., 2001). It is 
continuously expressed at the apical surface of endometrial luminal 
epithelium during the menstrual cycle and the level increases in the secretory 
phase (Aplin, 2006). MUC-1 prevents the adhesion between trophoblast and 
uterine epithelial cells (Aplin, 1997), acting as a protective agent against 
infection (Aplin and Kimber, 2004). It is thought to act as a barrier by 
inhibiting the binding of integrin receptors to their ligands (Staun-Ram and 
Shalev, 2005).  
Unlike other species, there is an increase in the level of MUC-1 during the 
apposition stage and the presence of the blastocyst in humans. At the stage 
of adhesion, the blastocyst produces an enzyme that metabolises MUC-1 in 
the area of implantation thereby removing its repulsive anti-implantation 
properties (Dey et al., 2004). Moreover, the presence of a large quantity of 
desmosomes in the lateral sides of the epithelial surfaces is another anti-
adhesion factor that impairs blastocyst implantation (Lunghi et al., 2007).        
1.5.3. Integrins 
Integrins are transmembrane glycoproteins, cell surface receptors (Sunder 
and Lenton, 2000), consisting of α and β subunits that bind to different ECM 
substances as well as cell adhesion molecules (Staun-Ram and Shalev, 
2005). Each unit contains three domains: extracellular, transmembrane and 
intracellular (Singh and Aplin, 2009). The expression of integrins on the 
endometrium is under the control of steroids and cytokines such as IL-1 (van 
Mourik et al., 2009). It is suggested that integrins have an important role in 
fertilization and implantation, including blastocyst attachment and invasion 
through the ECM as well as cell to cell signalling (Carson et al., 2000, 
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Sunder and Lenton, 2000). At the time of implantation, integrins are 
expressed by both the uterine endometrium and human trophoblast. They 
each bind to a particular ECM element including osteopontin produced by the 
uterine epithelium and oncofetal fibronectin (FN) which is generated by the 
trophoblast. This binding provides embryonic adhesion in the form of a 
sandwich model (Achache and Revel, 2006). Integrins participate in other 
physiological processes by cell-matrix and cell–cell adhesion, such as wound 
healing, thrombosis, haemostasis, oncogenic transformation and immune 
and non-immune defence mechanisms (Achache and Revel, 2006). 
1.5.4. Cytokines  
Various cytokines and cytokine receptors are expressed in both the embryo 
and uterine endometrium and have a role in the different phases of embryo 
implantation (Dey et al., 2004). Cytokines secreted by the embryo and the 
uterus play a role in embryo-maternal interaction, and in promoting 
receptivity of the endometrium, by regulating the activity of adhesion and 
anti-adhesion proteins (Cavagna and Mantese, 2003). In addition, it is 
suggested that they have an essential role in the regulation of the activity of 
MMPs and TIMPs (Lim, 2003). Cytokines that appear to participate in human 
implantation include Interleukin-1,6 (IL-1, IL-6) and Leukaemia inhibitory 
factor (LIF) (van Mourik et al., 2009). However,  a range of other cytokines 
are also expressed during this process including IL-11 (Dimitriadis et al., 
2005), IL-10 and IL-5 which are reported as an autocrine regulator in 
trophoblast invasion (Bischof and Campana, 2000). 
IL-1 is secreted by trophoblast cells and stromal endometrial cells. It 
stimulates the secretion of some MMPs that act as extracellular remodelling 
factors essential for implantation and placentation (Dimitriadis et al., 2005). 
Moreover, IL-1 stimulates LIF production by the endometrium and enhances 
the expression of integrin β3, an adhesive molecule crucial for apposition 
and adhesion (van Mourik et al., 2009). Nonetheless, it has been 
emphasised that IL-1 stimulates the production of human chorionic 
gonadotropin by the embryo (Dimitriadis et al., 2005). 
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 IL-6 is another cytokine that is suggested to contribute in implantation and 
placentation in humans. Moreover, it regulates a variety of aspects of 
immunity reaction (Dimitriadis et al., 2005). Throughout the luteal phase IL-6 
is highly expressed in the epithelium and glandular cells more than the 
stromal cells (Achache and Revel, 2006).  
Leukaemia inhibitory factor is a glycoprotein produced by the endometrial 
glands in the uterus and considered to play a significant but as yet ill-defined 
role in implantation (Singh et al., 2011). LIF and its receptors are highly 
expressed between six and nine days after the luteinizing hormone (LH) 
surge and this rise corresponds to the appearance of pinopodes 
(Makrigiannakis et al., 2006) while the uterine endometrium is under the 
influence of progesterone (Aghajanova, 2004). Investigators have 
demonstrated that LIF regulates gelatinases and urokinase plasminogen 
activator production, both of which play a vital role in trophoblast invasion of 
the endometrial stroma during implantation (Sunder and Lenton, 2000). LIF 
acts as both a stimulator and a mediator in the implantation process and 
pregnancy establishment (Aghajanova, 2004), it has been shown that LIF 
stimulates tissue inhibitors of MMPs in fibroblast (Bischof and Campana, 
2000). 
1.5.5. Growth factors 
Various growth factors are expressed in early pregnancy as well as during 
the menstrual cycle. As a result, they are considered essential to 
implantation (Dey et al., 2004). Growth factors are suggested to participate in 
all stages of implantation including apposition, attachment and invasion 
(Giudice, 1999).  
Epidermal growth factor (EGF) is expressed in the endometrium during the 
secretory and proliferative phases of the menstrual cycle, especially from the 
uterine decidua (Bischof and Campana, 2000). It has been found that EGF 
promotes the invasion of the endometrium by cytotrophoblast (Staun-Ram 
and Shalev, 2005), possibly by the direct stimulus of MMP-1 and MMP-3 
(Bischof and Campana, 2000). However, these observations remain 
controversial as the receptors of the epidermal growth factor are expressed 
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in proliferative but not invasive cytotrophoblast (Bischof and Campana, 2000) 
suggesting that EGF plays a vital role in the cytotrophoblast proliferation 
(Staun-Ram and Shalev, 2005) as well as the formation of the 
syncytiotrophoblast (Bischof and Campana, 2000). 
Transforming growth factor beta (TGF-β) is expressed in human uterine 
epithelium, stroma (Makrigiannakis et al., 2006) as well as the cells of the 
deciduae, and has been localized in cytotrophoblast and syncytiotrophoblast 
(Bischof and Campana, 2000). Studies have shown that TGF acts as an 
inhibitory factor for both proliferation and invasion of trophoblast (Staun-Ram 
and Shalev, 2005) through promoting MMP-2 and MMP-9 secretion and 
inhibiting TIMPs, activities (Bischof and Campana, 2000). Therefore, 
dysregulation in their expression and activity may result in partial or complete 
embryo implantation failure (Singh et al., 2011). 
Several studies have shown that many growth factors play fundamental roles 
in implantation and placentation, such as heparin-binding epidermal growth 
factor, it is expressed in uterine epithelium and stroma and is thought to 
regulate blastocyst implantation (Staun-Ram and Shalev, 2005). Insulin-like 
growth factor binding protein is the most significant endometrial decidual 
secretion (Bischof and Campana, 2000), it is found to be involved in the 
trophoblast migration and invasion by stimulating the gelatinolytic effect of 
trophoblast (Staun-Ram and Shalev, 2005). 
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1.6. Extracellular matrix (ECM) 
The ECM is a three-dimensional complex, non-cellular scaffold. All organs 
have an ECM with a unique structure that is created in early embryonic 
phases (Frantz et al., 2010). The ECM is a compound active network of 
many components that provides structural support to the tissues in the form 
of cartilage, bone and tendon. These components also play profound roles in 
many biological activities such as cellular proliferation and differentiation 
(Matrisian, 1990).   
Beyond their structural-mechanical functions, ECM molecules control diverse 
cellular roles, and play a significant role in various physiological and 
pathological processes, such as embryonic development, haemostasis, 
fibrosis of several organs, wound healing and inflammation, tumour growth 
and metastasis and angiogenesis (Bonnans et al., 2014). 
1.6.1. Components of extracellular matrix 
There are two main kinds of ECM: the interstitial connective tissue matrix, 
which surrounds cells and is responsible for structural support for tissues and 
the basement membrane, which separates the epithelium from the adjacent 
stroma (Bonnans et al., 2014). The interstitial matrix is essentially composed 
of collagen type I and fibronectin, elastin, proteoglycans, glycosaminoglycan 
and tenascin-C. The basement membrane is mainly composed of collagen 
type IV, laminins, heparin sulphate proteoglycan, entactin and nidogen 
(Bonnans et al., 2014). They are organised as a complex and dynamic 
meshwork for cell adhesion (Adams and Watt, 1993). The ECM acts as a 
barrier or a filter for soluble molecules, and as a structural supporter for cells. 
The cells may be surrounded by an ECM from all sides as in chondrocytes, 
or it may be on one side like the epithelial and endothelial cells (Adams and 
Watt, 1993). They also influence cell migration and adhesion process as well 
as tissue morphogenesis (Matrisian, 1990). There are cell receptors that 
mediate adhesion of cells to the ECM. These receptors belong to the family 
of integrins (Loke et al., 1995).  
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In the endometrium, collagen, laminin and fibronectin are the main 
components of ECM (Skrzypczak et al., 2007a). The human endometrium 
contains collagen type I, III, IV, V and VI. Collagen types I, III and V are 
responsible for the integrity of the structure and tissue strength (Adams and 
Watt, 1993). Collagen type IV, which is present in the basement membrane, 
promotes trophoblast invasion. Several enzymes contribute to the 
degradation of ECM and basement membrane, but the MMPs are 
considered as the most essential factors in this event, and their functions are 
highly regulated (Hulboy et al., 1997).  
MMPs and TIMPs govern trophoblast invasion of ECM (Jokimaa et al., 
2002). In the first trimester of pregnancy, both fibronectin and laminin are 
plentiful in the decidual stroma (Loke et al., 1995). Although the function of 
decidual fibronectin and laminin have not yet been clearly identified, one 
possible role is preserving tissue structure of the decidual stroma (Burrows et 
al., 1996).  
1.7. Matrix metalloproteinases (MMPs) 
Proteases family can be categorised into cysteine proteases, aspartate 
proteases, serine proteases and matrix metalloproteases. The matrix 
metalloproteases are members of a unique family which are responsible for 
degradation and remodelling of the basement membrane and ECM 
components (Hulboy et al., 1997). 
1.7.1. Structure of the matrix metalloproteinases 
The mammalian family of MMPs comprises about twenty-six members 
(Cohen et al., 2006). They are zinc-dependent enzymes and have the 
fundamental multidomain feature: it contains pro-domain, a catalytic domain, 
a hemopexin domain and a hinge domain as illustrated in figure 1.6. They 
function extracellularly at a neutral pH (Amalinei et al., 2007). However, they 
are divided into six groups with respect to their structural and functional 
properties: collagenases, gelatinases, matrilysins, stromelysins, membrane 
type and heterogeneous group (Amalinei et al., 2007). All the six groups of 
30 
 
MMPs share common functional domains and activation methods. (Goldman 
and Shalev, 2003) (Table 1.1).   
They are frequently secreted into the ECM as proenzymes or inactive 
enzymes except the MT-MMPs (Nagase and Woessner, 1999). The 
proenzymes need proteolytic activation by proteases including plasmin, 
elastase, tryptase and activated MMPs as illustrated in figure 1.7 
(Salamonsen and Nie, 2002). However, cell behaviour is regulated by MMPs 
in several ways including cell-cell and cell-matrix interactions, stimulation or 
inhibition of paracrine and autocrine signalling molecules and receptors on 
the cell surface (Staun-Ram and Shalev, 2005). The regulation of MMPs 
activity occurs at different levels including regulation of gene transcription, 
secretion, activation, inactivation and degradation (Cohen et al., 2006).   
The function of MMPs are under the regulation of Tissue Inhibitors of 
Matrixmetaloproteinases (TIMPs). TIMPs inhibit MMPs through Binding of 
their inhibitory domain the amino-terminal domain to the active site of the 
MMPs to form tight 1:1 complexes (section 1.8) (Murphy, 2011). Their 
dysregulated metabolism has been implicated in several pathological 
conditions such as tumour invasion, endometriosis, abnormal wound healing 
amongst others (Amalinei et al., 2007), nephritis, arthritis, fibrosis and 
chronic ulcer (Nagase et al., 2006). They are also involved in bone 
development, corneal repair and cartilage remodelling (Curry and Osteen, 
2003). The trophoblast implantation aggressiveness is similar to that in a 
tumour cell invasion. The fundamental dissimilarity is that the invasion 
process of the trophoblast is tightly controlled by MMPs and TIMPs 
(Salamonsen, 1999). 
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     Table 1.1. Summary of members of the Matrix metalloproteinase family of enzymes expressed in human tissue. 
 
Metalloproteinase MMP kDa Substrates Source 
Collagenase MMP-1 43 Collagen type (I, II, III) Fibroblast, endothelial cells, keratinocytes, hepatocytes, macrophages, 
chondrocytes and blasts 
MMP-8 58 Collagen type (I, II), nonmatrix proteins for instance 
serpins, angiotensin I, bradykinin and substance P 
Activated macrophages, chondrocytes, endothelial cells and smooth muscle 
cells.  
MMP–13  
 
55 Collagen (II, IV, IX, X and XIV) , fibronectin, laminin, 
aggrecan core protein, fibrillin–1 and serine 
proteinase inhibitors 
 
 
Gelatinases 
 
MMP–2 72 Collagen type IV, the main BM component Fibroblasts, keratinocytes, endothelial cells, chondrocytes, osteoblasts and 
monocytes 
MMP–9 92 Collagens (IV, V, VII, X and XIV) gelatin entactin, 
elastin, fibronectin, Aggrecan, plasminogen, 
osteonectin and MB componenet 
Invading trophoblasts, polymorphonuclear leukocytes, keratinocytes, 
osteoclasts and normal alveolar macrophages 
Stromelysins 
 
MMP–3,  
MMP–10  
MMP–11  
46 
46 
44 
Collagen type (IV, V, IX and X), proteoglycans, 
fibronectin, gelatin, laminin and fibrillin-1 
Fibroblastic cells,  
Matrilysins 
 
MMP-7  20 Fibronectin, laminin, collagen type IV and 
proteoglycans 
Glandular epithelial cells in the endometrium, parotid, mammary gland, liver, 
pancreas, small intestinal crypts, prostate, skin and conducting airways in 
the lung.  
MMP-26   Uterus, kidney and placenta 
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Membrane-type 
MMPs  
 
MT1–MMP  54 Collagen type (I, II and III), gelatin, laminin–1, 
fibronectin, cartilage proteoglycans and vitronectin. 
Dermal fibroblasts and osteoclasts. 
MT2–MMP  61 of laminin, fibronectin and tenascin Human placenta, heart and brain. 
MT3–MMP  55 Collagen type III, gelatin, fibronectin and casein Placenta, ovary, lung, kidney, prostate, intestine, spleen, skeletal muscle and 
heart 
MT4–MMP  54 Fibrinogen and fibrin Ovary, testis, leukocytes, colon and brain. 
MT5–MMP   Unknown Kidney, brain, pancreas and lung 
MT6–MMP 
(MMP–25)  
 Collagen type 4, fibronectin, fibrin and gelatin Leukocytes 
Other MMPs 
 
MMP–12  45 Type IV collagen, elastin, type I gelatin, laminin, 
fibronectin, vitronectin and proteoglycans 
Placenta 
MMP–18   unknown Placenta, ovary, mammary gland, lung, pancreas, thymus, small intestine, 
colon, spleen, testis, prostate and heart. 
MMP–19    unknown Leukocytes and in a variety of human tissues including placenta, ovary, 
mammary gland, lung, pancreas, thymus, small intestine, colon, spleen, 
testis, prostate, heart, skeletal muscle, kidney, liver and brain 
MMP–20   Amelogenin Dental tissues, the developing human teeth in the secretory enamel.  
MMP–21   Unknown Placenta, ovary, liver, kidney, brain, lung and peripheral blood leucocytes 
MMP–22  
MMP–23  
 Unknown unknown 
MMP–27    Testis, intestine, lung and skin 
MMP–28   Casein Human placenta 
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Figure 1.6. MMPs family 
MMPs family contains a single peptide, pro-peptide domain, catalytic domain with the zinc-
binding site and hemopexin-like domain. Some of the MMPs (gelatinases) have a fibronectin 
domain while other MMPs hold a furin-susceptible site. The membrane-linked MMPs have a 
glycophosphatidyl inositol domain while transmembrane type matrix metalloproteinases 
possess a transmembrane linker domain. Adapted from (Curry and Osteen, 2003). 
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Figure 1.7. MMPs system regulation mechanism 
The stimulation process acts via membranous or intracellular receptors. Intracellular 
stimulation cascades lead to the release of the MMP mRNA that is translated into the pro-
MMP protein. Specific MMPs are activated inside the cell for instance MT-MMPs and MMP-
11 while most of the MMPs are produced in an inactive form and need activation by other 
MMPs, serine proteinases. Active MMPs act on ECM leading to extracellular degradation or 
react with tissue inhibitor matrix metalloproteinase leading to suppression of matrix 
metalloproteinase activity. Adapted from (Curry and Osteen, 2003). 
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1.7.2. Role of matrix metalloproteinase in implantation 
Even though numerous studies have investigated the role of MMPs in early 
embryo implantation, its precise role is still unclear. MMPs are suggested to 
play a crucial role in embryogenesis, ovulation, implantation and 
menstruation (Amalinei et al., 2007). The first step of successful placentation 
is the implantation of the blastocyst into the endometrium, where a 
considerable transformation of the uterine endometrium happens in the area 
of implantation (Amalinei et al., 2007). MMPs are the main mediators in the 
process of remodelling and degradation of ECM (Cohen et al., 2006). They 
have a potential action related to the bioactivity regulation of the molecules 
that are likely to play a vital role in the trophoblast-endometrial interaction. 
These molecules include cytokines, growth factors, vasoactive factors, 
angiostatic and angiogenic factors. The activation is either by releasing these 
factors from ECM stores or by activating the molecules by degradation or 
cleavage of the binding protein. Matrix metalloproteinases also modulate the 
stimulation of the other factors such as angiogenesis inhibitor factors and 
endostatin (Salamonsen and Nie, 2002). 
The regulation of MMPs and TIMPs activity appears to be critical during the 
fetal-maternal interface for a successful implantation and placentation. 
Trophoblast cells express MMPs and therefor invasive by nature. Various 
studies using animal models, found that most MMPs are produced not only 
by trophoblast cells, but also by endometrial stromal cells and natural killer 
cells within the maternal uterus tissues. They suggest that decidual stromal 
cells have higher expression levels of MMP than trophoblast cells, and the 
decidua susceptibility to invasion appears to be increased in the presence of 
cytotrophoblast cells (Zhu et al., 2012). 
Differences in MMPs production have also been founded. For instance, 
production of MMP-2 and MMP-9 has been localized in during early 
pregnancy most strongly than other MMPs. At 6–8 weeks the pro-MMP-2 
expression is elevated over MMP-9 with subsequent decreasing 
concentrations, while the expression of pro-MMP-9 increases from 8 to 11 
weeks, this lead to conclude that MMP-2 has a key role during implantation 
and MMP-9 during invasion (Espino et al., 2017). However, with the 
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progression of pregnancy the expression of pro-MMP and active MMPs by 
trophoblast are expressed with deferent variations, differential MMP 
production has also been confirmed before and after delivery. Therefore, 
dysregulation of the controlled process of trophoblast invasion can lead to 
adverse pregnancy outcomes. Excessively shallow invasion may result in 
fetal intrauterine growth retardation (IUGR) and preeclampsia. Proper 
trophoblast invasion is therefore essential for maternal health and adequate 
fetus growth and development (Kim and Kim, 2017). 
The roles of MMP-2 and MMP-9 in implantation and placentation have been 
described (Xu et al., 2000). During the first trimester when invasiveness is 
maximal, human trophoblast secretes both gelatinases MMP-2 and MMP-9 
(Hulboy et al., 1997). However, accumulating evidence has showed that 
MMP-9 is the more potent mediator compared to MMP-2 (Cohen et al., 
2006). Both MMP-2 and MMP-9 degrade collagen IV, the main basement 
membrane collagen (Staun-Ram and Shalev, 2005). They also degrade 
other ECM proteins including collagen I, V, VII, IX, laminin, fibronectin, 
vitronectin and elastin (Cohen et al., 2006).  
In humans, throughout the first trimester of pregnancy, MMP-2 is produced 
by extra villous trophoblast while MMP-9 is produced by villous 
cytotrophoblast (Cohen et al., 2006). MMP-2 is expressed mainly in early first 
trimester between 6-8 weeks while MMP-9 is expressed the main gelatinase 
later, between 9-12 weeks (Staun-Ram and Shalev, 2005). 
Other MMPs involved in the trophoblast invasion process include MMP-3, 
MMP-11, MT1-MMP as well as MT2-MMP (Curry and Osteen, 2003). MT1-
MMP and MT2-MMP are expressed in the tissue of human placenta during 
the 1st trimester. Apart from the degradation of laminin, fibronectin and 
gelatine, it has been found that these MMPs play a role in the activation 
process of other MMPs especially MMP-2 (Cohen et al., 2006). 
Hurskainen et al studied five placentae obtained from legal abortions cases 
between 8-10 weeks of pregnancy and employed in situ hybridization. They 
showed that membrane type1-MMP (MT1-MMP) may have a role in the 
cytotrophoblast invasion and tissue organization of early placenta, because 
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of its abundantly expressed during trophoblast invasion, MT1-MMP might 
have a key in this process (Hurskainen et al., 1998). In support of these 
observations, another study indicated that MT1-MMP expressed in the 
uterine endometrium and decidua takes part in the adhesion and invasion of 
the blastocyst into the endometrium, and in the degradation and remodelling 
of the ECM (Nakano et al., 2001).  
1.8. Tissue inhibitor of matrix metalloproteinases  
Tissue inhibitor of matrix metalloproteinases (TIMPs) are a family of protein 
MMP inhibitors consisting of four members (Table.1.2). They act as key 
regulators of MMPs. The MMPs bind to TIMPs through the zinc binding site. 
The inhibitory effect of TIMPs on MMPs involves interaction between the 
active site of the MMPs, which is found in the catalytic domain and the 
TIMPs N-terminal domain (Curry and Osteen, 2003) as illustrated in figure 
1.8.  
TIMP-1, secreted by most cells (Skrzypczak et al., 2007a), acts as an 
inhibitory factor for most MMPs except MT1-MMPs and MMP-2 (Amalinei et 
al., 2007). TIMP-2, secreted by endothelial and fibroblast cells (Skrzypczak 
et al., 2007a), it acts as an inhibitory factor for most of the MMPs. TIMP-3 
inhibits MMP-1, MMP-2, MMP-3, MMP-9 and MMP-13, which is expressed 
as a result of mitogenic stimulation. TIMP-4 is expressed mainly in the heart 
and following vascular injury and wounds, it acts as an inhibitor to MMP-2, 
MMP-9 and MMP-7 (Amalinei et al., 2007). However, some studies have 
observed that the TIMP-4 is also located in reproductive tissues, and it is 
suggested to have a mode of action similar to TIMP-2 (Curry and Osteen, 
2003). In addition, to inhibition of MMPs, TIMPs have other biological 
activities such as erythroid potentiating activity, inhibition of endothelial cell 
proliferation and angiogenesis (Visse and Nagase, 2003). Furthermore, they 
also stimulate proliferation of cells and development of the embryo (Staun-
Ram and Shalev, 2005). TIMP-1 and TIMP-2 act as antiapoptotic while 
TIMP-3 acts as proapoptotic factors (Amalinei et al., 2007).  
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TIMPs and MMPs are expressed during human embryo implantation. TIMP-
1, TIMP-2 and TIMP-3 are secreted by trophoblast cells and decidual tissues 
during pregnancy (Staun-Ram and Shalev, 2005). TIMP-2 is also secreted 
by fibroblast cells and endothelial cells as a soluble protein and has high 
affinity to active or inactive MMP-2 (figure 1.8) (Skrzypczak et al., 2007b). 
Furthermore, TIMP-2 plays a significant role in the metabolism of MMP-2 and 
MT1-MMP (Staun-Ram and Shalev, 2005) 
 
 
 
     Table 1.2. Human tissue inhibitors of MMPs (TIMPs) family. 
 
TIMPs Other names Molecular 
mass (Da) 
Location of gene MMP substrate 
TIMP-1 MMP inhibitor 1 
erythroid potentiating 
activity fibroblast 
collagenase inhibitor 
collagenase inhibitor 
23 171 Chromosome X MMP-1, -2, -3, -7, 
-8, -9, -10, -11, -
12, -13, -16 
TIMP-2 MMP inhibitor 2,  
CSC-21K 
24 399 Chromosome 17 MMP-1, -2, -3, -7, 
-8, -9, -10, -13, -
14, -15, -16, -19 
TIMP-3 MMP inhibitor 3, MIG-5 
protein 
24 145 Chromosome 22 MMP-1, -2, -3, -7, 
-9, -13, -14, -15 
TIMP-4 MMP inhibitor 4 25 502 Chromosome 3 MMP-1, -2, -3, -7, 
-9 
     Adapted from (Cohen et al., 2006). 
 
 
 
 
 
 
 
  
39 
 
 
 
 
 
 
 
 
 
Figure 1.8. Structure of the proMMP-2/TIMP-2 complex 
The figure shows the interaction of MMP-2 and TIMP-2 through their C-terminal domains. 
The MMP-2 catalytic site and TIMP-2 the inhibitory active site are turned away from each 
other. Catalytic, structural Zn2+ ions, Ca2+ ion, the hemopexin domain numbered from I 
to IV and number III and IV indicate two areas of interaction between proMMP-2 and 
TIMP-2 molecules. 
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1.9. Relaxin 
Relaxin is a 6 kDa peptide hormone derived from the family of insulin-like 
growth factor (Sunder and Lenton, 2000). It was discovered by Dr Frederick 
Hisaw in the 1920s (Bathgate et al., 2013). There are three relaxin genes in 
humans: relaxin-H1, relaxin-H2 and relaxin-H3. In 1991, scientists 
determined the crystal structure of human relaxin that is found to be similar 
to that of insulin as illustrated in figure 1.9 (Ivell and Einspanier, 2002). 
Human relaxin-H1 and H2 genes are located on chromosome 9 and situated 
at a single locus while relaxin H3 gene is located on chromosome 19. 
Relaxin is secreted as a preprohormone and then converted by tissue 
convertases to relaxin hormone by cleavage of the c-domain (Hayes, 2004) 
and development of the disulfide bridge between A and B domains 
(Wilkinson et al., 2005).  
 
 
Figure 1.9. Crystal structure of RLX-2 hormone 
Representation of the structure of H2 relaxin based on the crystal structure the separate A 
and B chains and the relaxin receptor binding motif. Adopted from (Samuel et al., 2006). 
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1.9.1. Reproductive functions of Relaxin 
Relaxin is a hormone that has several effects in a variety of tissues, It has 
both reproductive and non-reproductive functions (Wilkinson et al., 2005). 
The major circulating form secreted and stored in human is Relaxin-H2 
(RLX-2). It is produced mainly by the corpus luteum (Bogic et al., 1997, 
Vogel et al., 2006a) and considered as the predominant subtype in the 
human circulation (Wilkinson et al., 2005). During pregnancy, it is secreted in 
large amounts (Bathgate et al., 2013). The pattern of relaxin secretion in 
human pregnancy is different from other species. In human pregnancy, the 
peak serum levels are attained between 10-12 weeks gestation, followed by 
a gradual decline toward 24 weeks when levels remain steady until the end 
of gestation (Vogel et al., 2002), attaining maximum concentrations of only 1 
ng/ml (Anand-Ivell and Ivell, 2014). In contrast, in other species such as rats, 
pigs and mice, the concentrations are higher and increasing throughout 
pregnancy with maximum levels about 100-200 ng/ml (Anand-Ivell and Ivell, 
2014), declining just prior to parturition (Bathgate et al., 2013). However in 
women with ovarian failure who lack corpus luteum and become pregnant by 
IVF, circulating relaxin is undetectable (Bathgate et al., 2013) consistent with 
a primarily ovarian source in early pregnancy. Relaxin is also expressed in 
amniotic fluid in increasing concentrations from 10 to 14 weeks of pregnancy 
(Johnson et al., 1994). 
In pregnancy, relaxin has endocrine functions (Bathgate et al., 2013) and 
plays a vital function in early pregnancy implantation, embryogenesis and 
placentogenesis (Anumba et al., 2009). Investigators have found that relaxin 
hormone enhances the uterine endometrial growth, including endothelial cell 
proliferation at the distal end of maternal spiral arteries. This suggest a role 
in endometrial preparation for implantation (Sherwood, 2004). It is an 
extreme stimulatory factor of a variety of growth factors and hormones 
including prolactin and insulin-like growth factor binding protein (Bonnans et 
al., 2014). Relaxin regulates the biochemical process of the ECM remodeling 
of the cervix and vagina throughout pregnancy (Parry and Vodstrcil, 2007).  
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Relaxin is suggested to act as a supportive factor for embryo implantation 
(Ivell and Einspanier, 2002). It has been demonstrated that endometrial 
receptors interact with RLX, therefore, they promote endometrial stromal 
cells differentiation in the decidualisation process which is important for 
embryo implantation (Ivell and Einspanier, 2002, Telgmann and Gellersen, 
1998). Furthermore, it has been suggested that relaxin hormone acts as 
human chorionic gonadotropin by the reflection of the corpus luteum 
function. Therefore, it could be suggested that the low concentration of the 
serum relaxin in early pregnancy may indicate corpus luteum dysfunction 
that results in either spontaneous miscarriage or placental dysfunction (Vogel 
et al., 2006b).  
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1.10. Implantation failure (IF) 
Unsuccessful implantation can result from abnormalities of the conceptus or 
the uterus. The rate of implantation failure is estimated to range between 
30% and 70% of conceptus, although many women may not be aware that 
they were pregnant (Kennedy, 1997). Approximately 50% of IF are probably 
due to genetic defects in the conceptus while the others are of unknown 
aetiology (Gagnon, 2003). Failure of implantation may result in miscarriage, 
preeclampsia, Intrauterine growth retardation (IUGR), stillbirth or preterm 
birth (King and Loke, 1994). 
1.10.1. Placenta dysfunction 
The mechanism of the placental pathology that leads to the placental 
deterioration is still unidentified (Gagnon, 2003). Insufficient placentation may 
lead to progressive placental functional decline that results in fetal growth 
restriction due to a decrease in the transfer of nutrition and oxygen from the 
placenta toward the fetus (Fox, 1976). Placental dysfunction is one of the 
serious obstetric problems which should be considered carefully, as it has a 
significant influence on the fetus and the placenta. Moreover, placental 
insufficiency can result in longer term conditions in surviving fetuses such as 
cardiovascular, metabolic and neurological complications (Gagnon, 2003).  
The Doppler flow velocity in the umbilical artery is an indirect measure of 
placental insufficiency, if abnormal it reflects an abnormal increase in 
umbilical placental vascular resistance which results in decreased umbilical 
blood flow. The placental pathology that leads to a reduction in umbilical 
blood flow can be due to abnormal function or structure of the primary unit of 
the placenta (Gagnon, 2003). Numerous studies reveal that defects in the 
decidua, placenta or its vascular bed may result in pre-eclampsia, fetal 
growth retardation, placenta abruption and preterm birth (Rasmussen et al., 
1999). 
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1.10.2. Intrauterine growth retardation (IUGR) 
Fetal growth restriction (FGR) is defined as “the rate of fetal growth that is 
below normal in light of the growth potential of a specific infant as per the 
race and gender of the fetus” (Sharma et al., 2016), and also defined as “the 
failure of fetus to reach its growth potential for various reasons, leading to 
multiple perinatal complications and adult diseases of fetal origins” (Tang et 
al., 2017). Fetal growth restriction is the second commonest cause of 
perinatal death after prematurity. Up to 4-6% of all pregnancies can be 
complicated by intrauterine growth restriction, 60% of which are due to 
placental insufficiency (Gagnon, 2003) and impaired growth of the feto-
maternal placental unit. This problem is attributed to defective interaction 
between embryo trophoblast cells and maternal luminal uterine cells (King 
and Loke, 1994, Barut et al., 2010). Fetal well-being at term coordinates with 
normal development of the placenta. However the abnormal growth of fetal 
placenta may contribute to serious adverse pregnancy outcomes including 
pregnancy loss, preeclampsia, placenta abruption and intrauterine growth 
restriction (Kingdom et al., 2000). Several studies concluded that intrauterine 
growth restriction is related to the high incidence of abnormalities in 
adulthood. These include metabolic, endocrine and cardiovascular disorders 
amongst others (Fowden et al., 2006).   
A recent study demonstrated that lower level of MMP-1 in the extra villous 
trophoblast might be associated with defective trophoblast invasion in 
pregnancies complicated by intrauterine growth restriction and preeclampsia 
(Lian et al., 2010). Another study analysed the amniotic fluid samples from 
44 pregnant women with intrauterine growth restriction and 98 pregnant 
women with appropriate intrauterine fetal growth between 15-17 weeks’ 
gestation by PCR. They concluded that pregnancies at high risk for 
intrauterine growth restriction were associated with fetal expression of the 
MMP-2-1306 single nucleotide polymorphism genes, while MMP-9-1562 
single nucleotide polymorphism genes and MMP-9 microsatellite showed no 
association (Gremlich et al., 2007).  
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1.10.3. Stillbirth 
The rate of stillbirth in the UK is estimated to be one in every two hundred 
infants (Smith and Fretts, 2007). It is defined as in utero fetal death after 20 
weeks gestation (Cnattingius and Stephansson, 2002). Smith et al reported 
that threatened miscarriage in the first trimester is associated with high risk 
of such adverse pregnancy outcomes as stillbirth, pre-eclampsia, preterm 
birth, IUGR and placental abruption (Smith et al., 2004). However, further 
research is required to understand the cellular and molecular basis of 
placentation (Smith and Fretts, 2007). To our knowledge, there are no 
studies that have investigated pregnant women with stillbirth and the 
expression of relaxin, MMPs or TIMPs in early pregnancy. 
1.10.4. Premature birth 
Preterm birth is described as delivery before 37 weeks of gestation. It affects 
10% of all pregnancies (Cockle et al., 2007). The perinatal mortality and 
morbidity in preterm birth are 70% which is more among infants deliver prior 
to 32 weeks gestation, and with a weight less than 1500g (Cockle et al., 
2007). Over the last three decades, preterm birth has been investigated by 
many scientists seeking to unravel the principal mechanism of the initiation of 
labour, which remains ill-understood (Dubicke et al., 2008). The key point in 
the protection of the fetal membrane strength and tensity is the ECM 
homeostasis (Vadillo-Ortega and Estrada-Gutierrez, 2005). Remodelling of 
the ECM during the softening of the cervix is associated with expression of 
several mediators including hormones and cytokines (Dubicke et al., 2008). 
In a recent study done by Anumba and his colleagues found that a strong 
association between high serum MMP-3 levels during the 20 weeks 
gestation and women who delivered preterm (Anumba et al., 2010).   
A prospective cohort study showed that women delivering preterm had a 
different expression pattern of serum RLX-2 throughout pregnancy. In early 
pregnancy, they expressed lower serum RLX-2 and later in pregnancy they 
tend to have a high level of serum RLX-2 compared with term deliveries 
because it reduced slowly in women delivering preterm than women 
delivering at term. To determine the time of intersection, they need at least 
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two serum RLX-2 measurement in early pregnancy to define the accurate 
intersection time and this was the main limitation of this study (Vogel et al., 
2006b). 
1.10.5. Miscarriage 
Early pregnancy loss or miscarriage is counted as the most frequent problem 
during pregnancy. It is defined by World Health Organization (WHO) as “the 
expulsion or extraction from its mother of an embryo or fetus weighing 500g 
or less” (Garcia-Enguidanos et al., 2002). The incidence of miscarriage 
among clinically-recognised conceptions is 15%, and it is increased if we 
consider the early reproductive losses which are near to 50% (Rai and 
Regan, 2006). Spontaneous miscarriage is sub-categorised into missed 
miscarriage, complete miscarriage, incomplete miscarriage, inevitable 
miscarriage, septic miscarriage, threatened miscarriage and recurrent 
miscarriage depending on the clinical feature (Griebel et al., 2005). This 
review will concentrate on threatened and recurrent miscarriage as they are 
the primary subject of the research. 
1.10.5.1. Threatened miscarriage 
A threatened miscarriage is defined as first-trimester vaginal bleeding in 
women with a viable pregnancy (Griebel et al., 2005). Approximately 25% of 
all conceptions have vaginal bleeding in the first trimester (Wijesiriwardana et 
al., 2006). Half of them end in spontaneous miscarriage, whereas the 
remaining half continue their pregnancy without complications (Wieringa-de 
Waard et al., 2002). It has been reported in a large retrospective cohort study 
that, primigravida women with a history of the first trimester bleeding are at 
higher risk of adverse pregnancy outcomes compared with those without a 
history of early pregnancy vaginal bleeding (Wijesiriwardana et al., 2006). 
The retrospective nature of the study considered as one of its drawbacks, 
another point is that data on the amount of bleeding were not gathered, as a 
result, they were not able to study the relationship between severity of 
bleeding and the adverse pregnancy outcomes. Most of the studies in the 
literature regarding threatened miscarriage investigate the relationship of 
early pregnancy vaginal bleeding and risk of obstetric complications. To our 
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knowledge, there are no studies that have investigated women with 
threatened miscarriage and the expression of RLX-2, MMPs or their tissue 
inhibitors of MMPs in early pregnancy. 
1.10.5.2. Recurrent miscarriage 
Recurrent miscarriage is defined as three or more consecutive spontaneous 
miscarriages. It has an incidence rate of 1% of women (Mtiraoui et al., 2004). 
Recurrent pregnancy loss is a heterogeneous situation with multifactorial 
causes. Although our understanding of recurrent miscarriage aetiology is 
limited, approximately 50% of cases have no known aetiology (Prakash et 
al., 2005, Laird et al., 2003, Li, 1998). Many cases are associated with 
impaired uterine receptivity (Dekel et al., 2010). However, unexplained 
recurrent miscarriage has received more attention from both researchers and 
clinicians and considered as a tough challenge.   
The aetiology of recurrent pregnancy loss can be attributed to two main 
factors: embryological factors that are mainly due to abnormal karyotype and 
maternal factors including endocrine disorders, autoimmune defects, 
coagulation disorders and endometrial defects that may affect the 
endometrium, placenta or both (Laird et al., 2003). The risk of pregnancy 
loss is 30% in women with a history of two recurrent miscarriage while it is 
33% in women with a history of three recurrent miscarriage and no history of 
live birth (Ford and Schust, 2009). Women with a history of recurrent 
miscarriage whose pregnancy progressed further than 24 weeks are at risk 
of adverse pregnancy outcomes. They have a high incidence of preterm 
delivery, intrauterine growth restriction and risk of caesarean section 
suggesting closer surveillance during pregnancy (Jivraj et al., 2001). 
A number of serum molecules are changed in some women with a history of 
recurrent miscarriage although no one of these markers reliably predicts 
recurrent pregnancy loss (Anumba et al., 2010). Anumba and his colleagues, 
have recently found in a longitudinal prospective case-controlled study that 
pregnant women with a history of recurrent pregnancy loss have lower serum 
human RLX-2 and higher serum TIMP-2 in comparison with pregnant women 
with no history of recurrent miscarriage, while no differences in the 
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expression of MMP-1, MMP-3, MMP-9 and TIMP-1 between the two groups, 
suggesting a role for these two molecules (RLX-2 and TIMP-2) in 
implantation and angiogenesis (Anumba et al., 2010). They suggested that 
dysfunction of RLX-2 and TIMP-2 at the implantation stage may contribute to 
repeat pregnancy loss, perhaps by inhibiting endometrial and placental 
angiogenesis. This was the first study that investigated serum levels MMPs 
and TIMPs throughout human pregnancy. It has been suggested that the 
lower serum relaxin levels are likely to reflect reduced expression in 
reproductive tract tissue (Anumba et al., 2009). In a follow-on study, 
assessing TIMP2 levels in the same cohort of women. They also 
demonstrated that between 10 and 12 weeks gestation, a ratio of RLX-2: 
TIMP-2 < 0.1 was best associated with a history of recurrent miscarriage  
(Anumba et al., 2010).   
The main limitation of these observations was the small sample size that 
limited the ability of the study to detect any association between serum 
marker levels and adverse clinical outcomes such as: stillbirth, premature 
delivery, repeat miscarriage and placental abruption. Furthermore, the study 
measured systemic serum marker levels rather than the production of RLX-2 
and TIMP-2 from local reproductive tract tissue. This limited the conclusions 
that could be drawn from their observations since various non-reproductive 
tracts may contribute to the systemic expression of the serum markers 
studied (Anumba et al., 2010).     
To explore these observations further, a prospective study of four cohorts of 
pregnant women is planned: pregnant women with a viable pregnancy with a 
history of recurrent miscarriage, normal pregnant group with no history of 
recurrent miscarriage with the same matching gastitional age, and women 
being seen in early pregnancy with a history of threatened miscarriage and 
their healthy normal pregnant group with no history of recurrent miscarriage 
with the same matching gastitional age. We will investigate whether serum 
RLX-2, MMP-2 and TIMP-2 levels have predictive potential for the following 
adverse pregnancy outcomes: repeat miscarriage, fetal growth restriction or 
premature delivery. We will also study in vitro endometrial-trophoblast cell 
line interactions and the effect on matrix protein and relaxin expression at 
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that interface. We will employ cell lines validated in previous studies most 
likely to mirror the in vivo situation.  
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Hypothesis 
Trophoblast-endometrial interactions are affected by altered expression of 
TIMP-2, MMP-2 and human RLX-2 during early implantation. 
 
Research question 
1- Is there an association between the serum levels of RLX-2, MMP-2 and 
TIMP-2 and the timing of pregnancy loss in the index pregnancy? 
2- Could these proteins (RLX-2, MMP-2 and TIMP-2) be employed as useful 
clinical markers for adverse pregnancy outcomes?  
 
Objectives 
1- To determine whether RLX-2, MMP-2 and TIMP-2 levels could be 
clinically useful markers of impending pregnancy loss during the current 
pregnancy. 
2- To identify any associations between the serum levels of RLX-2, MMP-2 
and TIMP-2 with adverse pregnancy outcomes including miscarriage, 
spontaneous preterm birth, fetal growth restriction, placental abruption and 
preeclampsia. 
3- To determine whether dysregulation of the metabolism of RLX-2, MMP-2 
and TIMP-2 characterises the endometrial implantation site prior to 
conception. 
4- To explore, using appropriate cell lines and 3D endometrial model, 
trophoblast-endometrial interactions and the effect of RLX-2, MMP-2 and 
TIMP2 functional expression levels on implantation stages.  
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 Materials and Methods 
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2.1. In vivo study 
2.1.1. Health and safety 
The requirements and precautions recommended by the Control of 
Substances Hazardous to Health (COSHH) were followed before starting the 
laboratory work. All blood samples, materials and reagents were handled 
according to University Health and Safety regulations. Laboratory coats and 
gloves were worn during work in the laboratory.  
2.1.2. Ethical approval 
Ethical approval for this study was granted by South Yorkshire Research 
Ethics Committee (06/Q2305/128). Each participant was provided with a 
detailed information sheet about the study and written informed consent was 
obtained from all participants. 
2.1.3. Study subjects 
2.1.3.1. Recruitment  
Women who fulfilled the inclusion criteria were recruited from the antenatal 
booking clinic, recurrent miscarriage clinic and the Early Pregnancy 
Assessment Unit at the Jessop Wing, Royal Hallamshire Hospital, Sheffield 
Teaching Hospitals, NHS Foundation Trust. Potential participants were 
approached by their doctor or midwife and provided with an information 
leaflet. If they agreed to take part in the study, a meeting was arranged with 
the researcher who explained what the study entails and written informed 
consent was obtained. Four cohort groups of women were recruited into this 
study.  
2.1.3.2. Recurrent miscarriage women 
The first group included women with a history of recurrent pregnancy loss; 
defined as three or more consecutive miscarriages. Women attending for 
their first antenatal (booking) visit were recruited from the recurrent 
miscarriage clinic at the Jessop Wing, Royal Hallamshire Hospital, Sheffield 
Teaching Hospitals, NHS Foundation Trust.  
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Inclusion criteria: 
1. Maternal age between 20-40 years. 
2. Pregnant women between 10-13 weeks’ gestation  
3. Pregnant women with a history of recurrent miscarriage.  
Exclusion criteria: 
1. Women who may have difficulty in understanding the protocol or in 
giving informed written consent.  
2. Women with recurrent pregnancy loss attributed to uterine tumour, 
uterine malformation, or proven cervical weakness. 
3. Women who are smokers.  
2.1.3.3. Healthy pregnant women between 10-13 weeks’ gestation (Control) 
The women in the control group were recruited from the routine antenatal 
clinics at the Jessop Wing, Royal Hallamshire Hospital, Sheffield Teaching 
Hospital, NHS Foundation Trust. Women were attending for their first 
antenatal (booking) visit. 
Inclusion criteria: 
1. Maternal age between 20-40 years. 
2. Pregnant women between 10-13 weeks’ gestation. 
3. Pregnant women without a history of recurrent miscarriage or 
infertility.  
Exclusion criteria: 
1. Women who may have difficulty in understanding the protocol or in 
giving informed written consent.  
2. Pregnant women with a history of recurrent miscarriage, threatened 
miscarriage or infertility 
3. Women who are smokers.  
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2.1.3.4. Threatened miscarriage women 
The third group comprised women in early pregnancy with threatened 
miscarriage, between 6-10 weeks gestation. These women were recruited 
from an Early Pregnancy Assessment Unit at the Royal Hallamshire Hospital, 
Sheffield Teaching Hospitals NHS Foundation Trust. 
Inclusion criteria: 
1. Maternal age between 20-40 years. 
2. Pregnant women between 6-10 weeks gestation presented with 
early vaginal bleeding and viable pregnancy  
3. Pregnant women without a history of recurrent miscarriage or 
infertility.  
Exclusion criteria: 
1. Women who may have difficulty in understanding the protocol or in 
giving informed written consent.  
2. Women who are smokers.  
2.1.3.5. Healthy pregnant women between 6-10 weeks’ gestation (control) 
The fourth group included healthy pregnant women from an Early Pregnancy 
Assessment Unit at the Royal Hallamshire Hospital, Sheffield Teaching 
Hospitals NHS Foundation Trust  
Inclusion criteria: 
1. Maternal age between 20-40 years. 
2. Pregnant women between 6-10 weeks gestation with out a history 
of recurrent miscarriage, threatened miscarriage or infertility .  
Exclusion criteria: 
1. Women who may have difficulty in understanding the protocol or in 
giving informed written consent.  
2. Pregnant women with a history of recurrent miscarriage, 
threatened miscarriage or infertility.  
3. Women who are smokers.  
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2.1.3.6. Blood samples 
Investigations were carried out on subjects not exceeding 13 weeks 
gestation. 15 ml of peripheral venous blood was collected from consenting 
subjects and divided between two tubes: a serum test tube (BD Biosciences, 
USA) and a vacutainer tube with K2 EDTA (BD Biosciences, USA). The 
samples were transported to the lab immediately and were centrifuged (MSE 
Mistral 2000, DJB Lab care, UK) within 30 minutes of collection at 1300 g for 
10 minutes to obtain serum and plasma. Serum and plasma samples were 
each aliquoted into three vials and stored at -80°C (Revco, USA) before 
analysis.  
2.1.3.7. Outcome measure 
The primary clinical outcome was miscarriage. Secondary clinical outcomes 
included, the birth of a small infant for gestation age (birth weight less than 
the 10th customized centile for gestation), premature delivery before 34 
weeks gestation, stillbirth, placental abruption and the development of pre-
eclampsia.     
2.1.4. Enzyme-linked ImmunoSorbant Assay 
Enzyme-linked ImmunoSorbant assay (ELISA), is an immunoassay used to 
quantify the amount of test substance in a sample. ELISA is based on 
antibody specificity for a target antigen. The capture antibody is coated onto 
the surface of a well, then captures the antigen from the test solution if it is 
present. A secondary antibody is used (detection antibody) that binds to the 
same antigen but at a different site on the molecule. The detection antibody 
is usually conjugated with an enzyme that can covert a substrate into a 
colour product the optical density of which can be determined 
spectrophotometrically. The amount of colour product formed is directly 
related to the amount of test antigen in the sample. This amount can be 
quantified using a standard curve.  
In this project, ELISA was used to measure the amount of RLX-2, MMP-2, 
MMP-9, TIMP-2 and MMP-2/TIMP-2 complex in the serum of the four groups 
of subjects studied. The main advantage of ELISA is high sensitivity and 
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specificity, it can be used to investigate a large numbers of samples at one 
time, and it is a safer alternative to radio-immunoassay (RIA) that uses 
radioactive labels. 
The ELISA kits used in this study were as follows: 
1. Human RLX-2 immunoassay (R&D Systems, Minneapolis, USA) the 
minimal detected dose (MDD) of human RLX-2 is between 0.26-4.57 pg/ml. 
The kit is highly specific for human RLX-2, as insulin, IGFs, relaxin-1 and 
relaxin-3 showed no significant cross-reactivity. The detection range of the kit 
is between 7.8 - 500 pg/ml. 
2. Human MMP-2 ELISA assay (DuoSet development kit, R&D Systems, 
Minneapolis, USA). This kit is highly specific for human pro-MMP-2 and 
active MMP-2, but does not recognise MMP-2/TIMP-2 complex. There is no 
detectable cross-reactivity with other MMPs and TIMPs, but there is cross-
reactivity with TIMP-2 at a concentration of more than 1.56 ng/ml. The 
detection range of the kit is between 0.6 - 20 ng/ml.  
3. Human MMP-9 ELISA assay (DuoSet development kit, R&D Systems, 
Minneapolis, USA). This kit is highly specific for human pro-MMP-9 and 
active MMP-9. There is no detectable cross-reactivity with other MMPs and 
TIMPs, but there is cross reactivity with recombinant human TIMP-1 at a 
concentration of more than 1.56 ng/ml. The detection range of the kit is 
between 31.2 - 2,000 pg/ml. 
4. Human TIMP-2 ELISA assay (DuoSet development kit, R&D Systems, 
Minneapolis, USA). This kit is highly specific for human TIMP-2. There is no 
detectable cross-reactivity or interference with any other TIMPs. The 
detection range of the kit is between 31.2 - 2,000 pg/ml. 
5. Human MMP-2/TIMP-2 complex ELISA assay (DuoSet development 
kit,R&D Systems, Minneapolis, USA). This kit is highly specific for human 
MMP-2/TIMP-2 complex. There is no detectable cross-reactivity with other 
MMPs and TIMPs, but there is cross reactivity with MMP-2/TIMP-3 at a 
concentration of more than 12.5 ng/ml. The detection range of the kit is 
between 125 - 8,000 pg/ml. 
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6. βhCG ELISA Assay, this assay allows for the quantitative detection of 
βhCG (Abcam, Cambridge, UK) and was used to measure βhCG released 
by JAR spheroids. The assay was performed according to a manufacturers 
protocol, the intra-assay coefficient of variation (CV) was calculated at <10%, 
and the inter-assay was <12%. The mean minimal detected dose was 50 
pg/ml. The kit is highly specific for βhCG and shows no cross-reactivity with 
the following cytokines including IL-1α, IL-1β, IL-2, IL-3, other interleukins, 
Leptin, TIMP-1, TIMP-2, TNF-α, TNF-β and others. The detection range of 
the kit is between 54.87 - 40000 pg/ml. 
2.1.4.1. General sandwich ELISA protocol 
The concentration of human RLX-2, MMP-2, MMP-9, TIMP-2 and MMP-
2/TIMP-2 complex was measured in the supernatents and the serum blood 
samples of the four groups according to the manufacturers’ protocol.  
The capture antibody was diluted to the working concentration using PBS. 
Then a high binding 96-well plate was immediately coated with 100 µl of the 
recommended diluted capture antibody in each well. The plate was sealed 
and incubated overnight at room temperature. The following day, the coating 
solution was removed and the plate was washed with 400 µl wash buffer 
three times. Complete removal of the liquid after each wash was important. 
Following the last wash, any remaining wash buffer was removed by 
inverting the plate and blotting it against clean, absorbent paper towels. Non-
specific binding sites were blocked using 300 µl reagent diluent to each well. 
The plate was incubated for a minimum one hour at room temperature before 
wells were rinsed with wash buffer three times as previously described. At 
this point, the plate was ready for addition of standards and samples.  
One hundred microliters of standard solutions or samples (serum/ 
supernatant) were added to each well to bind to the capture antibody. The 
standards were run in duplicate while the serum/supernatant samples were 
run in triplicate. The plate was covered with an adhesive strip and incubated 
at room temperature for two hours after which the solutions were discarded 
and wells washed with wash buffer following the same step as mentioned 
previously. After the detection antibody was diluted in a reagent diluent, 100 
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µl of the diluted detection antibody was added to each well and incubated for 
two hours at room temperature. The solutions were then discarded and 
washed with wash buffer as previously described.  
Streptavidin-HRP was diluted to working concentration using a reagent 
diluent, and 100 µl were added to each well, the plate covered to avoid direct 
light and incubated at room temperature for 20 minutes. After plate washing 
100 µl of the substrate solution [1:1 mixture of colour reagent one A (H2O2): 
colour reagent B (tetramethylbenzidine)] was added to each well and 
incubated at room temperature in the dark for 20 minutes. Finally, 50 µl of 
stop solution was added to each well to stop the enzyme reaction. The plate 
was gently tapped to ensure mixing and the optical density of the solution in 
the wells measured at 450 nm with a wavelength correction set to 540 nm 
using a spectrophotometer (Infinite 200 PRO, Tecan, Reading, UK). 
DeltaSoft Microplate Analysis Software (BioMetallics, Inc) was used to 
analyse the data. Details of capture and detection antibodies, standards and 
solutions used in the procedures are illustrated in (Table 2.1) and (Table 
2.2).    
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   Table 2.1. ELISA kits 
    
 
  
Elisa kit Capture antibody Detection Antibody Standard  
Human MMP-2 -360 µg/ml 
-Mouse anti-human MMP-2 
-Working concentration 2 
µg/ml 
-90 µg/ml 
-Mouse anti-human MMP-2 
-Working concentration 
500 ng/ml 
-1920 ng/ml 
-High Standard: 
20 ng/ml 
Human MMP-9  -180 µg/ml 
-Mouse anti-human MMP-2 
-Working concentration 1 
µg/ml 
-54 µg/ml 
-Gout anti-human MMP-9 
-Working concentration 
300 ng/ml 
-95 ng/ml 
-High Standard: 
2000 pg/ml 
Human TIMP-2 -360 µg/ml 
-Mouse anti-human MMP-2 
-Working concentration 2 
µg/ml 
-9 µg/ml 
-Gout anti-human TIMP-2 
-Working concentration 50 
ng/ml 
-95 ng/ml 
-High Standard: 
2000 pg/ml 
Human MMP-2 /TIMP-2 
complex 
-288 µg/ml 
-Goat anti-human MMP-2 
-Working concentration 1.6 
µg/ml 
-72 µg/ml 
- Goat anti-human TIMP-2 
-Working concentration 
400 ng/ml 
-160 ng/ml 
-High Standard: 
8000 pg/ml 
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       Table 2.2. Solutions used in the ELISA procedure 
 
Solution  Ingredients  Company  Catalog no. 
PBS 137 mM NaCl  
2.7 mM KCl  
8.1 mM Na2HPO4  
1.5 mM KH2PO4 
R&D Systems DY006 
Wash buffer  0.05% Tween 20 in PB R&D Systems WA126 
Reagent Diluent  1% BSA (Bovine Serum 
Albumin) in PBS 
R&D Systems DY995 
Substrate solution 1:1 mixture of  
Colour Reagent A (H2O2) 
and Colour Reagent B 
(Tetramethylbenzidine) 
R&D Systems DY999 
Stop solution 2 N H2SO4 R&D Systems DY994 
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2.1.4.2. Human Realxin-2 and βhCG ELISA protocol 
The assay procedure for Human Realxin-2 ELISA started by preparing all 
reagents, working standard and samples as directed by manufacture 
instruction. Then 100 µl of the Assay diluent RD1-19 were added to each 
well. Fifty microliters of standard solution and serum sample or supernatant 
were added to each well. The standards were run in duplicate while the 
serum/ supernatant samples were run in triplicate. The plate was covered 
with an adhesive strip and incubated at room temperature for two hours, after 
which the solutions were discarded and wells washed with wash buffer 
following the same step as mentioned previously. The rest of the steps are 
the same as mentioned in the previous protocol. Two hundred microliter of 
RLX-2 conjugate was added to each well. The plate was covered with new 
adhesive strip and incubated for 2 hours at room temperature. The washing 
step was repeated as mentioned in the previous protocol. The rest of the 
steps are similar to the previous general ELISA protocol (section: 2.1.4.1). 
The assay procedure for βhCG ELISA started by adding 100 µl of standard 
solution and sample supernatant to each well. The standards were run in 
duplicate while the supernatant samples were run in triplicate. The plate was 
covered with an adhesive strip and incubated at room temperature for two 
hours after which the solutions were discarded and wells washed with wash 
buffer following the same step as mentioned previously. The rest of the steps 
are the same as mentioned in the previous general ELISA protocol (section: 
2.1.4.1). 
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2.1.5. Data collection and management  
Data regarding adverse pregnancy outcomes including miscarriage, 
spontaneous preterm birth, fetal growth restriction, placental abruption and 
pre-eclampsia were collected using a predesigned proforma, from the study 
subjects directly and/or from their notes and entered into a computer 
database for analysis. The computer on which data was entered was 
secured by encryption and password protected, and the forms were securely 
kept in a locked cabinet in a locked office that was accessible only to the 
lead investigator.  
2.1.6. Statistical analysis  
Both parametric and non-parametric tests were employed as appropriate to 
compare means or medians. The Student’s t-test or the Mann-Whitney U test 
or ANOVA with multiple comparisons for data containing a number of groups 
was used to compare the serum levels of RLX-2, MMP-2, MMP-9, TIMP-2 
and MMP-2/TIMP-2 complex.  
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2.2. In vitro study 
2.2.1. Health and safety 
Materials and reagents were handled as stated by the University of Sheffield 
Health and Safety Regulations. The precautions and requirements 
mentioned in Control of Substances Hazardous to Health (COSHH) were 
followed before starting the laboratory work. Laboratory coats and gloves 
were worn at all times during laboratory work. 
2.2.2. General cell culture 
All cell culture procedures were performed under sterile conditions in a 
biological safety class II laminar flow cabinet (Walker Safety Cabinets Ltd, 
Glossop, UK). Equipment and solutions were sterilized by autoclaving (MP 
25 Control, Rodwell Scientific Instruments, UK) for 20 minutes at 121°C.  All 
equipment that could not be sterilised by autoclaving were sterilised using 
70% ethanol. Cells were cultured according to manufacturers instructions, 
and incubated at 37°C with an atmosphere of 5% CO2, 95% humidity 
(Galaxy R Plus CO2 incubator, Scientific Laboratory Supplies, Nottingham). 
2.2.3. Cell lines and their complete growth media  
2.2.3.1. HEC-1-A  
An endometrial epithelial cell line derived from a 71-year-old female 
(Catalogue no. HTB-112) was obtained from American Type Culture 
Collection (ATCC, Manassas, VA). The characteristics of the HEC-1-A are 
human epithelial endometrium adenocarcinoma, with adherent growth 
properties (Hannan et al., 2010). HEC-1-A cells were grown in McCoy’s 5A 
medium supplemented with 1.5 mM L-glutamine, 2200 mg/L sodium 
bicarbonate (ATCC, Manassas, VA) 10% fetal bovine serum (FBS) (ATCC, 
Manassas, VA), 100 IU/ml penicillin and 100 µg/ml streptomycin (Sigma-
Aldrich, Poole, UK) (Kuramoto et al., 1972).  
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2.2.3.2. RL95-2  
An endometrial epithelial cell line that was originally derived from a 65-year-
old female (ATCC, catalogue no. CRL-1671). The characteristics of the 
RL95-2 are a human epithelial endometrium carcinoma with adherent growth 
properties (Hannan et al., 2010). RL95-2 cells were grown in a 1:1 volume of 
Dulbecco's Modified Eagle's Medium (DMEM) and Ham's F-12 medium 
supplemented with 2.5 mM L-glutamine, 0.5 mM Sodium pyruvate, 15 mM 
HEPES, 1200 mg/L sodium bicarbonate, 0.005 mg/ml insulin (ATCC, 
Manassas, VA), 10% FBS (ATCC, Manassas, VA), 100 IU/ml penicillin and 
100 µg/ml streptomycin (Sigma-Aldrich, Poole, UK) (Way et al., 1983). 
2.2.3.3. Ishikawa cell line 
An endometrial epithelial cell line derived from a 39-year-old female (Sigma-
Aldrich, Poole, UK, catalogue no.99040201). The characteristics of the 
Ishikawa cell line are human epithelial endometrium adenocarcinoma with 
adherent growth properties (Hannan et al., 2010). Ishikawa cells were grown 
in a Modified Eagle's Medium (MEM) supplemented with 2mM Glutamine, 
1% Non-Essential Amino Acids (NEAA) (Sigma-Aldrich, Poole, UK), 5% FBS 
(ATCC, Manassas, VA), 100 IU/ml penicillin and 100 µg/ml streptomycin 
(Sigma-Aldrich, Poole, UK) (Castelbaum et al., 1997). 
2.2.3.4. JAR cell line (trophoblast cell line) 
A trophoblast cell line derived from a male foetus (ATCC, catalogue no. HTB-
144). The characteristics of the human epithelial choriocarcinoma are 
adherent growth properties. JAR cells were grown in a RPMI-1640 medium 
(ATCC, Manassas, VA) supplemented with 10% FBS (ATCC, Manassas, 
VA), 100 IU/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich, Poole, 
UK) (Sasaki et al., 1982). 
2.2.3.5. Endometrial stromal cell (T-HESCs) 
Fibroblast cells immortalized with hTERT that was derived from an adult 
female (ATCC, catalogue no. CRL-4003™). The characteristics are of human 
endometrial fibroblasts with culture adherent growth properties. T-HESCs 
were grown in a DMEM/F12 at a 1:1 v/v ratio (without phenol red) 
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supplemented with 3.1 g/L glucose, 1mM sodium pyruvate, 1.5 g/L sodium 
bicarbonate, 1% Insulin-Transferrin-Selenium (ITS)+ Premix (BD Cat no. 
354352), 500 ng/mL puromycin, 10% charcoal/dextran-treated FBS 
(HyClone Cat no. SH30068.03), 100 IU/ml penicillin and 100 µg/ml 
streptomycin (Sigma-Aldrich, Poole, UK) (Krikun et al., 2004). 
2.2.4. Cell culture 
Cell lines, frozen in 1 ml vials stored in liquid nitrogen, were thawed in a 37°C 
water bath for 2-3 minutes, the water was kept lower than the O-ring and the 
cap. After the vial contents, had thawed, the vial was removed from the water 
bath and decontaminated by spraying with 70% ethanol. In a class II hood, 
the contents of the vial were transferred to a universal centrifuge tube and 
diluted with 9 ml of the recommended pre-warmed complete growth medium. 
The tube was centrifuged at 200 x g for 5 minutes. The supernatant was 
removed and the cells pellet resuspended in 10 ml of the recommended 
growth medium. Cells were added to a 75 cm² tissue culture flask (Nunclone, 
Fisher Scientific UK, Loughborough, UK) at the desired concentration and 
incubated at 37°C with an atmosphere of 5% CO2, 95% humidity. Complete 
growth medium was renewed every other day. In all the experiments, 
decidualisation of T-HESCs was performed in DMEM/F12 by treatment with 
0.5 mM 8-Bromoadenosine 3′,5′-cyclic monophosphate (8-Br-cAMP) (Sigma-
Aldrich, Poole, UK) for five days (Gonzalez et al., 2011). Cells were washed 
twice with PBS before used. 
 2.2.5. Cell line subculture  
Once the cells had reached 70%-90% confluence, cells were subcultured. 
The growth culture medium was removed and discarded and cells briefly 
rinsed twice with 10 ml phosphate-buffered saline (PBS) (Sigma-Aldrich, 
Poole, UK). This step is necessary to remove any traces of serum that would 
suppress the activity of the trypsin. The cell monolayer was completely 
covered with 5 ml 0.25% Trypsin-EDTA solution (Sigma-Aldrich, Poole, UK) 
for 5-10 minutes. Cells were incubated at 37°C to facilitate cell detachment. 
Then the cells were gently aspirated and added to 5 ml of complete medium 
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and the mixture centrifuged (Sigma 3-18K, Scientific laboratory supplies, UK) 
at 200 x g for 5 minutes. The supernatant was removed and the cell pellet re-
suspended in 10 ml recommended complete growth medium. The cell 
suspension was diluted to the appropriate seeding volume to obtain the 
required seeding density and reseeded in fresh 75 cm² culture flasks. Cells 
were incubated at 37°C with an atmosphere of 5% CO2, 95% humidity. 
Complete growth medium was renewed every 2-3 days. 
2.2.6. Cryopreservation of cell lines 
Cryopreservation of cells by freezing maintains cell reserves. Cell lines were 
removed from the surface of flasks as described in (section: 2.2.5.). Cell 
pellets were resuspended in the recommended complete culture medium 
supplemented with 5% dimethyl sulphoxide (DMSO) (Sigma-Aldrich, Poole, 
UK). One ml of the suspension was transferred to labelled cryovials (Greiner 
Bio-one, Germany) and stored in a Nalgene cryo-freezing container 
(Nalgene, USA) at -80ºC with a steady decrease in temperature. After 24 
hours, all cryovials were transferred to liquid nitrogen until required.  
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2.2.7. Local expression of MMP-2, MMP-9, TIMP-2, RLX-2, endometrial 
epithelial markers and endometrial stromal cell markers by all cell lines using 
immunohistochemistry  
2.2.7.1. Agarose/formaldehyde for fixing cell lines for wax processing  
After 80% confluency all cell lines were detached from cell culture flasks as 
described in (section: 2.2.5.). After centrifugation the cell supernatants were 
discarded and cell pellets washed three times with PBS. Excess PBS was 
removed and cells were fixed with 10% PBS-buffered formalin for at least 2 
hours. Following centrifugation excess fixative was removed and 100 μl 
agarose/formaldehyde [2g Agarose (Sigma, A-9539), 90 ml distilled water 
and 10 ml 40% formaldehyde (BDH/Merk, 28421)] was carefully added to 
make sure the cell pellets was not disturbed. The agarose was allowed to set 
for 20 minutes, and then the agarose containing cells pellet was gently 
removed and placed in small plastic cassette for processing, and then this 
was wax-embedded as described in (section: 2.2.8.2).   
2.2.7.2. Principles of immunohistochemistry  
Immunohistochemistry, a procedure used to identify and localize antigens. 
Antibodies are used to detect the target antigens based on an antibody-
antigen reaction. The process involves locating proteins in cells and tissue 
specimens through the use of a visual marker. Immunohistochemistry 
methods are divided into two techniques, direct and indirect technique. The 
direct technique involves a single conjugated antibody reacting directly with 
the antigen in tissue sections. However, this technique is often seen as 
insensitive due to small signal amplification. The indirect method involves 
identification of antigen by a primary antibody with signal amplification 
provided by conjugated secondary antibodies that are raised against the 
primary antibody.  
Immunohistochemistry requires several steps. The first step is fixation of 
samples and is considered to be a critical step as any inadequate fixation will 
lead to unsuccessful or impaired Immunostaining. The substances used for 
immunohistochemistry fixation should maintain the morphology of the cell 
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and tissue and the target epitopes antigenicity. The most common fixative 
substance used is 10% neutral buffered formalin although other fixatives 
include paraformaldehyde, ethanol, methanol and Boulin solution. Fixation 
with formalin leads to masking of antigens by generating cross-linking 
methylene bridges between basic amino acids residues in tissue samples. 
Samples are often embedded in paraffin after fixation, sectioned using 
microtomes to approximately 5 microns, then mounted onto tissue-adhesive-
coated slides and left at room temperature overnight to remove excess water 
or dehydration. 
The second step is deparaffinization and rehydration of tissue sections. This 
is an essential step before Immunostaining as inadequate removal of paraffin 
can lead to poor staining of sections because antibodies cannot react or 
reach with the target epitope. Deparaffinization is performed using xylene 
and tissues rehydrated using serial dilutions (100%, 90%, 70% and 50%) of 
alcohol. Next, antigen sites are unmasked using various forms of antigen 
retrieval such as heating via microwave oven, pressure cooker, autoclave 
heating, steam heating or water bath heating in a citrate, Tris-buffered or 
EDTA solution. Enzymes (trypsin, pronase etc) are sometimes used to 
unmask antigens. Endogenous peroxidase in tissues/cells is then quenched 
using a hydrogen peroxide solution followed by protein blocking (usually BSA 
or serum) to avoid high background staining and a false positive result due to 
antibodies binding nonspecifically to proteins. 
Two types of antibodies are used to detect the antigen: the first type is 
polyclonal antibodies and the second type is monoclonal antibody. Polyclonal 
antibodies are heterogeneous antibodies that identify multiple epitope while 
monoclonal antibodies are homogeneous and specific for a single epitope. 
Consequently, monoclonal antibodies are more specific to the target 
epitopes than the polyclonal antibodies. Unconjugated primary antibodies 
react with the antigen of interest, whereas secondary antibodies reacted with 
the primary antibody. The secondary antibody is commonly conjugated to a 
linker molecule, such as biotin, which then recruits reporter molecules such 
as enzyme-conjugated avidin often termed the avidin-biotin complex (ABC).  
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There are several techniques used to identify the antigen of interest; the 
most common methods are the chromogenic and fluorescent techniques. 
The chromogenic technique identifies the target antigen by relying on 
labelled enzyme that binds to a substrate to form coloured end product that 
can be investigated with an ordinary light microscope. Horseradish 
peroxidase and alkaline phosphatase are the most common enzymes used, 
whilst DAB and Vector Red are common substrates. Moreover, the 
fluorescent technique that identifies the target antigen by the fluorophore that 
conjugated with primary or secondary antibody and it is analysed by 
fluorescent microscopy. Tissue and cells are often counterstained with 
haematoxylin to provide contract to the immunostain. Sections are then 
dehydration, in serial alcohol concentrations and dehydrated in xylene before 
being mounted to visualize the sections under the microscope. 
2.2.7.3. Immunohistochemical staining in wax-embedded endometrial 
epithelial cell lines and T-HESCs  
Immunohistochemistry was used to identify antigens in sections from the 
wax-embedded cell lines and tissues. The technique was optimized for each 
individual antigen of interest. All steps were performed at room temperature 
unless otherwise stated. Paraffin-embedded endometrial cell lines (5 µm) 
were de-waxed with xylene and rehydrated through ethanol (5 minutes each 
concentration) and then washed in distilled water twice for five minutes. 
Antigen retrieval was performed by immersing the slides into a heat resistant 
plastic staining dish containing citrate buffer (10 mmol/l) and microwaved on 
high power for 8 minutes. Endogenous peroxidase activity was quenched by 
incubating the slides in 3% hydrogen peroxide for 20 minutes after rinsing 
the slides briefly in PBS for five minutes. Slides were washed twice in Tris-
buffered saline and Tween 20 (TBS+ 0.1% tween-20) for five minutes and 
then samples were circled with a solvent resistant pen. Slides were blocked 
with 5% serum from the animal species of the primary antibody in PBS for 30 
minutes at room temperature. After washing, slides were incubated with 200 
µl of primary antibody diluted in (5% serum + PBS) as illustred in table 2.3, 
and incubated overnight at 4°C. Optimisation to find the best concentration of 
the antibody was performed using serial dilutions of the antibody (table 2.3) 
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to obtain minimal background staining. The negative control slides had the 
primary antibody omitted to control for non-specific binding of the detection 
system. Slides were removed from the refrigerator and washed twice for five 
minutes with PBS. After washing, 200 µl the secondary biotinylated antibody 
solution was added to each slide and incubated in humidified chamber for 30 
minutes at room temperature. The slides were then rinsed for 5 minutes in 
PBS twice. The ABC reagent was prepared as described in the 
manufacturer’s instructions and the solution was allowed to stand for 30 
minutes before use. 200 µl of ABC reagent was added to each slide then 
incubated for 30 minutes at room temperature, then slides were rinsed and 
incubated for 5 minutes twice in PBS. Antibody binding to target antigens of 
interest was visualised using DAB (3, 3’- diaminobenzidine) stain. The DAB 
reagent was mixed well and added to slides and incubated for 5 minutes at 
room temperature until the stain had developed to the required intensity. 
Slides were rinsed for 5 minutes in distilled water and placed in distilled 
water until counterstained with hematoxylin using a Shadon linear stainer. 
Finally, slides were mounted in Distyrene, a plasticizer, and xylene mounting 
(DPX) and covered with glass slide. 
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Table 2.3. Details of antibodies used in immunohistochemistry 
 
DF = Dilution factor                                                                                                                                                     
  
Antibody Clonality Clone DF Company Cat no 
Galectin 9 Rabbit polyclonal  1:250 Abcam, Cambridge, UK  ab69630 
Cytokeratin 7 Mouse monoclonal RCK105 1:1000 Abcam, Cambridge, UK  ab9021 
Vimentin Mouse monoclonal V9 1:1000 Abcam, Cambridge, UK  ab8069 
CD10 Mouse monoclonal 56C6 1:25 Abcam, Cambridge, UK  ab951 
Relaxin-2 
Rabbit monoclonal EPR14205 1:500 Abcam, Cambridge, UK  ab183505 
TIMP-2 Mouse monoclonal 3A4 1:25 Abcam, Cambridge, UK  ab1828 
MMP-2 Mouse monoclonal 4D3 1:25 Abcam, Cambridge, UK  ab2462 
MMP-9 Rabbit polyclonal  1:100 Abcam, Cambridge, UK  ab744277 
hCG Rabbit monoclonal EPHCGR2 1:100 Abcam, Cambridge, UK  Ab131170 
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2.2.8. Expression of MMP-2 and MMP-9 secreted from cell lines using 
gelatin zymography 
2.2.8.1. Basic principles of zymography 
Matrix metalloproteinases are important for protein catabolism. The family of 
MMPs contains at least 26 members that have been divided into subgroups 
based on the molecular structure and the substrate preference (Cohen et al., 
2006). MMPs are secreted as proenzymes (inactive form) (Snoek-van 
Beurden and Von den Hoff, 2005) and converted to an active form by 
cleavage. MMPs play a fundamental role in extracellular remodelling in a 
wide range of physiological processes such as implantation, embryogenesis 
and angiogenesis. On the other hand, they also contribute to the pathological 
process of many diseases such as inflammation, tumour metastasis, arthritis 
and a number of cardiovascular pathologies such as heart failure, ischemic 
heart disease and atherosclerosis. The activity of matrix metalloproteinases 
is controlled by tissue inhibitors of the matrix metalloproteinases that are a 
group of four antagonists that inhibit proteases by binding to the catalytic site 
(Snoek-van Beurden and Von den Hoff, 2005).  
MMPs can be identified by a number of techniques, however, the most 
common used is zymography. This assay detects MMPs based on their 
molecular weight and on the degradation of their preferred substrate such as 
gelatin, albumin, casein, etc. Gelatin zymography is the technique mainly 
used for the identification of MMP-2, MMP-9 (often termed gelatinases) in 
cells and conditioned medium samples (Snoek-van Beurden and Von den 
Hoff, 2005).  
Gelatin zymography is an electrophoretic method, it is a simple, powerful, 
quantifiable and functional technique to identify the latent and activated 
forms of MMPs. The gelatin zymography method depends on sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and a 
gelatin substrate that is copolymerised within a polyacrylamide matrix. 
Samples are prepared using the standard SDS-PAGE buffer in the absence 
of heating or reducing agents such as dithiothreitol (DDT) or 
mercaptoethanol. When the electrophoresis is completed, the SDS is 
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removed from the zymogram gel. The movement of the molecule through the 
gel rely on many factors including the size, the shape, the net charge of the 
molecule, the field strength, the ionic strength and the medium properties 
through which the molecules migrate such as pore size and viscosity (Snoek-
van Beurden and Von den Hoff, 2005, Claudia M. d'Avila-Levy, 2012). After 
electrophoresis the gel was incubated in non-ionic detergent (Triton X-100) 
to renature the peptidases through removing the denaturing SDS, 
subsequently the gel was incubated in an appropriate activation buffer which 
reactivates enzyme activity allowing the MMPs to cleave the gelatin in the 
gel. After the gel is stained areas of enzyme activity are distinguished,  these 
appear as clear bands on a blue stained background due to Coomassie 
staining (Claudia M. d'Avila-Levy, 2012). 
2.2.8.2. Gelatin zymography 
Gelatin Zymography gel was made with the use of gels (10% polyacrylamide 
containing 0.1% gelatin. Before starting the procedure, all solutions were 
prepared as mentioned in (Table 2.4). All materials were purchased from 
Sigma, Poole, UK unless otherwise stated.   
 
 
Table 2.4. Preparation of gelatin zymography solutions  
 
Solution Volume 
2X Sample loading buffer 
0.5 M Tris-HCL, pH 6.8  2.5 ml 
10% SDS 4.0 ml 
Glycerol 2.0 ml 
0.1% Bromophenol Blue 0.5 ml 
Distilled water To 10 ml 
10% Ammonium persulfate solution (Mw=228.2 gm) 
ammonium persulfate 500mg 
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Distilled water 5 ml 
1 % Gelatine substrate 
Gelatine 1g 
Distilled water 100 ml 
10 % SDS solution 
SDS 10 g 
Distilled water 100ml 
Coomassie blue stain stock 
Coomassie blue stain R-250 2.0 g 
Distilled water 200 ml 
Coomassie blue stain 
Coomassie blue stain stock 62.5 ml 
Methanol 250 ml 
Acetic acid 50 ml 
Distilled water 200 ml 
Destain Solution 
Methanol (50%) 500 ml 
Acetic acid (10%) 100 ml 
Distilled water (40%) 400 ml 
1.5 M Tris base pH 8.8 
Tris base 23.64 g 
Distilled water 100 ml 
0.5 M Tris base pH 6.8 
Tris-HCl 7.88 g 
Distilled water 100 ml 
1X Gel running buffer (pH=8.3) 
Tris base 2.9 g 
Glycine 14.4 g 
SDS 1.0 g 
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Distilled water Up to 1 L 
1X Renaturing buffer 
Triton X-100 12.5 ml 
Distilled water 500 ml 
10X Developing Buffer (pH=7.5) 
0.5 M Tris 60.57 g 
2M NaCl (Mw=58.44) 116.88 g 
50 mM CaCl2.2H2O (Mw=147.01) 7.35 g 
1% Triton X-100 10 ml 
Distilled water Up to 1L 
 
 
Preparation of separating (resolving) gel: 
The separating gel was prepared first with a final 10% acrylamide 
concentration according to order as mentioned in (table 2.5) for detecting 
MMP-2 and MMP-9.  
 
Table 2.5. Separation gel 
 
Resolving Gel Volume  
40% Acrylamide  5 ml 
Resolving gel buffer 1.5 M Tris (pH=8.8) 5 ml 
Distilled water  7.66 ml 
1% Gelatin substrate  2 ml 
10% SDS 200 μl 
10% Ammonium persulfate  100 μl 
TEMED 20 μl  
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The SDS was used without delay after addition of 
Tetramethylethylenediamine (TEMED) as the polymerization process is 
relatively quick. A pipette was used to add the resolving gel solution into 
sandwich plates slowly. Isopropanol was added to the top of the gel to 
remove bubbles. The resolving gel was allowed to polymerise for 
approximately 30 minutes. Once polymerised the alcohol was decanted, and 
the gel was rinsed with distilled water to remove any remaining alcohol. Any 
remaining distilled water on top of the gel was drained from the unit with a 
small thin strip blotting paper.  
While the resolving gel was polymerised, the stacking gel was prepared 
accordingly as mentioned in (table 2.6). 
 
Table 2.6. Stacking gel 
 
Stacking gel  Volume 
40% Acrylamide  720 μl 
Stacking gel buffer 1.5 M Tris (pH=6.8) 2.4 ml 
Distilled water  6.28 ml 
10% SDS 100 μl 
10% Ammonium persulfate  100 μl 
TEMED 10 μl 
 
The stacking gel was mixed and poured onto the separating gel. The well 
comb (10 combs) was inserted and the gel was allowed to polymerise for 
another 30 minutes. The protein sample (cell supernatant or cell lysate) was 
prepared using the 2 x zymogram loading buffer (20 μl sample + 20 μl 
loading dye) and incubated at room temperature for 30 to 60 minutes, 
samples were not boiled and no reducing agents were used.  
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Once the stacking gel had polymerised, the well combs were removed, then 
the gels inserted into the electrophoresis apparatus. The apparatus was filled 
with running buffer (both the upper and lower container). Samples were 
loaded with the equivalent amount into the wells using fine tipped pipette 
tips. The molecular weight marker was loaded into the first lane and a 
positive control in the last lane and the electrophoresis run at 125 V, for 
approximately 70 minutes until the blue dye had run off the end of the gel. 
Once the electrophoresis was completed the plates were removed from the 
apparatus and opened carefully to remove the gel, which was then inserted 
into transparent plastic box and washed with Renaturing buffer on a shaker 
at room temperature for 1 hour. This was repeated four times with fresh 
buffer each time (15 minutes for each wash). The Renaturing buffer was 
decanted and replaced with 1X developing buffer and incubated for 24 hours 
at 37°C. 
After 24 hours, the developing buffer was removed and the gel was stained 
with coomassie stain and placed on the rotator for 3 hours at room 
temperature. The gel then was destained with destaining solution for 1 hour 
to reveal transparent bands representing an area of protease activity against 
a dark blue background.    
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2.2.9. Expression of MMP-2, MMP-9 and TIMP-2 secreted from T-HESCs 
and JAR cell line treated with various concentrations of RLX-2   
At 80% confluency in a 75 cm² flask, T-HESCs and JAR cells were 
trypsinised, centrifuged and seeded at about (2 x 105 cells/ml and 4x 105 
cells/ml) respectively into 6 well plate (each contained 1 ml) and allowed to 
adhere overnight. Cells were treated with recombinant RLX-2  human (1 to 
100 ng) (Sigma-Aldrich, Poole, UK), or medium alone as a control in 
triplicate. Cell culture conditioned medium (section: 2.2.3.4 and 2.2.3.5) was 
collected at 24, 48 and 72 hours, centrifuged at 10,000 x g for 10 minutes 
and stored at -80°C for further analysis by ELISA. 
2.2.10. Expression of MMP-2 and MMP-9 secreted from T-HESCs and JAR 
cell line treated with various concentrations of TIMP-2 and Batimastat.  
At 80% confluency in a 75 cm² flask, T-HESCs and JAR cells were 
trypsinised, centrifuged and seeded at about (2 x 105 cells/ml and 4x 105 
cells/ml) respectively into 6 well plate (each contained 1 ml) and allowed to 
adhere overnight. Cells were treated with increasing dose of either 
recombinant TIMP-2 human, broad-spectrum matrix metalloproteases 
inhibitor (Batimastat) (Sigma-Aldrich, Poole, UK) (1 to 100 ng) or medium 
alone as a control in triplicate. Cell culture conditioned medium (section: 
2.2.3.4 and 2.2.3.5) was collected at 24, 48 and 72 hours, centrifuged at 
10,000 x g for 10 minutes and stored at -80°C for further analysis by ELISA. 
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2.2.11. Preparation of tissue engineered 3D uterine endometrial models 
To produce a tissue engineered 3D uterine endometrial model, the following 
components listed in (Table 2.6.) were mixed on ice in 50 ml conical tubes. 
All materials were purchased from Sigma, Poole, UK unless otherwise 
stated.   
 
Table 2.7. Reagents for three gels 
 
 
 
 
 
 
 
 
 
 
 
 
The mixture was acidic (determined by the colour-yellow), and so a few 
drops of 1N NaOH were added to neutralise it and the tube was inverted to 
mix (the colour then became light pink). T-HESCs were added to the mixture, 
with each culture made to contain 1 x 106 T-HESCs. The mixture was 
inverted gently several times to mix the solution. Seven hundred µl of the cell 
mixture was added into each cell culture transwell insert (Nunc serving the 
life science, Denmark). The inserts were then transferred gently to 6-well cell 
culture plates (Greiner Bio-one, Germany) and incubated at 37°C, 5% CO2 in 
a humidified atmosphere for two hours until the mixture was solidified. The 
gels were then submerged with endometrial epithelium growth medium from 
outside and inside the inserts and incubated at 37°C, 5% CO2 in a humidified 
atmosphere. After 24 hours, the T-HESCs growth medium was aspirated 
10 gels  Volume (µl) 
10x DMEM  
(13.48g of DMEM powder in 100ml distilled water) 
940 
Reconstitution Buffer 
(2.2g sodium bicarbonate, 5.2g HEPES, 0.24g NaOH) 
940 
Fetal calf serum 780 
L-Glutamine  96 
5 mg/ml rat-tail collagen (Trevigen, Gaithersburg, US) 6060 
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from the inserts, and endometrial epithelial cells were seeded over the gels 
(1 x 106 cells diluted in 400 µl medium for each insert). Sterile forceps were 
used to place the inserts on top of the three metal stands with 0.3 cm² size 
and 0.15 cm height stood inside each well. The endometrial epithelium 
growth medium was gently added to each well outside the inserts, and the 
gel surfaces were kept dry as an air-to-liquid interface for cell differentiation. 
The cell culture plate was transferred carefully to an incubator and incubated 
at 37°C, 5% CO2 in a humidified atmosphere. The medium was replaced 
every other day for two weeks. 
 
 
Figure 2.1. Procedure outlines of 3D endometrial models with monolayer epithelial 
 
 
2.2.12. Preparation of 3D models for histology 
2.2.12.1. Chemical fixation with 10% formalin, processing, embedding and 
sectioning samples. 
3D models were fixed with 10% formalin overnight. Each model was then 
placed into a processing/embedding cassette and further soaked in buffered 
10% formalin to preserve cells and tissues from degradation and to maintain 
cellular and subcellular structure. Tissues were processed through alcohol 
gradients to xylene and paraffin wax using a Shandon Citadel 2000 tissue 
processing machine (GMI, USA). Each biopsy model was cut into two pieces 
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from the middle and placed in the embedding moulds (the cut edges were 
faced down). External embedding by wax was achieved using the 
Histoncentre 2 external embedding unit (Thermo Shandon, UK). The tissue 
was then covered with the cassette and kept for 15-20 minutes to form 
hardened blocks. Paraffin wax blocks containing tissue were sectioned using 
a microtome machine (Leica RM 2235, Germany) at 5 μm thickness. The 
tissue sections were transferred to a water bath and mounted on slides for 
staining. 
2.2.12.1. Staining 
Haematoxylin and Eosin (H&E) staining was performed automatically by a 
Shandon Linistain GLX Linear Stainer machine (Thermo Scientific, UK). 
Slides were mounted using DPX mounting media (Raymond A Lamb, East 
Sussex, UK) and cover-slipped ready for histology examination. Slides were 
examined under a light microscope (Olympus BX51, Germany) and sections 
imaged using Olympus imaging solution GmbH Camera (Olympus, 
Germany).  
2.2.13. Tissue engineered 3D models with monolayer epithelium 
To improve the model and make it resemble the endometrium in vivo, the 
epithelium layer needs to be a monolayer. To achieve this, after the epithelial 
cells were seeded, the model was incubated for two hours at 37°C, 5% CO2 
in a humidified atmosphere to enhance epithelium attachment. Gently, 1.5 ml 
of fibroblast growth medium was added to the wells outside the inserts and 
incubated for 24 hours. Then the medium was replaced with endometrial 
epithelium growth medium inside and outside the inserts and incubated for a 
further 2-3 days until the cells became confluent (Csibra et al., 2000). The 
epithelial layer of the model was kept covered with endometrial epithelium 
growth medium instead of airlifting in order to control the differentiation of the 
cells. The six-well plate was incubated at 37°C, 5% CO2 in a humidified 
atmosphere for 5-7 days, the medium being replaced every 2-3 days. After 
one weeks, the models were ready for histology study.  
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2.2.14. Attachment Assay of Human Choriocarcinoma JAR spheroids to the 
endometrial epithelium monolayer cell lines (RL95-2, HEC-1-A and Ishikawa) 
and T-HESCs. 
2.2.14.1. Optimisation of JAR spheroids 
In order to mimic trophoblasts, spheroids from JAR trophoblast cells were 
produced on the basis of a method defined by Korff et al,. (Korff et al., 2004) 
Initial experiments were performed to optimise the kinetics of JAR spheroids 
growth. JAR monolayers were trypsinization washed with PBS and harvested 
as mentioned in (section: 2.2.5). The cells pellet was suspended with 
recommended growth media and cells counted and resuspended at 1 x 106 
cells/ml. Increasing JAR cell concentrations per 100 µl RPMI-1640 media 
(100, 250, 500, 1000, 5000 and 10,000 cells) were added to wells of a non 
adherent U-bottom 96 well plates (Greiner Bio-one, Germany, catalogue No.: 
650970) and centrifuged in a swinging bucket rotator at 300 x g for 3 
minutes. Plates were then transferred to an incubator and cultured at 37°C, 
5% CO2 in a humidified atmosphere to determine the ideal JAR spheroids 
size, which is from 150 µm to 250 µm. Spheroids were measured every day 
for nine days using the 4X objective. Media were changed every other day, 
the supernatant collected every other day and stored at -80C° for further 
ELISA analysis. 
2.2.14.2. Measurement of βhCG secreted by JAR spheroids  
JAR spheroids of two different sizes from 150-250 µm and from 1500 - 2000 
µm were cultured for 8 days and the conditioned medium from these were 
collected on days 2, 4, 6 and 8 and stored at -80°C for further βhCG ELISA 
analysis, refer to (section: 2.1.4.) 
2.2.15. Attachment of JAR spheroids to endometrial cell lines 
The RL95-2 cell line was used alongside HEC-1-A, Ishikawa and T-HESCs 
cell lines to establish an in vitro attachment assay. However, after the 
establishment of the attachment assay, only RL95-2, Ishikawa cell line and 
endometrial stromal cell line were used for further experiments. All cell lines 
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used were grown until 80% confluent in T75 flasks. Subsequently, cells were 
harvested using trypsin/EDTA as outlined in (section: 2.2.5). All cell lines 
were cultured in a 6 well plate and incubated until confluent. Confluent 
monolayers of Ishikawa, HEC-1-A, RL95-2 and T-HESCs were co-cultured 
with 20 JAR spheroids that were gently picked and delivered to each well 
using a wide pipette tip. Each cell line was co-cultured in the recommended 
media. Tissue culture plates were transferred to the tissue culture incubator 
at 37°C, 5% CO2 in a humidified atmosphere. Adhesion of spheroids was 
measured at (1, 6, 24 and 48 hours). The non-adherent spheroids were 
removed from the well by washing gently twice using Dulbecco’s phosphate-
buffered saline with Ca2+ and Mg2+ (Sigma-Aldrich, Poole, UK). Each wash 
lasted for 5 minutes and the well were completely filled with Dulbecco’s 
phosphate-buffered saline with Ca2+ and Mg2+ and covered with adhesive 
tape to dislodge the loosely adherent and non-adherent spheroids. The final 
number of JAR spheroids was counted and the results expressed as the 
percentage of spheroids attached to the monolayer from the initial total 
number of spheroids added.  
2.2.16. The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 treatment on JAR 
spheroids co-cultured with endometrial monolayers.  
In a 6-well plate cell monolayers grew in complete growth media (section: 
2.2.3), JAR spheroids were co-cultured and treated at the same time with 
RLX-2 (10 ng/ml), MMP-2 (10 ng/ml), MMP-9 (10 ng/ml) and TIMP-2 (10 
ng/ml) all obtained from (Sigma-Aldrich, Poole, UK). Untreated cells were 
used as controls. Twenty JAR spheroids were added onto the top of the 
different monolayer cell lines (Ishikawa, RL95-2 and T-HESCs) using a 
sterile Pasteur pipette. All JAR spheroids were between 200 and 300 µm. 
After each co-culture time (2, 6 and 24 hours) the wells were washed twice 
using Dulbecco’s phosphate-buffered saline with Ca²+ and Mg²+ (Sigma-
Aldrich, Poole, UK) to remove the non-adherent JAR spheroids and the per 
cent adherent spheroids calculated as mentioned before (section: 2.2.15). 
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2.2.17. The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 treatment on JAR 
spheroids co-cultured with 3D endometrial model  
To study the attachment of JAR spheroids to the 3D endometrial model, the 
3D endometrial culture system was set up in 4-well plate (Nunc, Roskilde, 
Denmark), and then cultured for 4-5 days before starting the assay. Twenty 
JAR spheroids were transferred onto the top of each 3D model using a 
Pasteur pipette. For each four wells a different treatment was applied 
including control (without treatment), RLX-2 (10 ng/ml), MMP-2 (10 ng/ml), 
MMP-9 (10 ng/ml) and TIMP-2 (10 ng/ml). After each co-culture time (6 and 
24 hours), models were washed twice using Ca2+ and Mg2+ Dulbecco’s 
phosphate-buffered saline to remove the loosely adherent JAR spheroids as 
described in (section: 2.2.15). The final number of JAR spheroids was 
calculated and the results were expressed as the percentage of spheroids 
attached to the initial total number of spheroids added.  
2.2.18. Invasion study using 3D matrix invasion assay and JAR spheroids 
under the effect of of RLX-2, MMP-2, MMP-9 and TIMP-2.  
An invasion assay kit (Trevigen, Gaithersburg, US) was used to study the 
invasion of JAR spheroids in the 3D matrix. JAR spheroids were produced as 
in (section: 2.2.15.1). Breast cancer MDA-MB-231 cells were used as a 
positive control. All cells were cultured, trypsinised, harvested and counted 
as previously described. A single cell suspension was prepared with 1 x 
spheroid formation extracellular matrix (basement membrane extract (BME)). 
The 10 x spheroid formation ECM was thawed overnight at 4°C, diluted with 
the complete growth media at 4°C and mixed by pipetting up and down using 
a sterile pipette. Cells were re-suspended in 1 x spheroid formation ECM and 
50 µl of the cell suspension added to each well of the 96 well plate at 
approximately 100-150 cells per well. The 96 well plate was centrifuged at 
200 xg for 3 minutes in a swinging bucket rotator at room temperature. The 
plate was incubated at 37°C in a tissue culture incubator for 72 hours to 
promote JAR spheroids formation. 
After 72 hours, the invasion matrix was thawed at 4 C° overnight and 
centrifuged at 300 x g for 5 minutes at 4°C to avoid bubbles and the 96 well 
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spheroids formation plate was placed on ice for 15 minutes to cool the wells. 
Working on ice, 50 µl of invasion matrix was added to each well. The 96 well 
plate was centrifuged at 300 x g for 5 minutes at 4C° in a swinging bucket 
rotator to avoid bubbles and make the spheroids within the invasion matrix 
locate in the middle of the well. The plate was then incubated at 37°C for 1 
hour to promote the invasion matrix to form a gel. After 1 hour, 100 µl of 
warm (37°C) cell culture media was added to each well. Treatments 
included: control (no treatment), RLX-2 (10 ng/ml), MMP-2 (10 ng/ml), MMP-
9 (10 ng/ml) and TIMP-2 (10 ng/ml) performed in quadruplicate. Then the 96 
well plate was incubated at 37°C in a tissue culture incubator for 5 days. 
Spheroids in each well were photographed every 24 hours using the 4x 
objective and images were analysed using Image J software (NIH, USA). 
2.2.19. Spheroid expansion assay under the effect of RLX-2, MMP-2, MMP-
9, TIMP-2 and Batimastat.  
T-HESCs was plated in 12 well plates at a density of 1 x 105 cells/ml 
complete growth media DMEM/F12 (section: 2.2.3.5). When the cells 
reached 80% confluent, JAR spheroids were added to the T-HESCs 
monolayer in 20 µl culture media, one spheroid per well. Treatments applied 
were: control (without treatment), RLX-2 (10 ng), TIMP-2 (10 ng), MMP-2 (10 
ng), MMP-9 (10 ng) and Batimastat (10 ng). The 12 well plates were 
incubated at 37°C in a tissue culture incubator for 4 days. Using a digital 
camera, spheroids in each well were photographed every 24 hours with a 4x 
objective, and this was counted as time point d0, d2, d3 and d4 respectively. 
Finally, all spheroid areas were measured using Image J software (NIH, 
USA). Expansion of individual spheroid over the 4 time points was 
calculated, each time relative to the previous time point. Each treatment was 
carried out on triplicate wells and each experiment was repeated 3 times.  
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 Expression of MMP-2, MMP-9, TIMP-2 and 
RLX-2 in the serum of pregnant women with and 
without a history of recurrent miscarriage 
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3.1. Introduction 
Recurrent miscarriage is defined as three or more repeated spontaneous 
miscarriage and occurs with a rate of 1% of all women (Mtiraoui et al., 2004).  
However, recurrent miscarriage is a heterogeneous condition that may be as 
result of multifactorial fundamental causes. In approximately 50% of cases 
the aetiology is unidentified (Prakash et al., 2005, Laird et al., 2003, Li, 
1998), although many recurrent miscarriage cases are related to impaired 
uterine receptivity (Dekel et al., 2010).  
Implantation is the most critical process during the establishment of 
conception. The study of the molecular basis of embryo implantation has 
widely expanded and has not only been explored in animals but also now in 
humans. Human implantation starts with the invasion of the epithelium of the 
uterus and underlying stroma by embryonic trophoblast cells. This process is 
complicated and involves a series of molecular and cellular interactions 
(Burrows et al., 1996). Failure of implantation may cause many clinical 
pathological problems such as early miscarriage, preeclampsia, intrauterine 
growth restriction (IUGR), stillbirth and preterm birth (King and Loke, 1994). 
A number of serum molecules are altered in some women with recurrent 
miscarriage, although no single one of these markers can reliably predict 
recurrent miscarriage (Anumba et al., 2010). Recently, in a longitudinal 
prospective case-controlled study Anumba and colleagues demonstrated 
that women with a history of recurrent miscarriage have lower serum human 
RLX-2 and higher serum TIMP-2 levels, suggesting roles for these molecules 
in implantation and angiogenesis. These authors suggested that dysfunction 
of RLX-2 and TIMP-2 at the implantation stage may contribute to repeat 
pregnancy loss, attributable in part, to inhibition of endometrial and placental 
angiogenesis (Anumba et al., 2009, Anumba et al., 2010). 
To explore these observations further, a prospective study of four cohorts of 
pregnant women was planned: normal pregnant women with no history of 
recurrent miscarriage, pregnant women with a viable pregnancy but who 
have a history of recurrent miscarriage, and women being seen in early 
pregnancy with a history of threatened miscarriage and their controls. The 
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idea was to evaluate whether serum RLX-2, MMP-2, MMP-9 and TIMP -2 
levels have the predictive potential for the following adverse pregnancy 
outcomes: miscarriage, foetal growth restriction or premature delivery 
(Anumba et al., 2009, Anumba et al., 2010).  
 
Hypothesis 
Trophoblast-endometrial interactions are affected by altered expression of 
MMP-2, TIMP-2 and human RLX-2 during early implantation. 
Objectives 
To determine whether RLX-2, MMP-2 and TIMP-2 levels could be clinically 
useful markers of impending pregnancy loss during the current pregnancy. 
Furthermore, to identify any associations between the serum levels of RLX-2, 
MMP-2 and TIMP-2 with adverse pregnancy outcomes including miscarriage, 
spontaneous preterm birth, fetal growth restriction, placental abruption and 
preeclampsia. 
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3.2. Materials Methods  
3.2.1. Subjects and samples 
Frozen aliquots of serum from 22 pregnant women between 10-13 weeks 
gestation (first trimester) with a history of recurrent miscarriage, and a control 
cohort of 23 gastitional age-matched pregnant women between 10-13 weeks 
gestation without history of recurrent miscarriage. The third group comprised 
13 women in early pregnancy between 6-10 weeks gestation with threatened 
miscarriage (who presented with vaginal bleeding and a viable pregnancy 
confirmed on ultrasound) from an Early Pregnancy Assessment Unit. The 
fourth group comprised a healthy control group of 9 pregnant women with no 
vaginal bleeding between 6-10 weeks gestation, recruited from an Early 
Pregnancy Assessment Unit, Royal Hallamshire Hospital, University of 
Sheffield, UK. The samples were stored at -80°C and assayed for MMP-2, 
MMP-9, TIMP-2, MMP-2/TIMP-2 and RLX-2 using ELISA.  
3.2.2. Enzyme-linked ImmunoSorbant Assay (ELISA) 
ELISA kits were used to identify the serum levels of MMP-2, MMP-9, TIMP-2, 
MMP-2/TIMP-2 and RLX-2 provided by (R&D Systems, Minneapolis, USA). 
The procedures were done according to the manufacturer instructions. (For 
more details refer to (section: 2.1.4.1). 
3.2.3. Statistical analysis 
The statistical analysis was performed using Graph Pad Prism version 6.0. 
Both parametric and non-parametric tests were employed as appropriate to 
compare means or medians between the groups. The Student t-test or the 
Mann-Whitney U test were used to compare the serum levels of RLX-2, 
MMP-2, MMP-9 and TIMP-2 levels. P<0.05 were considered to be 
significantly different. 
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3.2.4. Outcome measure 
Serum concentrations of RLX-2, MMP-2, MMP-9, TIMP-2 and TIMP-2/MMP-
2 complex, were determined and their individual associations with the 
following clinical outcomes tested: spontaneous miscarriage, premature 
delivery (before 37 weeks gestation), stillbirth, placental abruption and small 
for gestational age (fetal estimated birth weight less than the 10th customized 
centile). 
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3.3. Results 
3.3.1. Clinical results 
3.3.1.1. Recurrent miscarriage group and their controls 
Table 3.1 summarises the general clinical details of the recurrent miscarriage 
group and their healthy controls and the outcomes of their pregnancies. 
There was no significant difference in the rate of miscarriage, preterm birth 
and pre-labour spontaneous rupture of foetal membrane. However, there 
was a significant increase in the rate of caesarean section and the rate of 
post-delivery blood loss in the recurrent miscarriage group. 
 
Table 3.1. Subjects (recurrent miscarriage and controls) clinical details and 
pregnancy outcomes 
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3.3.1.2. Threatened miscarriage group and their controls 
Table 3.2 summarises the general clinical details of the threatened 
miscarriage group and their healthy controls and the outcomes of their 
pregnancies. There was no significant difference in the rate of miscarriage, 
preterm birth, pre-labour spontaneous rupture of fetal membrane, rate of 
caesarean section and post-delivery blood loss between the both groups. 
 
Table 3.2. Subjects (threatened miscarriage and controls) clinical details and 
pregnancy outcomes 
 
 
 
 
 
  
93 
 
3.3.2. Laboratory analysis  
3.3.2.1. Serum expression of TIMP-2 
TIMP-2 levels in serum from the recurrent miscarriage group were higher 
than those in normal healthy pregnant women, and the data was statistically 
significant (p value < 0.0001) as illustrated in figure 3.1. 
 
 
 
Figure 3.1. Comparison of serum TIMP-2 expression in pregnant women with history 
of recurrent miscarriage and healthy pregnant controls. 
(**** p< 0.0001)  
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There was no significant difference in TIMP-2 serum levels between women 
with threatened miscarriage and normal healthy pregnant group with the 
same matching gestational age (p value = 0.3109) as illustrated in figure 3.2. 
 
 
 
Figure 3.2. Comparison of serum expression of TIMP-2 in threatened miscarriage 
group and healthy pregnant controls  
(p value = 0.3109) 
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3.3.2.2. Serum expression of MMP-2 
There was a significant decrease in the expression of MMP-2 in the serum 
samples of pregnant women with a history of recurrent miscarriage group 
compared to their healthy controls matched for gestational age (p value =  
0.0009) as illustrated in figure 3.3. 
 
 
 
Figure 3.3. Comparison of serum expression of MMP-2 in pregnant women with 
history of recurrent miscarriage and healthy pregnant controls  
(p value = 0.0009) 
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However, there was no significant difference in MMP-2 levels between the 
threatened miscarriage group and the normal healthy pregnant group 
matched for gestational age (p value = 0.9113) as illustrated in figure 3.4. 
 
 
 
 
Figure 3.4. Comparison of serum expression of MMP-2 in threatened miscarriage 
group and healthy pregnant controls  
(p value = 0.9113) 
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3.3.2.3. Serum expression of MMP-9 
The expression of MMP-9 in the serum samples showed no significant 
difference between recurrent miscarriage group and their healthy controls 
with the same matching gestational age (p value = 0.0608) as illustrated 
figure 3.5.   
  
 
 
 
Figure 3.5. Comparison of serum expression of MMP-9 in pregnant women with 
history of recurrent miscarriage and healthy pregnant controls  
(p value = 0.0608)  
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The expression of MMP-9 in the serum samples shows no significant 
difference between threatened miscarriage group and their normal healthy 
pregnant group with the same matching gestational age (p value = 0.3109) 
as illustrated in figure 3.6.   
 
 
 
Figure 3.6. Comparison of serum expression of MMP-9 in threatened miscarriage 
group and healthy pregnant controls  
(p value = 0.9113)   
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3.3.2.4. Serum expression of MMP-2/TIMP-2 Complex 
The serum levels of MMP-2/TIMP-2 Complex from the recurrent miscarriage 
group were significantly lower than those in normal healthy pregnant women 
(p value = 0.0014) as illustrated in figure 3.7.   
 
 
 
Figure 3.7. Comparison of serum expression of TIMP-2/MMP-2 Complex in pregnant 
women with history of recurrent miscarriage and healthy pregnant controls  
(p value = 0.0014) 
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There was no significant difference in the MMP-2/TIMP-2 complex serum 
levels between threatened miscarriage group and their normal healthy 
pregnant group with the same matching gestational age (p value = 0.3197) 
as illustrated in figure 3.8.   
 
 
 
Figure 3.8. Comparison of serum expression of TIMP-2/MMP-2 Complex in threatened 
miscarriage group and healthy pregnant controls  
(p value = 0.3197) 
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3.3.2.5. Serum expression of RLX-2  
Serum RLX-2 levels from the recurrent miscarriage group were significantly 
lower than those in normal healthy pregnant women (p value = 0.0190) as 
illustrated in figure 3.9. 
 
 
Figure 3.9. Comparison of serum expression of RLX-2 in pregnant women with history 
of recurrent miscarriage and healthy pregnant controls  
(p value = 0.0190) 
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There is no significant difference in the RLX-2 serum levels between the 
threatened miscarriage group and their normal healthy pregnant group with 
the same matching gestational age (p value = 0.9508) as illustrated in figure 
3.10. 
 
 
Figure 3.10. Comparison of serum expression of RLX-2 in threatened miscarriage 
group and healthy pregnant controls  
(p value = 0.9508) 
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3.3.2.6. The expression trends of MMP-2, MMP-9, TIMP-2, MMP-2/TIMP-2 
complex and RLX-2 in the healthy control groups at 6-10 weeks and 10-14 
weeks. 
The figures in 3.11 show the trend of the different proteins measured for the 
healthy pregnant women with no history of recurrent or threatened 
miscarriage at two different gestational age time points (at 6-10 weeks and at 
10-14 weeks of gestation). It is clear that the expression levels of all the 
proteins rise with in serum with increasing gestational age attaining statistical 
significance for MMP-2 (A), TIMP-2 (C) and RLX-2 (E) (p value = 0.03, 0.001 
and 0.02 respectively). However, the expression of MMP-9 decreased slowly 
toward 10-14 weeks of gestation but this did not attain statistical significance 
(p value = 0.0702). 
 
Figure 3.11. The expression of MMP-2, MMP-9, TIMP-2, MMP-2/TIMP-2 complex and 
RLX-2 in the healthy control groups at 6-10 weeks and 10-14 weeks 
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3.4. Discussion 
The clinical data results of this study indicate that there was no significant 
difference in the rate of miscarriage, preterm birth and pre-labour 
spontaneous rupture of foetal membrane between the recurrent miscarriage 
group and their healthy controls, while there was a significant increase in the 
rate of caesarean section and the rate of post-delivery blood loss in the 
recurrent miscarriage group compared to their controls. Despite the limited 
sample sizes to draw a firm conclusion, there was no significant difference in 
the rate of miscarriage, preterm birth, pre-labour spontaneous rupture of 
foetal membrane, rate of caesarean section and post-delivery blood loss 
between the threatened miscarriage group and their healthy controls.  
Consistent with data in a previous study, Jivraj and colleagues found that 
women with recurrent miscarriage had a high risk of caesarean section. They 
also found that women with recurrent miscarriage had a high risk of small for 
gestational age, preterm delivery and perinatal mortality (Jivraj et al., 2001).  
Wijesiriwardana et al, in a large epidemiology study about the pregnancy 
outcomes in women with threatened miscarriage, found that women with 
threatened miscarriage had a high risk of caesarean section, preterm 
delivery and antepartum hemorrhage (Wijesiriwardana et al., 2006), while 
our study did not determine any difference in the pregnancy outcomes. 
Moreover, Ahmed, S.R. and his colleagues also suggested that patients 
having threatened miscarriage had a significantly increased risk of complete 
miscarriage, preterm labour and low birth weight infants. Other pregnancy 
adverse outcomes such as preeclampsia, IUGR, PROM and caesarean 
section rates were relatively increased (Ahmed et al., 2012). Results from 
another study confirm findings from other authors, that threatened 
miscarriage is not only associated with miscarriage but also with an 
increased risk of pregnancy outcomes such as preterm labour, placental 
abruption, PPROM and IUGR (Dadkhah et al., 2010). However, the number 
of women in our study is too small for any recognized statistical analysis or 
conclusions to be made, and limited the ability of the study to detect any 
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association between serum marker levels and adverse clinical outcomes 
such as: miscarriage, stillbirth, premature delivery and placental abruption. 
Reproductive tract tissue is the primary site for relaxin hormone secretion 
(Goldsmith and Weiss, 2009, Parry and Vodstrcil, 2007). The relaxin plays a 
role in stimulating placental growth factor and vascular endothelial growth 
factor, these factors promote neo-vascularisation to increase blood flow to 
the endometrium, placenta and other reproductive tract tissue (Unemori et 
al., 1999). Thus, a dysregulation in relaxin activity is likely to contribute to the 
pathogenesis of implantation. 
In this study two groups were compared, the first group was pregnant women 
with viable pregnancy and history of recurrent miscarriage compared to their 
healthy pregnant women controls, and the second group was pregnant 
women with a viable pregnancy presenting with threatened miscarriage 
compared to healthy pregnant controls, both groups being matched for age 
and gestation. This study shows that there is a significant increase in the 
serum expression of TIMP-2 in pregnant women with history of recurrent 
miscarriage compared to their healthy controls and low expression of MMP-2 
and MMP-2/TIMP-2 complex and RLX-2 hormone. In contrast, there were no 
significant differences in the expression of TIMP-2, MMP-2, MMP-2/TIMP-2 
complex and RLX-2 between the threatened miscarriage group and their 
healthy controls, while there were no significant differences in the serum 
expression of MMP-9 in both groups. The results suggest that the matrix 
metalloproteinases and their inhibitors and RLX-2  hormones may play a key 
role in early pregnancy development, and that dysregulation may result in 
implantation failure by affecting remodeling of the endometrial matrix. It is 
plausible that altered angiogenesis may influence the occurrence of adverse 
pregnancy outcomes.   
The findings observed in this study regarding the serum expression of TIMP-
2 and RLX-2 in the recurrent miscarriage group are consistent with previous 
work undertaken by members of the Anumba group (Anumba et al., 2009, 
Anumba et al., 2010). In a longitudinal study, they reported for the first time, 
that pregnant women with a viable pregnancy with history of recurrent 
miscarriage have a significant increase in the expression level of TIMP-2 
106 
 
compared to healthy pregnant women without history of recurrent 
miscarriage, while there was no significant difference in the levels of MMP-1, 
MMP-3 and MMP-9 between two groups during the first trimaster. They also 
reported a significant decrease in the level of serum RLX-2 hormone in 
recurrent miscarriage groups compared to healthy pregnant women 
(Anumba et al., 2010). Although one study has suggested that the serum 
expression levels of RLX-2 were low in women during miscarriage and 
ectopic pregnancy compared to those with healthy early pregnancy 
(Petersen et al., 1995), we have not been able to confirm these observations 
in our series. In contrast, Jiang and Qi determined that MMP-9 and TIMP-3 
mRNA expression levels in the villi of pregnant women undergoing early 
spontaneous miscarriage was higher than that of the normal pregnant 
women requesting abortion at the same gastational age (Jiang and Qi, 
2015). However, to our knowledge, this is the first study investigated the 
serum expression levels of MMPs, TIMPs and RLX-2 in pregnant women 
with viable pregnency and thretened miscarriage.    
The Matrix mettaloproteinaes family of proteins are key in the remodelling of 
the extracellular matrix of the endometrium throughout implantation and 
pregnency (Hulboy et al., 1997, Woessner, 1991). MMPs are suggested to 
have numerous potential roles in stimulating the growth of reproductive 
tissue, including altering the integrity of the basement membrane to prepare 
tissue for expansion and growth factor activation. The ability of RLX-2 to 
promote tissue growth and remodlling suggest a regulatory interaction 
between RLX-2 and MMPs. In a recent study Mi Kang et al (2017) reported 
that RLX-2 inhibits excessive extracellular matrix synthesis by reducing the 
expression of its components, such as fibronectin, phosphorylated Smad2 
and a-SMA, through increasing the levels of MMPs, whilst simoultaneously 
decreasing the levels of TIMPs (Kang et al., 2017). In another study by 
Lenhart ( 2001), it was suggested that RLX-2 stimulates MMP-2 and MMP-9 
secretion in uterine flushes during growth and remodlling of the uterus and 
cervix of the pig (Lenhart et al., 2001).    
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One of the weakness of this study is that the serum results represent the 
systemic levels of the serum markers as several tissues contribute to this 
measurement and the local expression may show a difference from one 
tissue to another. Although we studied the systemic expression of the 
proteins rather than the local expression of MMPs, TIMPs and relaxin 
hormone, profound local changes associated with implantation and 
placentation could well have been undetected. Nevertheless, the significant 
difference in the serum expression of these proteins suggest that these 
molecules have a role in the biology of human reproduction. However, a 
larger sample size will be required to confirm if the serum marker can be 
used as a clinical predictive value for adverse pregnancy outcomes.  
In summary, this study has demonstrated that women with history of 
recurrent miscarriage have a high expression of TIMP-2 and low expression 
levels of MMP-2, MMP-2/TIMP-2 complex and RLX-2. These data suggest 
that any dysregulation of any of these proteins may play a role in the 
implantation pathogenesis and pregnancy loss. Further studies with a large 
sample size are required to confirm and explain these data. However, an in 
vitro study is needed to explore if there is any interaction between RLX-2, 
MMPs and their inhibitors, and the effect of all these molecules on the early 
implantation stages to support or refute these in vivo observations.  
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 The potential effect of RLX-2 on MMP-2, 
MMP-9 and TIMP-2 expression by T-HESCs and JAR 
cells, and the effect of TIMP-2 on MMP-2 and MMP-9 
expression by T-HESCs and JAR cells 
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4.1. Introduction 
During pregnancy, growth of the uterus and cervix are a result of cellular 
proliferation and connective tissue remodelling to facilitate tissue expansion. 
The tissue remodelling process is a fine balance between breakdown and 
remodelling of the ECM that is highly coordinated. Some of the main factors 
involved in this process are matrix metalloproteinases (MMPs) enzymes that 
belong to a family of extracellular proteinases that target the extracellular 
matrix and are vital for tissue remodelling (Hulboy et al., 1997). MMPs 
expression and production are regulated by various stimulatory factors, 
including growth factors, cytokines and hormones. MMP-2 (gelatinase A) and 
MMP-9 (gelatinase B) are MMP subclasses that mediate basement 
membrane degradation in the early embryo implantation stages of the 
cellular invasion process and tissue expansion, and therefore they are 
essential for growth and remodelling of the reproductive tissue (Staun-Ram 
et al., 2004).  
Several modulatory molecules interact at the trophoblast-endometrial 
interface to generate a favourable environment for blastocyst implantation. 
Successful implantation requires a delicate balance between the activators 
and inhibitors of MMPs that control the synthesis and degradation of the 
ECM. Relaxin has been reported to stimulate MMPs activity in various 
species including humans, pigs and rats (Lenhart et al., 2001). 
Numerous studies have shown that during pregnancy, the hormone relaxin 
stimulates growth of the uterus and increases its collagenous framework 
distensibility that is essential for foetal accommodation. The primary target 
for relaxin in the reproductive tract is the connective tissue, it has an 
important collagenolytic role in the remodelling the connective tissue matrix 
structure to prompt ripening and dilation of the cervix in preparation for 
parturition. These observations point to the significant association between 
relaxin and enzyme activity within the connective tissue (Lenhart et al., 
2001).  
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Hypothesis  
RLX-2 regulates the expression of MMP-2, MMP-9 and TIMP-2 secreted 
from trophoblast and endometrium cells during early implantation stages.  
Aims  
The experiments performed in this chapter aim to define the impact of RLX-2 
on the production and activity of MMP-2, MMP-9 and TIMP-2 from 
endometrial stromal (T-HESCs) and trophoblast (JAR) cells, and also to 
determine the effect of MMP inhibitors on the expression of MMP-2 and 
MMP-9.  
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4.2. Materials Methods  
In this chapter, the expression of MMP-2, MMP-9, TIMP-2, RLX-2, 
endometrial epithelial markers and endometrial stromal cell markers in all the 
cell lines (Ishikawa, RL95-2, JAR and T-HESCs) were examined using 
immunohistochemistry (see chapter 2 for details, section: 2.2.7). In addition, 
the secretion of MMP-2, MMP-9 and TIMP-2 was determined from T-HESCs 
and JAR cells upon stimulation with increasing concentrations of RLX-2 over 
time using ELISA. The effect of TIMP-2 and broad spectrum matrix 
metalloproteases inhibitor (Batimastat) on the production and activity of 
MMP-2 and MMP-9 was also assessed (see chapter 2 for details, section: 
2.2.9 and 2.2.10). The data described in this chapter are from 4 independent 
experiments, with each experiment performed in triplicate. The expression 
levels for each group of samples were compared with each other using 
ANOVA with post-hoc tests within Graph Pad Prism version 6.02 statistical 
software. 
4.3. Results  
4.3.1. Immunohistochemistry 
4.3.1.1. Haematoxylin and eosin H&E staining 
All the cell lines were cultured, fixed with agarose/formaldehyde for wax 
processing, sectioned and stained with haematoxylin and eosin (H&E). It is a 
routine histological stain used for examining and localising the cell pallets in 
the section. Figure 4.1 shows H&E stained sections of (RL95-2, Ishikawa, 
JAR and endometrial stromal cell lines (T-HESCs)), the cytoplasm stained 
red/pink and the nuclei stained blue. Cells were present as individual cells 
scattered throughout the agarose. The sections showed typical phenotypes 
for epithelial cells with large nuclei surrounded by cytoplasm.  
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Figure 4.1. Haematoxylin and eosin (H&E) stained sections of (RL95-2, 
Ishikawa, JAR and endometrial stromal cell lines). 
Scale bar = 200 μM. 
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4.3.1.2. Galectin-9 
Wax embedded cell lines were processed for immunohistochemical staining. 
DAB staining was performed to visualise the expression of galectin-9 in the 
endometrial cell lines and JAR cell line. Images of Immunostaining 
demonstrated a strong immunoreactivity for galectin-9 in the endometrial 
epithelial, stromal cell lines and the JAR cell line as illustrated in figure 4.2. 
No immune-reactivity was observed in the negative control where the 
primary antibody was omitted to assess the antigen dependent binding. 
Placental tissue was used as a positive control as it is known to express 
galectin-9.  
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Figure 4.2. Immunostaining for Gelactin-9 
Tissue sections of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial stromal 
cells and JAR trophoblast cells. Endometrial tissue and placenta were used as positive controls. 
Scale bar = 200 μM.     
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4.3.1.3. Vimentin 
Figure 4.3 shows examples of immune-reactive staining for vimentin in 
endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial stromal 
cells and the JAR cell line. Immunostaining demonstrated a strong reactivity 
for vimentin in the endometrial stromal cell line. No immune-reactivity was 
observed in the endometrial epithelial cell lines (RL95-2 and Ishikawa), 
whereas JAR cell line displayed a subpopulation of immune-positively 
stained cells. Immunoreactivity was not observed in the negative control 
where the primary antibody was omitted to investigate the antigen-dependent 
binding, whereas strong immune-positive staining was seen in placental 
tissue that was used as a positive control.  
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Figure 4.3. Immunostaining for vimentin 
Endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial stromal cells and JAR cell 
line. Omission of primary antibody showed no Immunostaining (negative control), whereas 
strong immune-reactive staining was observed in the positive control (placenta). Scale bar = 200 
μM 
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4.3.1.4. CD10  
Expression of CD10 was examined in the endometrial cell lines, stromal cells 
and the JAR cell line using a specific CD10 antibody followed by DAB 
staining. Strong immune-reactive staining for CD10 was observed in the 
endometrial stromal cell line. However, no immune-reactivity was observed 
in the endometrial epithelial cell lines (RL95-2 and Ishikawa) and the JAR 
cell line. Absence of immunoreactivity in the negative control where the 
primary anti body was omitted confirmed antibody specificity as did immune-
positive staining in the placental tissue as a positive control, as illustrated in 
figure 4.4. 
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Figure 4.4. Immunostaining for CD10 
Tissue section of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial stromal cells and 
JAR trophoblast cells. Omission of primary antibody showed no Immunostaining (negative control), 
whereas strong immune-reactive staining was observed in the positive control (placenta). Scale bar = 
200 μM.     
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4.3.1.5. TIMP-2 
DAB staining was performed to localise the expression of TIMP-2 in the 
endometrial cell lines and JAR cell line. Images of Immunostaining 
demonstrated a strong reactivity for TIMP-2 in the endometrial epithelial cell 
line RL-95-2, the stromal cell line and JAR cell line, where staining was 
strong in all cells. However, staining in the Ishikawa cell line was not 
widespread but was evident in a subpopulation of cells. No immune-reactivity 
was observed in the negative control where the primary antibody was 
omitted to assess the antigen-dependent binding. As expected, positive–
Immunostaining was observed in human placental tissue as illustrated in 
figure 4.5. 
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Figure 4.5. Immunostaining for TIMP-2 
Tissue section of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial 
stromal cells and JAR trophoblast cells. Omission of primary antibody showed no 
Immunostaining (negative control), whereas strong immune-reactive staining was observed 
in the positive control (placenta) and in the epithelium of human endometrial tissue. Scale 
bar = 200 μM.     
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4.3.1.6. RLX-2   
Expression of RLX-2 was observed in all cell lines tested and in each case, 
strong immuno-reactivity was evident. Strong expression of RLX-2 and 
Ishikawa was observed in the epithelium of human endometrial tissue, 
endometrial stromal cells and JAR cell line. No immune-reactivity was 
observed in the negative control where the primary antibody was omitted to 
assess the antigen dependent binding as illustrated  in figure 4.6. 
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Figure 4.6 Immunostaining for RLX-2 
Tissue section of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial stromal 
cells and JAR trophoblast cells. Omission of primary antibody showed no Immunostaining 
(negative control), whereas strong immune-reactive staining was observed in the positive control 
(placenta) and in the epithelium of human endometrial tissue. Scale bar = 200 μM.     
 
 
123 
 
4.3.1.7. MMP-2 and MMP-9 
Figure 4.7 and figure 4.8 show examples of Immunostaining for MMP-2 and 
MMP-9 in endometrial epithelial cell lines (RL95-2 and Ishikawa), 
endometrial stromal cells and JAR cell line respectively. Images of 
Immunostaining demonstrated a strong reactivity for MMP-2 in the 
endometrial stromal cells and RL-95-2. Weaker expression was observed 
with Ishikawa and JAR cells. Weak MMP-2 expression was detected in the 
positive control placenta tissue and no immune-reactivity was observed in 
the negative control where the primary anti body was omitted to assess the 
antigen dependent binding as illustrated  in figure 4.7. For MMP-9, strong 
immuno-reactive staining was observed for all cell lines tested as well as the 
positive control placental tissue whereas no immuno-reactive staining was 
seen in the negative control tissue as illustrated  in figure 4.8.  
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Figure 4.7. Immunostaining for MMP-2 
Tissue section of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial 
stromal cells and JAR trophoblast cells. Omission of primary antibody showed no 
Immunostaining (negative control), whereas immuno-reactive staining was observed in the 
positive control (placenta). Scale bar = 200 μM.     
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Figure 4.8 Immunostaining for MMP-9 
Tissue section of endometrial epithelial cell lines (RL95-2 and Ishikawa), endometrial 
stromal cells and JAR trophoblast cells. Omission of primary antibody showed no 
Immunostaining (negative control), whereas immuno-reactive staining was observed in the 
positive control (placenta). Scale bar = 200 μM.     
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4.3.2. Measurement of MMP-2 and MMP-9 secretion of different cell lines by 
zymography  
Conditioned medium from all the cell lines were analysed using zymography 
to determine the secreted levels of MMP-2 and MMP-9, as described in 
chapter 2 (section: 2.2.8). Gelatin zymography identified the amount of 
enzyme activity attributed to both pro and active forms of the enzymes. 
Figure 4.9 shows a representative image of a zymogram from the 
conditioned medium, media of the different cell line used: RL95-2, Ishikawa, 
HEC-1-A, JAR and T-HESCs. Conditioned medium from JAR cells and T-
HESCs shows stronger intensity of gelatinolytic bands for the pro-enzymatic 
forms of MMP-2 (72 kDa) when compared with the positive control 
supernatant from (PMA-treated HeLa cells), and the slightly lower molecular 
weight activate form of MMP-2 enzyme was expressed from the T-HESCs 
(62 kDa). Conditioned medium from endometrial epithelial cells (RL95-2, 
Ishikawa and HEC-1-A) showed weak intensity bands. Much smaller 
intensity bands corresponding to the pro-MMP-9 (92 kDa) were observed for 
all cell lines and the active form of MMP-9 (82 kDa) could only be detected 
with JAR cells as illustrated in figure 4.9.   
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Figure 4.9. Panel of representative gelatin zymogram of cell lines supernatant (RL95-2, 
Ishikawa, HEC-1-A, JAR and T-HESCs) 
T-HESCs and JAR cells expressed stronger intensity of gelatinolytic bands for pro-enzymatic forms 
MMP-2 (72 kDa) and the lower molecular weight activate enzyme (62 kDa) was expressed from the T-
HESCs. Expression bands for pro-MMP-9 (92 kDa) were detected in all cell lines but their intensity 
was much lower than for MMP-2. PMA-treated HeLa cells were used as a positive control. 
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4.3.3. Evaluation of the effect of various RLX-2 concentration on MMP-2, 
MMP-9 and TIMP-2 production. 
As described in chapter 2 (section: 2.2.9) functional studies were carried out 
to evaluate the effect of three different concentrations of RLX-2 at three 
different time-points on the production of MMP-2, MMP-9 and TIMP-2 by 
cultured T-HESCs and JAR cells.  
4.3.3.1. Expression of MMP-2 from endometrial stromal (T-HESCs) cells 
treated with RLX-2. 
Cultured T-HESCs were treated with increasing concentrations of RLX-2  (1, 
10 and 100 ng/ml) for a duration of 24, 48 and 72 hours (section: 2.2.9). 
Medium alone was used as controls. Figure 4.10. shows a time-dependent 
increase in the secretion of MMP-2 for all cultures of T-HESCs irrespective of 
treatment with RLX-2. Levels of MMP-2 were significantly increased (p value 
< 0.05) in all samples tested from 24 to 48 hours in culture. However, levels 
of MMP-2 began to plateau at 72 hours, and with the exception of controls, 
the levels of MMP-2 at this time point were not significantly different from 
those measured at 48 hours. Importantly, stimulation of T-HESCs with RLX-2 
did not alter the secretion of MMP-2 compared to unstimulated cells for any 
concentrations of RLX-2 and at any time point tested.   
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Figure 4.10. Comparison of MMP-2 levels secreted by T-HESCs treated with increasing 
concentrations of RLX-2 
2X105 T-HESCs were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml RLX-2 for (A) 
24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml RLX-2) was used as a control and MMP-2 was 
measured by ELISA. Data are the median and interquartile ranges from 4 independent experiments, 
with each experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA. The secretion of RLX-2 increased in a time dependent manner in both 
treated and untreated samples. There were no significant differences between RLX-2 -treated and 
untreated controls at any time point tested. 
 
130 
 
4.3.3.2. Expression of MMP-2 from JAR cells treated with RLX-2  
Cultured JAR cells were treated with increasing concentrations of RLX-2  (0, 
1 and 100 ng/ml) for a duration of 24, 48 and 72 hours (section: 2.2.9). There 
was a significant increase (p value = 0.016) in the levels of MMP-2 secreted 
by JAR cells in response to 100 ng/ml RLX-2 compared to cells cultured with 
medium alone and to treatment with 1 ng/ml (p value = 0.039) over a 24 
hours period. After 48 hours, no significant difference was detected in the 
levels of MMP-2 when JAR cells were treated with any concentration of RLX-
2 compared to medium alone controls. However, at 72 hours there was a 
significant increase in the secreted levels of MMP-2 when JAR cells were 
treated with 10 and 100 ng/ml but not 1 ng/ml RLX-2 concentrations, 
compared to medium alone control samples (p value = 0.0003 and 0.0002 
respectively), and when the 10 and 100 ng/ml treated cells were compared to 
the 1ng/ml treated cells (p value = 0.005 and 0.003 respectively) as 
illustrated in figure 4.11. 
 
Figure 4.11. Comparison of MMP-2 levels secreted by JAR cells treated with 
increasing concentrations of RLX-2 
4X105 ES cells were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml RLX-2 
for (A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml RLX-2) was used as a control 
and MMP-2 was measured by ELISA. Data are the median and interquartile ranges from 4 
independent experiments, with each experiment performed in triplicate. Differences between 
groups and time-points were performed using ANOVA. 
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4.3.3.3. Expression of TIMP-2 from T-HESCs treated with RLX-2  
Cultured T-HESCs were treated with increasing concentrations of RLX-2  (0, 
1 ng, 10 ng/ml and 100 ng/ml) for 24, 48 and 72 hours (section: 2.2.9). After 
24 hours, there was an increase in the expression levels of TIMP-2 secreted 
by T-HESCs in response to 1 and 100 ng/ml RLX-2, compared to untreated 
control samples (p value = 0.029 and 0.034 respectively). However, after 48 
hours no significant differences were detected in the TIMP-2 expression 
levels in any of the RLX-2 treated cells compared to controls. At 72 hours, 
there was significant increase in the expression levels of TIMP-2 secreted by 
T-HESCs treated with 10 ng/ml (p value = 0.03) RLX-2 compared to the 
control samples in which RLX-2 treatment had been excluded, and to 1 ng/ml 
RLX-2 treated cells (p value = 0.04). However, TIMP-2 levels secreted from 
cells treated with (100 ng/ml) RLX-2 were not significantly different from 
controls or other RLX-2 treated cells as illustrated in figure 4.12. 
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Figure 4.12. Comparison of TIMP-2 levels secreted by T-HESCs treated with increasing 
concentrations of RLX-2 
2X105 T-HESCs were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml RLX-2 for (A) 
24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml RLX-2) was used as a control and MMP-2 was 
measured by ELISA. Data are the median and interquartile ranges from 4 independent experiments, 
with each experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA. 
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4.3.3.4. Expression of TIMP-2 from JAR cells treated with RLX-2  
Cultured JAR cells were treated with increasing RLX-2 concentrations (0, 1 
ng/ml, 10 ng/ml and 100 ng/ml) for 24, 48 and 72 hours (section: 2.2.9). 
There was no significant difference detected in the expression levels of 
TIMP-2 between JAR cells treated with the different doses of RLX-2 at any of 
the three time points analysed as illustrated in figure 4.13. 
 
 
  
Figure 4.13. Comparison of TIMP-2 levels secreted by JAR cells treated with increasing 
concentrations of RLX-2 
4X105 JAR cells were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml RLX-2 for 
(A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml RLX-2) was used as a control and MMP-
2 was measured by ELISA. Data are the median and interquartile ranges from 4 independent 
experiments, with each experiment performed in triplicate. Differences between groups and time-
points were performed using ANOVA. 
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4.3.3.5. Expression of MMP-9 from T-HESCs and JAR cells treated with 
RLX-2  
Both T-HESCs and JAR cells treated with increasing concentration of RLX-2 
did not express MMP-9 at any time points tested as the levels of MMP-9 
were below the detection limit of the ELISA test.  
4.3.4. Evaluation of the effect of various TIMP-2 and Batimastat 
concentrations on the expression level of MMP-2 and MMP-9  
As described in chapter 2 (section: 2.2.10), studies were performed to 
evaluate the effect of increasing TIMP-2 and Batimastat concentrations on 
cultured T-HESCs and JAR cells at three different time points and the 
secretion of MMP-2 and MMP-9 was measured. 
4.3.4.1. Expression of MMP-2 from endometrial stromal cells (T-HESCs) 
treated with TIMP-2 
Cultured T-HESCs were treated with increasing concentrations of TIMP-2 (0, 
1, 10 and 100 ng/ml) for 24, 48 and 72 hours (section: 2.2.10). No significant 
changes were detected in the MMP-2 secreted levels when T-HESCs were 
treated with increasing doses of TIMP-2 compared to each other or controls 
after 24 hours of culture. In contrast, after 48 hours there was a significant 
dose-dependent decrease in the levels of MMP-2 detected in the conditioned 
medium derived from T-HESCs in response to 1, 10 and 100 ng/ml TIMP-2 
concentrations compared to cells treated with medium alone (p value = 
0.0014, 0.0001 and 0.0001 respectively). After 72 hours of incubation of T-
HESCs with TIMP-2, there was a recovery in the secretion of MMP-2 and a 
dose-dependent increase in MMP-2 levels was observed, and a statistically 
significant difference was achieved upon incubation with 100 ng/ml TIMP-2 
as illustrated in figure. 4.14. 
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Figure 4.14. Comparison of MMP-2 levels secreted by T-HESCs treated with 
increasing concentrations of TIMP-2 
2X105 T-HESCs were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml RLX-2 
for (A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml TIMP-2) was used as a control 
and MMP-2 was measured by ELISA. Data are the median and interquartile ranges from 4 
independent experiments, with each experiment performed in triplicate. Differences between 
groups and time-points were performed using ANOVA. 
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4.3.4.2. Expression of MMP-2 from JAR cells treated with TIMP-2 
Similar to T-HESCs, no significant differences were detected in the levels of 
MMP-2 in the conditioned medium of JAR cells were these cells were treated 
with increasing concentrations of TIMP-2 after 24 hours. However, there was 
a significant dose-dependent decrease in the levels of MMP-2 detected after 
48 hours of incubation with TIMP-2 at 1, 10 and 100 ng/ml concentrations 
compared to untreated controls (p value = 0.0023, 0.0001 and 0.0001 
respectively). Furthermore, there was a significant decrease in the 
expression levels of MMP-2 from JAR cells in response to 10 and 100 ng/ml 
TIMP-2 treatment compared to the 1 ng/ml TIMP-2 treated cells (p value = 
0.039 and 0.042 respectively), where the content of MMP-2 in these cultures 
was reduced to almost undetectable levels. After 72 hours, the overall levels 
of MMP-2 were increased in both TIMP-2 treated and untreated cells, and 
there were no significant differences detected in the expression levels of the 
MMP-2 when JAR cells were treated with increasing doses of TIMP-2 as 
illustrated in figure. 4.15. 
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Figure 4.15. Comparison of MMP-2 levels secreted by JAR cells treated with increasing 
concentrations of TIMP-2 
4X105 JAR cells were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml TIMP-2 for 
(A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml TIMP-2) was used as a control and 
MMP-2 was measured by ELISA. Data are the median and interquartile ranges from 4 
independent experiments, with each experiment performed in triplicate. Differences between 
groups and time-points were performed using ANOVA. 
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4.3.4.3. Levels of MMP-2 in the conditioned medium of T-HESCs treated with 
Batimastat. 
Cultured T-HESCs were treated with increasing concentrations (0 to 100 
ng/ml) of Batimastat, a broad spectrum MMPs inhibitor for 24, 48 and 72 
hours (section: 2.2.10). There was a dose dependent decrease in the levels 
of MMP-2 within the conditioned medium of T-HESCs upon treatment with 
Batimastat. A significant decrease in MMP-2 was observed when cells were 
treated with 100 ng/ml Batimastat compared to untreated control samples 
after 24 hours (p value = 0.017). Levels of MMP-2 continued to decline in a 
dose-dependent manner the medium of Batimastat-treated cells after 48 
hours, and significant differences between levels of MMP-2 in cells treated 
with 1, 10 and 100 ng/ml of Batimastat compared to untreated cells were 
observed (p value = 0.001, 0.0004 and 0.0009 respectively). The reduction in 
secreted levels of MMP-2 in Batimastat-treated cells was even more 
pronounced at 72 hours with significant decreases in the levels of secreted 
MMP-2 by T-HESCs treated with Batimastat concentrations (1, 10 and 100 
ng/ml) compared to controls (p < 0.0001) for all treated samples as illustrated 
in figure. 4.16. 
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Figure 4.16. Comparison of MMP-2 levels secreted by T-HESCs treated with increasing 
concentrations of Batimastat 
2X105 T-HESCs were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml Batimastat 
for (A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml Batimastat) was used as a control 
and MMP-2 was measured by ELISA. Data are the median and interquartile ranges from 4 
independent experiments, with each experiment performed in triplicate. Differences between 
groups and time-points were performed using ANOVA. 
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4.3.4.4. Expression of MMP-2 from JAR cells treated with Batimastat  
Cultured JAR cells were treated with different Batimastat concentrations (0, 1 
ng, 10 ng/ml and 100 ng/ml) for 24, 48 and 72 hours (section: 2.2.10). After 
24 hours, no significant changes in the levels of MMP-2 in the conditioned 
medium of JAR cells treated with different doses of Batimastat 
concentrations (1ng/ml, 10 ng/ml and 100 ng/ml) were detected. However, a 
significant dose-dependent decrease in the levels of MMP-2 was seen after 
48 hours of co-incubation with JAR cells with all Batimastat concentrations 
tested compared to controls (p value = 0.02, 0.0004 and 0.0001 
respectively). Moreover, the levels of MMP-2 in the conditioned medium of 
Batimastat-treated JAR cells were decreased further at 72 hours with levels 
of MMP-2 at the lower detection limit and significantly decreased compared 
to untreated controls for all concentrations tested (p value < 0.0001) for all 
Batimastat concentrations, as illustrated in figure 4.17.  
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Figure 4.17.Comparison of MMP-2 levels secreted by JAR cells treated with increasing 
concentrations of Batimastat 
4X105 JAR cells were cultured in 6 well plates and stimulated with 1, 10 or 100 ng/ml 
Batimastat for (A) 24, (B) 48 and (C) 72 hours. Medium alone (0 ng/ml Batimastat) was used 
as a control and MMP-2 was measured by ELISA. Data are the median and interquartile 
ranges from 4 independent experiments, with each experiment performed in triplicate. 
Differences between groups and time-points were performed using ANOVA 
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4.3.4.5. Expression of MMP-9 from T-HESCs and JAR cells treated with 
TIMP-2 and Batimastat. 
Both T-HESCs and JAR cells treated with increasing concentration of TIMP-
2 or Batimastat did not express MMP-9 over 24, 48 and 72 hours. The values 
recorded for MMP9 secretion were below the detection limit of the ELISA. 
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4.4. Discussion  
MMPs are involved in remodelling the ECM of the reproductive tissues 
during the menstrual cycle, embryo implantation, placentation and parturition. 
Numerous roles for MMPs in stimulating reproductive tissue growth have 
been suggested, including promoting tissue expansion by changing 
basement membrane integrity and release of growth factors from the ECM 
(Lenhart et al., 2001, Curry and Osteen, 2003, Amalinei et al., 2007).  
IHC studies were performed to characterise the cells for markers examined 
in this study. Results showed that endometrial epithelial cells, stromal cells 
and JAR cells were all galectin-9 positive as expected. As with other stromal 
cells like dermal fibroblasts (Driskell et al., 2013), endometrial stromal cells 
(T-HESCs) were positive for the stromal marker vimentin and CD10 whereas 
the endometrial epithelial cells and JAR cells were negative, confirming the 
phenotype of these cells. Although not quantifiable, immunohistochemical 
staining also showed that both endometrial epithelial, stromal and JAR 
trophoblasts expressed TIMP-2, RLX-2, MMP-2 and MMP-9. The stromal 
cells and JAR cells appeared to express more TIMP-2 than the endometrial 
epithelial cells. Zymography was used to provide a semi-quantitative 
measurement of both pro- and active MMP-2 and MMP-9 production by 
these cells and these experiments showed that the stromal and JAR cells 
constitutively expressed markedly more MMP-2 than the endometrial 
epithelial cells. In contrast MMP-9 levels were very low for all cell types 
suggesting that of the two MMPs tested, MMP-2 is the most abundant. 
RLX-2  has been illustrated  to have a role in promoting uterine growth and 
placentation, as well as stimulating cervical remodlling and ripening at 
parturition at the end of pregnancy (Lenhart et al., 2001). Although RLX-2 is 
an essential factor in the remodelling of connective tissue of the reproductive 
tract (Palejwala et al., 2001), little is known regarding the effects of relaxin on 
the expression of MMPs in humans. Given the ability of RLX-2 to promote 
tissue remodelling and growth, it was hypothesised that a regulatory 
interaction exists between relaxin and MMPs. 
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In this chapter, endometrial stromal (T-HESCs) and trophoblast (JAR) cells 
were used to investigate the effect of RLX-2 on levels of MMP-2, MMP-9 and 
TIMP-2. Various studies suggest that RLX-2 can up-regulate MMPs 
expression. Data presented by Lenhart et al (2001) showed that MMP-2 and 
MMM-9 were significantly increased in uterine flushes from relaxin-treated 
pigs. They also observed that the expression levels of MMP-2 and MMP-9 
were lower locally in both the cervix and the uterus after treatment with RLX-
2 (Lenhart et al., 2001). Palejwala et al demonstrated that RLX-2 had a 
positive effect on the expression of MMP-1 and MMP-3 by fibroblasts in the 
lower uterine segments in human tissue at both the mRNA and protein level 
(Palejwala et al., 2001). In addition, the same authors showed that RLX-2 
increased secretion of MMP-2 by the cervix as well as up-regulating the 
expression of various cytokines secreted by leucocytes and other cells in the 
cervix known to stimulate MMPs expression (Palejwala et al., 2001).  
In this study T-HESCs secreted MMP-2 constitutively and the levels of 
secreted MMP-2 increased in the medium over time with cell proliferation. 
Stimulation of T-HESCs with RLX-2 did not significantly alter secreted levels 
of MMP-2 when compared to unstimulated controls in both a time- and dose-
dependent manner. Moreover, T-HESCs did not express MMP-9 with or 
without treatment with RLX-2. Other studies found that RLX-2 negatively 
regulates endometrial MMPs expression (Goldsmith et al., 2004). Goldsmith 
et al (2004) found that RLX-2 had a negative effect on endometrial MMPs 
expression, where levels of both proMMP-1 and proMMP-3 were significantly 
lower in relaxin-treated rhesus monkey. These contradictory effects of RLX-2 
on MMPs may be due to experimental design (in vitro versus in vivo). For 
example, in an in vivo system, MMPs activity may be regulated locally by a 
number of tissue inhibitors of matrix metalloproteinases that may not be 
available in the in vitro environment (Lenhart et al., 2001). The data 
presented in this thesis strongly suggest that RLX-2 does not affect the 
expression of MMP-2 or MMP-9 by T-HESCs. Although there was no effect 
on MMP-2 activity in response to RLX-2 treatment this does not exclude the 
role of RLX-2 in extracellular remodelling in early implantation as alternate 
pathways utilising other proteases such as MMP-1/3 could be involved.  
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In contrast to MMP-2, relaxin-stimulated T-HESCs showed increased 
secretion of TIMP-2, this was significant but minimal at 24 hours, the 
difference increased by 72 hours when stimulated with 10 but not 100 ng/ml, 
suggesting that activation is reached at a maximal dose. These data are in 
agreement with Goldsmith et al who showed that TIMP-2 expression levels 
were significantly elevated in relaxin-treated animals compared to controls 
(Goldsmith et al., 2004). In contrast, Palejwala et al previously showed that 
RLX-2 negatively affected the expression of TIMP-2 in human uterine 
fibroblasts (Palejwala et al., 2001) although this difference may be due to 
tissue differences in these stromal cells.  
The invasion of trophoblast into the decidua is an essential step for early 
placenta development and early pregnancy maintenance. For successful 
embryo implantation, the invasion of trophoblast into the decidua is under a 
tight control and MMPs play a major role in this process. The production and 
action of RLX-2 hormone during pregnancy and parturition are highly species 
dependent. In human, the production of RLX-2 at the maternal-fetal interface 
is mainly by the placenta, decidua and foetal membranes (Maruo et al., 
2007). While there are numerous studies on the effect of RLX-2 as a positive 
regulator of MMPs in term placenta, there is little data regarding the 
interaction between RLX-2 and MMPs in early development of the placenta. 
The data presented in this chapter show that RLX-2 increased the secretion 
of MMP-2 by JAR trophoblast cells in a dose-dependent manner with 
significant differences being observed compared to unstimulated cells after 
72 hours in culture. These data are in agreement with Maruo et al who were 
the first to describe the effects of RLX-2 on MMP-2, MMP-3 and MMP-9 in 
early extra villous trophoblast cultured in vitro. These authors demonstrated 
that RLX-2 up-regulated gene expression of both MMP-2 and MMP-9 whilst 
down-regulating expression of TIMP-2. Gene expression of MMP3 was not 
altered by RLX-2 in the cultured early placental extra villous trophoblast 
(Maruo et al., 2007). In contrast, this study showed that relaxin-stimulated 
JAR cells did not show increased secretion of TIMP-2 and did not express 
MMP-9. Differences in the data provided in this study and that of Maruo et al 
could be due to the use of human early placental extra villous trophoblasts 
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compared to JAR trophoblasts and the method of analysis; qPCR (gene 
expression) compared to ELISA (protein) used in this study.   
Culture of T-HESCs and JAR cells with TIMP-2 showed a biphasic effect. 
The T-HESCs showed decreasd levels of MMP-2 in the conditioned medium 
after 48 hours in comparison to unstimulated controls. This was followed by 
almost a threefold increase in MMP-2 levels by 72 hours compared to MMP-
2 levels at 48 hours. Likewise, JAR cells displayed decreased levels MMP-2 
at 48 hours in comparison to unstimulated controls followed by an almost 
five-fold increase at 72 hours compared to MMP-2 levels at 48 hours. The 
likely explaination is that at 48 hours there was enough TIMP-2 to bind to 
and reduce the levels of MMP-2 in the medium (the MMP-2 is present but 
complexed with the TIMP-2, so the antibodies in the ELISA are blocked from 
binding and therfore can not detect it). However, at 72 hours the cells have 
proliferated and so there are more cells secreting MMP-2 into the medium. At 
this point MMP-2 is in excess of the exogenous TIMP-2 so there is more 
MMP-2 in the medium that can be bound by the antibidoes in the ELISA. 
Moreover, recombinant TIMP-2 has a limited half-life and so at 72 hours it is 
likely that the inhibitory effects of TIMP-2 are more limited.  
The effect of a broad spectrum MMPs inhibitor (Batimastat) on the levels of 
secreted MMP-2 was also investigated. Both T-HESCs and JAR cells treated 
with Batimastat showed a dramatic decline in secrted MMP-2 levels at both 
48 and 72 hours but not at 24 hours. Data that is not disimilar to use of 
recombinant TIMP-2. The prolonged inhibitor affect seen with Batimastat is 
likely due to the high concentrations of inhibitor used or due to the high 
affinity of Batimastat for MMP-2 (Rasmussen and McCann, 1997). In this 
instance Batimastat binds to and saturates all the MMP-2 in the medium so 
that the MMP-2 is not detected by the ELISA at 48 hours. Even when more 
MMP-2 is secreted at 72 hours the inhibitor is still present at saturating 
concentrations so any MMP-2 present is still complexed and is not detected. 
TIMP-2 regulates the activity of MMP-2 so any dysregulation of this 
relationship could lead to alterations in the remodelling of the ECM that may 
potentially cause failure of implantation. It is interesting to note that addition 
of either endogenous TIMP-2 or Batimastat did not affect MMP-2 levels after 
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24 hours, while MMP-2 levels were significantly affected at 48 hours. 
Inhibitors usually bind quickly to their ligands and so further experiments are 
required to determine why this was the case for both protein and synthetic 
MMP inhibitors.   
T-HESCs and JAR cells did not express MMP-9 with or without treatment by 
both ELISA and zymogram which could be due to the presence of α2-
macroglobulin in FCS which binds and inhibits the activity of MMPs. 
However, numerous investigators used supernatant including FCS from 
different cell lines to detect MMPs by ELISA and they were detected 
including MMP-9 (Barille et al., 1997, Sobrin et al., 2000, Verma et al., 2010), 
on other hand other investigator used serum free media to detect MMPs (Yu 
and Stamenkovic, 2000), therefor, a further investigations are required to 
compare the results obtained from same cell line cultured with serum free 
media and complete growth media including FCS.    
In summary this chapter has illustrated that endometrial cells, and in 
particular, T-HESCs and JAR cells express TIMP-2 and MMP-2. RLX-2  
increased the secretion of TIMP-2 by T-HESCs but has no significant effect 
on MMP-2 production. Conversely, RLX-2  increases the secretion of MMP-2 
by JAR trophoblast cells but has no affect on TIMP-2 production. Taken 
together these data suggest a role for RLX-2, MMP-2 and TIMP-2 in 
trophoblast-endometrial/stromal interactions that may affect trophoblast 
implantation. The next chapter will investigate the potential effect of RLX-2, 
MMP-2 and TIMP-2 on trophoblast-endometrial interactions using 2D and 3D 
endometrial in vitro models to study attachment and invasion stages.   
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 The effect of RLX-2 hormone, MMP-2, MMP-
9 and TIMP-2 on trophoblast-endometrial interactions in 
vitro 
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5.1. Introduction 
The implantation of the embryo to the wall of the uterus is an intricate 
process and a pivotal step for a successful pregnancy. Two key components 
are required for successful implantation; embryo quality and a receptive 
endometrium. However, a considerable transformation of the uterine lining is 
necessary to generate a favourable environment for embryo implantation, a 
process that is under the tight control of a complex network of molecules. A 
delicate balance exists between the molecules that promote endometrial 
receptivity and those that prevent it and any imbalance can lead to 
implantation failure, which is associated with several adverse pregnancy 
outcomes.  
The molecular mechanisms of early embryo implantation remain poorly 
understood. Studies of the process have been mainly descriptive and the 
information derived from in vivo studies are insufficient. Studying embryo 
implantation in vivo is a complicated area of research because of practical 
and ethical implications. As a result, scientists have developed numerous 
approaches or models to explore and investigate human embryo 
implantation. In vivo animal studies have led to important developments in 
the understanding of the process of embryo implantation. However, due to 
the differences in the reproductive system between the animal models used 
and humans, knowledge gained from these functional animal studies cannot 
always be directly translated to humans. In addition, for in vitro experiments, 
the use of primary cells derived from human endometrial tissue has 
limitations including, patient to patient variation, short cell life span and cell 
differentiation. Consequently, there is a need to establish multi-cellular in 
vitro models to investigate human embryo implantation (Weimar et al., 2013).   
In recent years, several studies using in vitro tissue culture models have 
shown a promising way forward to understand the embryo-endometrium 
cross-talk at early implantation stages and the pathophysiology of 
implantation failure.  
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Immortalized cell lines derived from the endometrium at different phases of 
the menstrual cycle that keep their cell behaviour and chracteristics have 
been generated. These include cells of the receptive endometrium (Ishikawa, 
EEC-1 and HES cell lines), non-receptive endometrium (HEC-1A) and 
glandular epithelium (Ishikawa and RL95-2) (Hannan et al., 2010). Similarly, 
human embryos used in IVF procedures have a very restricted access for 
research. As a result several different trophoblast cell lines derived from the 
human placenta have been established for research purposes. These have 
different migration and adhesion (AC1M-88 and HTR-8/Svneo), 
syncytialization (BeWo) and invasion (JAR, JEG-3, HTR-8/Svneo and BeWo) 
characteristics. (Hannan et al., 2010).  
Due to the difference in the developmental stages of endometrial and 
trophoblast cells, the selection of the appropriate cell line for experiments is 
considered fundamental (Hannan et al., 2010). In the present study, we 
investigated the trophoblast-endometrial interaction using an in vitro model of 
early human embryo implantation. The endometrium was simulated by the 
use of Ishikawa, RL95-2 and HEC-1A cell lines. RL95-2 and Ishikawa cell 
lines are highly adhesive to trophoblast cell lines compared to HEC-1A cells, 
and so these cells are considered a more appropriate model for receptive 
endometrial epithelial cells (Hannan et al., 2010). The human embryo was 
simulated using JAR trophoblast cell line, which was previously reported to 
have the ability to attach in a short time of co-incubation with endometrial 
epithelial cells (Thie et al., 1998).  
To complement the experiments performed in vivo in chapter three, 2D and 
3D endometrial in vitro models were optimised to study the trophoblast-
endometrial interaction. The attachment and the invasion stage under the 
stimulation of human RLX-2 hormone, MMP-2, MMP-9 and TIMP-2 was 
investigated to determine if stimulation of endometrial epithelial cells and 
endometrial stromal cells with these factors could interfere with attachment of 
trophoblast spheroids to different endometrial cell lines. 
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Hypothesis  
Altered expression of RLX-2 hormone, TIMP-2, MMP-2 and MMP-9 affect 
trophoblast-endometrial interaction during early human implantation. 
Aims  
The aims of this chapter are to gain insight into the role of RLX-2 hormone, 
MMP-2, MMP-9 and TIMP-2 during trophoblast-endometrial interaction, 
using an in vitro implantation model to measure the adhesion of JAR 
spheroids to an Ishikawa, RL95-2 or T-HESCs monolayer. Additionally, to 
explore the effect of recombinant human of RLX-2 hormone, MMP-2, MMP-9 
and TIMP-2 during trophoblast-endometrial interaction in the in vitro co-
culture model. 
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5.2. Materials Methods   
Refer to chapter 2 from (section: 2.2.11 to 2.2.20). 
5.3. Results  
5.3.1. Optimisation of JAR spheroids 
In order to establish an attachment assay, JAR spheroid size was optimised 
(150 - 250 µm to represent a trophoblast) so this could be produced in vitro. 
JAR spheroids were generated using the method of Korff et al with minor 
modifications (Korff et al., 2004) see (section: 2.2.14.1). JAR spheroids were 
produced in a cell density dependent manner ranging from an initial seeding 
density of (100, 250, 500, 1000, 5000 and 10,000 cells/100 µl) Figure 5.1 
shows the mean diameter of each spheroid group (6 spheroids per group). 
The size of spheroids increased gradually over time, from day one to day 
nine.  Cultures starting with 100 cells /100 µl media was the ideal number of 
cells at the start of the culture period in order to obtain spheroids with a 
diameter of 150 to 250 µm (the desired size) at the fourth to the fifth day of 
culture. 
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Figure 5.1. Optimization of JAR spheroids 
(A) Shows the mean diameter of each spheroids group over nine days, each group with 
different number of cells was used to form the spheroids (100, 250, 500, 1000, 5000 and 
10,000 cells/100 µl). (B) Figures of JAR spheroids each represent a number of cells/well  
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Figure 5.2. JAR spheroids with the mean diameter from (150 µm to 250 µm). 
Starting with 100 JAR cells/ 100 µl media was the ideal cell number to start with to develop 
spheroids with a 150 to 250 µm diameter by the fourth day.   
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5.3.2. Production of β-hCG by JAR spheroids  
To evaluate the functional properties of the JAR trophoblast spheroids, 
ELISA was used to measure the secreted hormone β-hCG in the spheroid 
conditioned medium over 8 days at 48 hours’ intervals. Figure. 5.3 shows 
that JAR spheroids secreted β-hCG in a cell density-dependent manner. 
However, the amount of β-hCG secreted every 48 hours per spheroid did not 
increase over time (Fig. 5.3). 
 
 
  
Figure 5.3. Secretion of β-hCG by JAR spheroids of human trophoblast cells.   
The secretion of β-hCG represented as pg/ml of β-hCG per spheroid in 1 ml medium at day 
2, 4, 6 and 8. Two different of spheroids were used to investigate the effect JAR spheroids 
on β-hCG secretion. The conditioned medium was analysed every 48 hours. Data are 
representative of 4 independent experiments.     
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5.3.3. In vitro adhesion assay of JAR spheroids to endometrial epithelial and 
stromal monolayer cell lines  
Figure 5.4 identified the attachment kinetics of JAR spheroids to monolayers 
of endometrial epithelial cell lines and an endometrial stromal cell line. The 
adhesion of JAR spheroids to the different monolayers increased over time. 
However, experiments with Ishikawa, RL95-2 and endometrial stromal cells 
(T-HESCs) showed a markedly higher attachment rate than the HEC-1-A cell 
line. Therefore, HEC-1-A cell line was excluded from further experiments, 
and the Ishikawa and RL95-2 cell lines were used as a receptive 
endometrium to study the attchment and inavsion stages.  
 
 
Figure 5.4. Attachment of 20 JAR trophoblast spheroids to epithelium endometrium 
monolayers (RL95-2, Ishikawa and HEC-1-A cell lines) and endometrial stromal cells 
over 48 hours 
Data are representative of 3 independent experiments. 
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Figure 5.5. Representative images showing the attachment of JAR trophoblast spheroids to 
epithelium endometrium monolayers 
(A) Ishikawa, (B) HEC-1-A, (C) RL95-2 endometrial epithelium cell lines and (D) endometrial stromal 
cells 
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5.3.4. The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
adhesion of JAR spheroids to endometrial epithelial and stromal cell 
monolayers 
To examine the potential effects of RLX-2, MMP-2, MMP-9 and TIMP-2 on 
the binding of JAR spheroids (20 per treatment) to the endometrial epithelial 
(Ishikawa and RL95-2) and stromal cells (T-HESCs) monolayers. An 
adhesion assay was performed in the absence of treatment (control) and 
under the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 treatment over 24 
hours (section: 2.2.16). In figure 5.6 the attachment rate of JAR spheroids to 
Ishikawa cell line monolayer after 2 and 6 hours shows no significant 
difference between the control (without treatment) and the attachment of JAR 
spheroids under the effect of different treatments. A similar response was 
also observed after 24 hours with all treatments with the exception of 
treatment with TIMP-2 that resulted in a significant reduction (p value = 
0.0413) in spheroid attachment compared to un-treated controls.  
Figure 5.6. Attachment of 20 JAR spheroids to Ishikawa cell line monolayer under the 
effect of RLX-2, MMP-2, MMP-9 and TIMP-2 and over 24 hours 
Data are the mean and standard deviations (SD) from 3 independent experiments, with each 
experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA. 
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The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 on the binding of 20 JAR 
spheroids to the RL95-2 shows no significant differences when compared to 
untreated controls at any of the time points examined (Figure 5.7). 
 
Figure 5.7. Attachment of 20 JAR spheroids to RL95-2 cell line monolayer under the 
effect of RLX-2, MMP-2, MMP-9 and TIMP-2 and over three different time points (2, 6 
and 24 hours) 
Data are the mean and standard deviation (SD) from 3 independent experiments, with each 
experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA. 
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In figure 5.8 the attachment of 20 JAR spheroids to T-HESCs monolayer was 
significantly decreased when the T-HESCs were treated with TIMP-2 at (6 
and 24 hours) compared to untreated control (p value = 0.0033 and 0.0016 
respectively). However, there was no significant difference between JAR 
spheroids attachment to the untreated control group or JAR spheroids under 
the effect of different treatments at any other time point tested. 
 
 
 
 
Figure 5.8. Attachment of 20 JAR spheroids to ESC cell line monolayer under the 
effect of RLX-2, MMP-2, MMP-9 and TIMP-2 and over three different time points (2, 6 
and 24 hours) 
Data are the mean and standard deviation (SD) from 3 independent experiments, with 
each experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA. 
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5.3.5. Characterisation and optimisation of 3D endometrial model  
For in vitro studies, the endometrial environment and early embryo 
implantation stages have, for a long time, been modelled by simple 
monolayer culture of endometrial epithelial cells. However, with the 
advancement of tissue engineering, an in vitro 3D tissue model was 
established in an attempt to mimic the endometrial tissue and to represent 
the attachment and invasion stages in early embryo implantation process. 
Tissue engineered 3D endometrial model was based on oral mucosal model 
previously described by Dongari-Bagtzoglou et al (2006) with minor 
modifications (Dongari-Bagtzoglou and Kashleva, 2006b) see (section: 
2.2.12 and 2.2.13). The 3D models were produced by culturing endometrial 
stromal cells at the air-to-liquid interface on a rat-tail type I collagen 
populated with endometrial epithelial cell line RL95-2 or Ishikawa cell line. 
The 3D models were fixed, sectioned and stained with haematoxylin and 
eosin (H&E) for histological analysis. Figure 5.9 shows H&E stained sections 
of 3D endometrial model cultured with Ishikawa cells. In the figure the nuclei 
are stained blue and the cytoplasm and connective tissue stained pink. The 
epithelium generated was multiple-layered, however, this does not represent 
the native phenotype of the tissue that is generally single layered. To make 
the 3D model similar to native endometrium the models were not cultured at 
the air-to-liquid interface but were kept submerged in the culture media. 
Figure 5.10 shows (H&E) stained sections of 3D endometrial models cultured 
with Ishikawa and RL95-2 cell lines respectively. Here, epithelial cells formed 
a single cell monolayer on the top of the 3D model with endometrial stromal 
cells incorporated into the collagen hydrogel, a phenotype more 
characteristic of native endometrium. 
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Ishikawa cell line was seeded onto the surface of a rat-tail type I collagen populated with 
endometrial stromal cells, and then the culture raised to an air-to-liquid interface and 
cultured for 7-10 days. Models were fixed, paraffin embedded, sectioned and H&E stained.   
 
 
 
 
 
 
 
 
 
Figure 5.9. Representative images of Haematoxylin and Eosin (H&E) stained 3D 
endometrial models. 
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To culture the endometrial models, endometrial stromal cells were suspended in rat-tail type 
I collagen, after 24 hours (A) Ishikawa and (B) RL95-2 cell lines respectively were seeded 
onto the surface and were left completely submerged in culture media. Following 5-7 days in 
culture the models were fixed, paraffin embedded, sectioned and H&E stained. 
 
 
 
 
 
 
 
 
 
 
Figure 5.10. Representative images of Haematoxylin and Eosin (H&E) stained 3D 
endometrial models. 
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5.3.5.1. Immunohistochemistry  
To verify the comparability of the endometrial 3D models with the native 
endometrial tissue, immunohistochemistry was conducted to detect the 
known endometrial markers galectin 9 and cytokeratin 7. Figure 5.11 shows 
diffuse immunostaining throughout the whole epithelium for galectin 9 that 
was comparable with the positive staining detected in native endometrium. In 
contrast, cytokeratin 7 showed a very week positive Immunostaining in the 
3D endometrial model and the same expression profile for the marker was 
observed with native endometrial tissue. No immune-reactivity was observed 
in the negative controls where the primary antibody was omitted to assess 
the antigen dependent binding. 
 
 
 
Figure 5.11. Endometrial epithelial markers (galectin 9 and cytokeratin 7) expressed in 
the 3D endometrial models and native human endometrial tissue visualised by 
immunohistochemistry 
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5.3.5.2. Histology of JAR spheroids attachment to the 3D endometrial model  
The attachment of JAR spheroids to the 3D culture system was investigated 
after 24 hours co-culture. Figure 5.12 shows H&E staining at 24 hours co-
culture (A, B and C) of the attachment of JAR spheroids to 3D culture 
system. JAR spheroids attached to the epithelial surface at random sites on 
the 3D model. Histological examination showed that the JAR spheroids were 
intimately attached and in some instances, had fused with the surface 
epithelium of the endometrial model (Fig. 5.12 A&B) and this occurred with 
models comprised of either RL-95-2 or Ishikawa epithelial cells.  
 
 
Figure 5.12. Representative images of JAR trophoblast spheroids attachment to the 
3D endometrial models 
(A) JAR spheroid attaching to RL95-2/ T-HESCs 3D culture model, (B and C) JAR spheroid 
attaching to Ishikawa / T-HESCs 3D culture model after 24 hours of implantation. The 
models were fixed, paraffin embedded, sectioned and H&E stained. 
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5.3.5.3. Immunohistochemical staining of βhCG as a functional marker of 
JAR trophoblast spheroids  
To investigate the properties of JAR spheroids, the expression of βhCG was 
evaluated by immunohistochemistry in the 3D trophoblast/model co-culture. 
Figure 5.13. Shows JAR spheroid immunostained with an antibody to βhCG, 
20-30% of cells within the JAR spheroid were positively stained for βhCG. 
 
 
Figure 5.13. JAR spheroids express βhCG in 3D co-culture models 
(A) Immunohistochemical staining for βhCG in trophoblast cells of JAR spheroid implanted 
over 3D culture system after 24 hours co-incubation (Brown, indicated by arrow). (B) 
Placental tissue was used as a positive control, scale bar 100 µm. 
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5.3.6. The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
adhesion of JAR trophoblast spheroids to 3D culture system 
The attachment of JAR spheroids to the 3D culture system using Ishikawa 
epithelial cells was investigated at 6 and 24 hours co-culture see (section: 
2.2.17). Figure 5.14 shows the percentage of JAR spheroids attached to the 
3D endometrial model under the effect of RLX-2, MMP-2, MMP-9 and TIMP-
2 at 6 and 24 hours. There was a significant decrease in the attachment rate 
of JAR spheroids to the endometrium when the models were treated with 
TIMP-2 at 6 and 24 hours (p value = 0.0193, and 0.0368 respectively), 
compared to untreated controls. In contrast, there was no significant 
difference detected when models were treated with RLX-2, MMP-2 and 
MMP-9 compared to untreated controls.  
 
  
Figure 5.14. Attachment of 20 JAR spheroids to the 3D culture system under the effect 
of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation at 6 and 24 hours.  
Data are the mean and standard deviation (SD) from 3 independent experiments, with each 
experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA (*p<0.05). 
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5.3.7. The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
invasion of JAR trophoblast spheroids into an invasion matrix 
A commercially available invasion assay was performed to examine the 
invasion on JAR spheroids into a tissue matrix and whether RLX-2, MMP-2, 
MMP-9 or TIMP-2 had an effect on invasion. MDA-MB-231 invasive breast 
cancer cells were used as a positive control as recommended by the 
manufacturer protocol, see (section: 2.2.18). The morphological results of the 
3D cell invasion over a four-day co-incubation showed that both JAR 
spheroids and the control MDA-MB-231 breast cancer spheroids do not 
invade into the invasion matrix but rather persisted as cell aggregates in the 
matrix. (Fig. 5.15, Fig. 5.16) shows the morphology of the 3D JAR 
trophoblast and MDA-MB-231 (as invasive cells control) spheroids invasion 
under the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 at day 1, 2, 3 and 4. 
 
 
. 
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Figure 5.15. Morphology of the 3D JAR trophoblast and MDA-MB-231 (as invasive cells control) spheroids 
invasion under the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 at day 1, 2, 3 and 4. 
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 Figure 5.16.  Morphology of the 3D JAR trophoblast and MDA-MB-231 (as invasive cells control) spheroids invasion 
under the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 at day 1, 2, 3 and 4. 
171 
 
5.3.8. The effect of RLX-2, MMP-2, MMP-9, TIMP-2 and Batimastat co-
incubation on the expansion of JAR trophoblast spheroids on endometrial 
stromal cells 
A co-culture 2D model was established to mimic trophoblast endometrial 
interaction in early implantation stages. Figure 5.17 (A) shows the effect of 
RLX-2, MMP-2, MMP-9, TIMP-2 and Batimastat (broad spectrum MMPs 
inhibitor) on JAR spheroids expansion on endometrial stromal cells after one-
day co-incubation, the expansion was significantly enhanced by the 
presence of MMP-2 and MMP-9 (p value = 0.0021 and 0.0052 respectively) 
compared to the untreated control, and significantly inhibited by co-
incubation with Batimastat (p value = 0.0203) compared to the no treatment 
control. Figure 5.17 (B) shows that the expansion was significantly enhanced 
(p value = 0.048) in the presence of MMP-2 co-incubation compared to the 
control after two days of co-incubation, while there was no significant 
difference with other treatments compared with the control.  On the third day 
of co-incubation as illustrated in figure 5.17 (C), the spheroid expansion was 
significantly enhanced by the presence of MMP-2 and MMP-9 (p value = 
0.0409 and 0.0164 respectively) compared to the untreated control, and 
significantly inhibited by co-incubation with Batimastat (p value = 0.0125) 
compared to the untreated control.  However, by day four of co-incubation as 
illustrated in figure 5.17 (D), a significant increase in the expansion rate was 
observed when the co-culture was treated with MMP-2 (p value = 0.0374) 
and a significant decrease in the expansion rate was observed when co-
incubated with Batimastat (p value = 0.0008) compared to untreated 
controls. Co-incubation with RLX-2, MMP-9 and TIMP-2 showed no 
significant difference compared to the controls at all-time points tested. 
Figure 5.18 shows the expansion of JAR trophoblast spheroids on 
endometrial stromal cells under the effect of RLX-2, MMP-2, MMP-9, TIMP-2 
and Batimastat at day 1, 2, 3 and 4.  
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Figure 5.17. Expansion of JAR trophoblast spheroids on endometrial stromal cells 
under the effect of RLX-2, MMP-2, MMP-9, TIMP-2 and Batimastat (BAT) 
Day 1 (A), day 2 (B), day 3(C) and day 4 (D). The area covered by the JAR spheroids is 
expressed relative to the day before. The results are expressed relative to JAR spheroids 
expansion in the present of each treatment compared to the control in square pixels. Data 
are the mean and standard deviations (SD) from 3 independent experiments, with each 
experiment performed in triplicate. Differences between groups and time-points were 
performed using ANOVA (p<0.05=*, p<0.01=**, p<0.001=***). 
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Figure 5.18. Representative images showing the expansion of JAR trophoblast spheroids on endometrial stromal cells under the 
effect of RLX-2, MMP-2, MMP-9, TIMP-2 and Batimastat (BAT) at day 1, 2, 3 and 4. The area covered by the JAR spheroids was 
measured using ImageJ. 
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5.4. Discussion  
Embryo implantation is a critical process initiated by the attachment of the 
trophoblast to the endometrium epithelial, followed by trophoblast invasion 
into the uterine stroma. Successful implantation requires two major factors, a 
receptive endometrium and a good quality of embryo. However, 
dysregulation during this process including inappropriate levels of hormones, 
adhesion factors, cytokines and proteases and their inhibitors may lead to 
failure of implantation (Singh et al., 2011). The aim of this chapter was to 
explore the effect of the hormone RLX-2, the matrix metalloproteinases 
MMP-2, MMP-9 and their inhibitor TIMP-2 on trophoblast-endometrial 
interaction. In vitro studies rely on model systems that mimic early 
implantation stages when the blastocyst has directly attached to and 
breached the epithelium and then the trophoblast invades the decidua cells.  
The experiments performed in this chapter represent important stages of 
implantation (attachment and invasion). The use of 2D models, in terms of 
JAR spheroids attachment to endometrial epithelial or endometrial stromal 
cells grown as monolayers, and a multi-cellular 3D culture system provide a 
means to investigate early adhesion and implantation events in detail.  
Although, it is difficult to evaluate precisely how well these human in vitro 
models represent what happens in human in vivo, they do provide the 
closest possible alternative to the native in vivo environment.  
The endometrial epithelial cell lines (RL95-2, Ishikawa and HEC-A-1) used in 
the experiments have different receptivity characteristics. RL95-2 and 
Ishikawa cell lines are highly receptive endometrial epithelial cells, while 
HEC-A-1 is considered as non-receptive endometrial epithelium cell line 
(Hannan et al., 2010).  In order to study the attachment and invasion stages 
under the stimulation of human RLX-2, MMP-2, MMP-9 and TIMP-2, an 
experiment was performed to confirm the receptivity character of the three 
different endometrial epithelial cell lines (RL95-2, Ishikawa and HEC-A-1) 
along with endometrial stromal cells.  
  
175 
 
The attachment rate of different endometrial epithelial cell lines has been 
well recognised using different cell line monolayers and trophoblast 
spheroids (Heneweer et al., 2005). However, the results presented here 
demonstrated that Ishikawa and RL95-2 cell lines were more receptive to 
JAR spheroids than HEC-A-1 cell line, that is consistent with the data from 
previous studies (John et al., 1993, Thie and Denker, 2002, Heneweer et al., 
2005, Wang et al., 2012).  
The JAR cell line was chosen as the trophoblast model as this cell line 
combines a characterisation of invasion extra villous trophoblast (EVT) and 
villous cytotrophoblast (VT) (Hannan et al., 2010). The multicellular JAR 
spheroids used as a model for trophoblast attachment and invasion were 
confirmed by positive staining for the functional trophoblast marker β-hCG, 
and the cultured media displayed positive β-hCG secretion by the cells with 
an increased secretion in a cell number dependent manner. The 
immunohistochemistry results for JAR spheroids showed that approximately 
20-30% of cells were positively stained for β-hCG. This result is consistent 
with previous studies, which demonstrated that approximately 25% of cells 
displayed positive Immunostaining for β-hCG (White et al., 1988, Wang et 
al., 2012) 
The effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
adhesion of JAR spheroids to the endometrial epithelial and stromal cells 
monolayers indicated that TIMP-2 significantly decreased the attachment 
rate of JAR spheroids to endometrial stromal cell lines after 6 and 24 hours 
of co-incubation. However, co-incubation of RL95-2, Ishikawa cell line and 
endometrial stromal cell line with RLX-2, MMP-2 and MMP-9 showed no 
significant difference in the attachment rate of JAR spheroids.  
The contribution of the TIMPs to the cell adhesion process either via direct 
interaction with cell adhesion molecules or with ECM components is much 
less studied. Ki-Kyung Jung (2006) and his colleagues demonstrated that 
TIMP-1 engaged with its cellular receptor, CD63, a member on the 
tetraspanins known to interact with cell adhesion molecules including 
integrins, modulating cell adhesion process (Jung et al., 2006). 
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It was also confirmed that TIMP-1 interacts with β1 integrin on the mammary 
cell membrane surface in a CD63-dependent manner, leading to inhibition of 
apoptosis. Dong-Wan Seo (2003) and his group confirmed that endothelial 
cell growth in vitro was inhibited by TIMP-2 by stimulation with endothelial 
growth factors, VEGF-A or FGF-2. The recognised mechanism is 
independent of TIMP-2 mediated MMP inhibition. It was also shown that 
extracellular TIMP-2 and Ala+2TIMP-2 (TIMP-2 mutant without MMP 
inhibitory activity) interact with integrin α3β1 located on the surface of tumour 
and endothelial cells, prompting an integrin-dependent signalling reaction 
(Seo et al., 2003). Dimitra Bourboulia (2010) and colleagues confirmed that 
TIMP-2 also stimulated RECK expression resulting in loss of cell migration. 
RECK is a protein on the plasma membrane that suppress a number of 
MMPs including MMP-2, MMP-9, MT1-MMP and ADAM10 (Bourboulia and 
Stetler-Stevenson, 2010).  
Studies have also attempted to investigate the effect of the MMPs on cell 
adhesion. Early on, it was shown that MMP-2 interacts with cell membrane 
bound components, directly affecting the properties of cell adhesion of 
human melanoma A2058 cells in vitro. They confirmed that, altering the 
production of TIMP-2 modulates the adhesion and spreading properties of 
the cells, not only proteolysis of the ECM. These effects of TIMP-2 appear to 
be mediated by inhibition of MMP-2 activity (Ray and Stetler-Stevenson, 
1995). 
To our knowledge, there are no previous studies that have explored the 
effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
trophoblast-endometrium interaction in vitro. However, further investigations 
are required to explore the interaction of TIMP-2 and cell adhesions 
molecules to identify the mechanism of inhibition of cell to cell adhesion.   
To investigate the attachment and invasion stages it was decided to develop 
a 3D culture system, based on oral mucosal models that have been used to 
mimic the oral mucosa (Dongari-Bagtzoglou and Kashleva, 2006a). These 
models are constructed of a connective tissue matrix comprised of type1 
collagen populated with fibroblasts and topped with oral keratinocytes. In our 
experiment, we developed a 3D endometrial model based on the oral 
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mucosa with modifications that make it imitate the native endometrial tissue 
by using type1 collagen populated with endometrial stromal cells and topped 
with endometrial epithelial cells. It is necessary to characterise these models 
histologically to validate their structure to native tissue. When cultured at an 
air-to-liquid interface the endometrial epithelium was several layers thick as  
seen with oral mucosal models (Dongari-Bagtzoglou and Kashleva, 2006a). 
However, this is not characteristic of native endometrial tissue that is only 1-2 
epithelial layers thick (Stevens and Lowe, 2005). When the endometrial 3D 
models were covered in medium, cell stratification did not occur and so 
models remained at 1-2 cell layers in thickness that was more representative 
of the native tissue. Similar observations were observed by Pinnock et al for 
oral mucosal models (Pinnock et al., 2014).  
Ishikawa cell line was selected as the endometrial epithelium for the 3D 
culture, as it represents a good model for trophoblast-endometrial 
interactions (Heneweer et al., 2005). Indeed, data from the 2D assays 
showed that Ishikawa was receptive and bound JAR spheroids rapidly. 
Moreover, models made from Ishikawa cells were positive for galectin-9, a 
specific marker for endometrial cells in vivo (Popovici et al., 2005). 
Furthermore, these cells are able to polarise and have the capacity for apical 
attachment for trophoblast cells in vitro (Heneweer et al., 2005). The 
potential effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation on the 
adhesion rate of JAR spheroids to 3D Ishikawa culture system indicated that 
TIMP-2 significantly decreased the adhesion of JAR spheroids to the 
endometrium epithelium.   
This study is the first in vitro study to explore the effect of RLX-2, MMP-2, 
MMP-9 and TIMP-2 on trophoblast-endometrial interaction using trophoblast 
spheroids and endometrial cell lines or a 3D endometrial model. The role of 
TIMP-2 and its negative effect on cell/spheroid adhesion is poorly 
understood and needs further investigation. Therefore, in addition to their 
function as inhibitors of metalloproteinases, it is essential to investigate 
whether TIMPs function to directly affect cell attachment and the potential 
mechanisms for these effects. A study conducted by Ray and Stetler-
Stevenson (1995) specified that altering the balance of MMPs and TIMP-2 by 
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genetic influence on the expression of TIMP-2 effects not only the proteolysis 
of the extracellular matrix but also cell attachment to the extracellular matrix, 
and alteration of TIMP-2 expression effects cell migration and attachment.  
Using the endometrial 3 D model, we were able to identify and histologically 
confirm attachment of the JAR spheroids to the endometrium. The cell 
adhesion and spreading of the JAR spheroids onto the endometrium were 
observed by histological analysis. However, invasion of JAR spheroids into 
the 3D endometrial matrix after implantation was not observed, and it seems 
that JAR spheroids failed to invade the stroma even after 24-hours co-
culture. This could be attributed to many reasons, one suggestion is that it 
could be due to the not using the correct collagen (rat tail type 1collagen), 
which is not similar to the native endometrium. However Wang, H. (2012) 
and his group developed a 3D endometrial model to investigate the 
attachment and invasion stages, and the 3D cultured system were developed 
with fibrin-agarose as a matrix (Wang et al., 2012). The 3D model performed 
in this study was constructed with rat tail type1 collagen to examine the role 
of MMPs and TIMPs and their potential effect on attachment and invasion so 
it was thought that collagen was the most appropriate matrix to use as 
scaffold as these enzymes are collagenases. However, the use of 
collagen/laminin or other matrix combinations may be more appropriate in 
future experiments. 
It was decided to develop an alternative model to study the invasion of JAR 
spheroids under the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-
incubation using a 2D assay. The endometrial stromal cell monolayer and 
JAR spheroids were used as an alternative invasion model. By measuring 
the expansion of JAR spheroids over the stromal cells monolayer every day 
for four days, adhesion and invasion were measured. These results indicated 
that the expansion of the trophoblast spheroids over the endometrial stromal 
cells was promoted mainly by MMP-2, and inhibited by Batimastat inhibitor. 
RLX-2 and TIMP-2 showed no significant effects during all time points of co-
incubation. It was surprising that the Batimastat inhibitor showed a significant 
difference in expansion whereas recombinant TIMP-2 did not. This could be 
due to other MMPs being involved in the process that are inhibited by the 
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Batimastat inhibitor and not by TIMP-2. An alternative explanation could be 
the half-life and relative affinity for the Batimastat inhibitor compared to 
recombinant TIMP-2. For example, recombinant TIMP-2 has a relatively 
short half-life and affinity compared to the Batimastat inhibitor and so its 
action may be limited over a 24 hours assay period. Indeed, at day 1 in figure 
5.17 it appears that TIMP-2 and the Batimastat inhibitor display equal 
potency for preventing adhesion. However, thereafter the inhibition of TIMP-2 
is lost whereas that of the chemical Batimastat inhibitor continues.  
To our knowledge, this study is the first to investigate the expansion of JAR 
spheroids over endometrial stromal cells under the effect of RLX-2, MMP-2, 
MMP-9 and TIMP-2. A previous study (Gonzalez et al., 2011) showed that 
the expansion of trophoblastic spheroids is enhanced by decasualised 
endometrial stromal cells, interleukin-1β and heparin-binding epidermal 
growth factor-like growth factor. Furthermore, Staun-Ram et al., 2004 and 
colleagues suggested that MMP-2 is the key-enzyme for JAR trophoblast 
invasion (Staun-Ram et al., 2004). The data presented in this chapter appear 
to suggest that the balance between MMP-2 and its inhibitor is heavily 
implicated in the adhesion and potentially invasion of trophoblasts to the 
endometrium. Although further experimentation is required, RLX-2 appears 
not to be involved in this process. 
Adding MMP-2 and MMP-9 directly into a culture media containing FCS and 
therefore α2-macroglobulin which binds and inhibits the activity of MMPs. 
However, our results showed that although the MMP-2 and MMP-9 were 
added to culture media containing FCS there was a significant increase in 
the expansion of JAR trophoblast spheroids on endometrial stromal cells 
under the effect of MMP-2 over four days compared to the untreated 
controls. MMP-9 shows a significant increase in the expansion of JAR 
trophoblast spheroids on endometrial stromal cells on 1st and 3rd of co-
culture, while there was no significant difference on 2nd and 4th day. In our 
experiment the complete growth media containing FCS used because of the 
long-time experiments, and using serum free media could effect on the 
growth and the physiology of the cell lines.           
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The main limitation of this study is that the cell culture models lack in vivo 
authenticity, and do not fully represent the in vivo trophoblast-endometrial 
interaction during early human embryo implantation. There is the issue of the 
concentrations of agents used in the different treatment regimens to study 
their potential effect of both attachment and invasion assays. This is difficult 
to determine, as there is no data available on the localised expression of 
MMP-2, MMP-9 and TIMP-2. For this reason, the concentrations used were 
based on the data obtained from the in vivo study. Even if the appropriate 
concentrations were identified, the expression pattern of the enzymes and 
hormone are likely to be quite different in vitro compared to in vivo.  
The early embryo implantation into the endometrium is a critical step in the 
establishment of pregnancy. This process is under a tight control of a very 
complicated network of molecules including cytokines, growth factors, 
hormone, cell adhesion molecules and proteases and their inhibitors, and it 
is clear that dysregulation of one of these molecules may lead to failure of 
implantation. The data in this chapter suggests that an imbalance of the 
MMP-2/TIMP-2 axis is implicated in this dysregulated process.         
In conclusion, there are huge difficulties in exploring human embryo 
implantation in vivo due to poor tissue accessibility and so there is a 
challenge for researchers to continue to search for an ideal in vitro cell 
culture model. In this chapter a cell culture model of attachment and invasion 
was used to mimic stages of implantation and also provide data for the first 
time on the effect of RLX-2, MMP-2, MMP-9 and TIMP-2 on trophoblast 
endometrium interaction. It appears that MMP-2 and TIMP-2 are implicated 
in this process; however, there are limitations. An optimal cell culture model 
will promote and assist in understanding the potential mechanism and the 
signalling pathways of trophoblast attachment and invasion during 
implantation, and may provide a platform for future opportunities to improve 
pregnancy successful rate in both spontaneous and assisted conception. 
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6.1. Summary of finding  
The maintenance of normal pregnancy is a vital process between the embryo 
and the mother. It is a complex phenomenon that starts with the attachment 
of embryo to the endometrial epithelial cells, followed by trophoblast invasion 
into the stroma. Successful pregnancy depends on two essential factors, a 
proper receptive endometrium and a good quality embryo. Any dysregulation 
in the intricate interaction including hormones, proteases, adhesion factors, 
growth factors and cytokines may lead to failure of embryo implantation 
(Merviel et al., 2009, Lim, 2003). The endometrial receptivity is a term used 
to refer to the time period when the endometrium undergoes morphological 
and molecular changes to favour the implantation of the embryo. These 
changes among others include proliferation of endometrial epithelial cells 
and stromal cells, alteration of cell morphology and polarization of cell 
adhesion molecules expressed on the apical cell membrane (Achache and 
Revel, 2006, Bentin-Ley et al., 1999).   
During implantation, trophoblast cells invade the uterine stroma. In order to 
perform that, they must degrade both ECM and basement membrane. 
Therefore, enzymes that target ECM and basement membrane components 
are required, mainly MMPs  (Hulboy et al., 1997). On the other hand, large 
quantities of TIMPs are produced to control trophoblast invasion and provide 
a protective role (Salamonsen, 1999). The integrity of the endometrial 
connective tissue needs a precise balance between the action of tissue 
inhibitors of MMPs that control the activity of the MMPs, and the MMPs that 
extract the ECM. Relaxin hormone has been identified to stimulate MMPs 
activity in various species including human, pig and rat (Goldsmith and 
Weiss, 2009).      
Over the past decade the knowledge of feto-maternal communication and 
decidualisation mechanism has developed extensively, however, knowledge 
of this complex dynamic process has not translated into predictive tests and 
useful interventions to improve pregnancy outcomes. Furthermore, RM is still 
poorly understood and therefore its management remain very challenging. 
This thesis has examined the effect of altered expression of MMPs, TIMPs 
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and RLX-2 on trophoblast-endometrium interaction. The hypotheses of the 
project were derived from clinical evidence presented previously in our 
research group, they identified an association between recurrent miscarriage 
and altered expression of proteinases and their inhibitors as well as RLX-2 
hormone (Anumba et al., 2009, Anumba et al., 2010).   
In chapter three, the in vivo study, we confirmed these observations and 
explored the expression levels of MMP-2, MMP-9, TIMP-2, MMP-2/TIMP-2 
complex and RLX-2 hormone in women with a history of recurrent 
miscarriage and healthy pregnant controls matched for gestational age. We 
also compared the concentrations of these peptides in women with 
threatened miscarriage and controls with healthy pregnancies, again 
matching for gestational age. Our data showed that there is a significant 
increase in the serum expression of TIMP-2 in recurrent miscarriage 
compared to their healthy controls (consistent with previous findings) and low 
expression of MMP-2 and MMP-2/TIMP-2 complex and RLX-2 hormone. In 
contrast, there were no significant differences in the expression of TIMP-2, 
MMP-2, MMP-2/TIMP-2 complex and RLX-2 between the threatened 
miscarriage group and their healthy controls, while there was no significant 
difference in the serum expression of MMP-9 in both groups. Given these 
findings, and the paucity of clinically applicable markers, more research is 
now needed to define more accurate predictive biomarkers of endometrial 
receptivity and adverse pregnancy outcomes that can be used in prenatal 
period in a clinical setting (Edgell et al., 2013). Development of biomarkers to 
predict adverse pregnancy outcomes could have clinical utility in managing 
women with a history of RM management, and for predicting the course and 
outcomes of pregnancy complications such as pre-eclampsia and preterm.   
Several studies have stressed that MMPs are involved in remodelling the 
extracellular matrix of the reproductive tissues during the menstrual cycle, 
embryo implantation, placentation and parturition. The potential roles for 
MMPs in stimulating reproductive tissue growth, including promoting tissue 
expansion by remodelling basement membrane integrity and stimulation of 
growth factors has been variously noted (Lenhart et al., 2001, Curry and 
Osteen, 2003, Amalinei et al., 2007). RLX-2 hormone has been shown to 
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have a role in stimulating uterine growth and placentation (Lenhart et al., 
2001), although it is an important factor in the remodelling of connective 
tissue of the reproductive tract (Palejwala et al., 2001), little is known 
regarding the effects of RLX-2 on the expression of MMPs in humans. Given 
the ability of RLX-2 to stimulate tissue remodelling and growth, it was 
hypothesised that a regulatory interaction exists between RLX-2 and MMPs. 
In chapter four, in vitro data indicated that stimulation of T-HESCs with RLX-
2 hormone did not significantly alter secreted levels of MMP-2 when 
compared to unstimulated controls in both a time- and dose-dependent 
manner. Furthermore, T-HESCs did not express MMP-9 with or without 
treatment with RLX-2, while relaxin-stimulated T-HESCs showed increased 
secretion of TIMP-2. Although there was no effect on MMP-2 activity in 
response to RLX-2 treatment this does not exclude the role of RLX-2 in 
extracellular remodelling in early implantation as alternate pathways could be 
involved. The data showed that RLX-2 increased MMP-2 expression by JAR 
trophoblast cells in a dose-dependent manner with significant differences 
being observed compared to unstimulated cells. In contrast, relaxin-
stimulated JAR cells did not show increased TIMP-2 expression and did not 
express MMP-9.  
As detailed in the thesis, proteases and their inhibitors are thought to be 
important in the implantation process. The dynamic balance between MMPs 
and their inhibitors within certain levels is critical for cytotrophoblast cell 
invasion into the maternal endometrium. This maintains the dynamic balance 
of MMPs/TIMPs within a certain range, and subjects the invasion of 
cytotrophoblast cells into the maternal body to certain restrictions.  
Culture of T-HESCs and JAR with TIMP-2 showed a biphasic effect. Both 
showed decreased levels of MMP-2 in the medium after 48 hours in 
comparison to unstimulated controls, this was followed by increase in MMP-2 
levels by 72 hours compared to unstimulated cells. While the effect of a 
broad spectrum MMPs inhibitor (Batimastat) on the levels of secreted MMP-2 
by both T-HESCs and JAR cells showed a dramatic decline in secreted 
MMP-2 levels in both a time- and dose-dependent manner.  
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The study of trophoblast endometrium interaction in early human 
implantation has always been challenging, it is difficult to perform in vivo due 
to strict ethical reasons to bypass these challenges during the study of 
implantation and reproductive development, other approaches have been 
used such as animal models and the use of trophoblast cell lines (mostly 
choriocarcinoma) and endometrial cell lines (Hannan et al., 2010).    
In chapter five, the kinetics of attachment between endometrial epithelial 
and/or endometrial stromal monolayers with the JAR spheroids under the 
effect of RLX-2, MMP-2, MMP-9 and TIMP-2 co-incubation indicated that 
TIMP-2 significantly decreased the attachment rate of JAR spheroids to 
endometrial stromal cell lines in a time dependent manner up to 6 and 24 
hours of co-incubation. However, co-incubation of RL95-2, Ishikawa cell line 
and endometrial stromal cell line with RLX-2, MMP-2 and MMP-9 showed no 
significant difference in the attachment rate of JAR spheroids.  
As identified in our results, we have demonstrated that the expansion of the 
trophoblast cells over the endometrial stromal cells was promoted mainly by 
MMP-2, and inhibited by a Batimastat inhibitor. RLX-2 and TIMP-2 showed 
no significant difference during all time points of co-incubation. It was 
surprising that the Batimastat inhibitor showed a significant decrease in 
expansion whereas recombinant TIMP-2 did not. This could be due to other 
MMPs being involved in the process that are inhibited by the Batimastat and 
not by TIMP-2. An alternative explanation could be the half-life and relative 
affinity for the Batimastat inhibitor compared to recombinant TIMP-2. The 
data presented in this chapter appear to suggest that the balance between 
MMP-2 and its inhibitor is heavily implicated in the adhesion, and potentially 
the invasion of trophoblast to the endometrium. Although further 
experimentation is required, RLX-2 appears not to be involved in this 
process. 
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6.2. Future work 
Local expression of the MMP-2, MMP-9, TIMP-2, MMP-2/TIMP-2 complex 
and RLX-2 in vivo  
The results of the in vivo data in this work identified that, there is a significant 
increase in the serum expression of TIMP-2 in women with a history of 
recurrent miscarriage compared to their controls with no such history, and 
also low expression of MMP-2, MMP-2/TIMP-2 complex and RLX-2 
hormone. Altogether, this in vivo study was designed to highlight 
observations that may be examined by definitive functional studies. A large 
sample size in each study group will be required and will be more informative 
to clarify the question.   
The serum results represent the systemic levels of the serum markers as 
several tissues contribute in this measurement and the local expression may 
show a difference from one tissue to another. It would be interesting to study 
the local expression levels of MMP-2, MMP-9, TIMP-2, MMP-2/TIMP-2 
complex and RLX-2 hormone in reproductive tract tissue such as 
endometrium derived from women with history of RM and healthy controls 
during the late secretory phase to examine the expression of the markers 
locally, it may be that the local expression of these markers may explain the 
changes observed in the serum. It would also be necessary to mount 
functional experiments that seek to explore the signalling mechanisms of 
these hormones and peptides at the endometrial trophoblast interface.  
Relaxin mechanisms that may be involved in the regulation of matrix 
metalloproteinases and their inhibitors  
To understand how RLX-2 hormone could be implicated in the regulation of 
matrix metalloproteinases and their inhibitors a further work is required to 
clarify the molecular mechanisms explaining these interactions. Altogether, 
our study has highlighted observations that provide insights and options for 
further investigations to explore the signalling pathways of RLX-2 in 
regulation of matrix metalloproteinases and their inhibitors. 
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Inhibitory pathway of TIMP-2 on trophoblast endometrial interaction  
Given the findings in this work, it would be interesting to explore the potential 
inhibitory effect of TIMP-2 on trophoblast-endometrial interaction. 
Understanding the mechanism whereby cells adhesion is inhibited by TIMP-2 
is crucially important as it may uncover potential therapeutic targets. 
Moreover, there is no obvious interpretation of these findings through either 
dependent and/or independent MMP-inhibitory activity. Further investigation 
on the interaction of TIMP-2 and cell adhesion molecules are required.   
The effect of absence of TIMP-2, MMP-2, MMP-9 and RLX-2 on trophoblast 
endometrium interaction   
In chapter five we studied the effect of RLX-2, TIMP-2, MMP-2 and MMP-9 in 
general using different assays including attachment, invasion and expansion 
assays of JAR spheroids on endometrial epithelial and stromal cell. Based 
on the in vivo observations where the group with a history of RM showed low 
expression of MMP-2, MMP-2/TIMP-2 complex and RLX-2 hormone, further 
in vitro investigations could explore the effect of the deficiency or absence of 
the mentioned protein employing knockout cell lines lacking receptors to 
MMP-2, MMP-9, TIMP-2 and RLX-2 hormone genes to clarify their role in the 
trophoblast endometrium interaction process. 
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Study Number: 
Patient Identification Number for this study: 
 
CONSENT FORM 
 
Changes in serum relaxin levels and maternal and fetal blood flow in 
pregnant women with or without a history of recurrent miscarriage. 
 
Researchers: 
Dr Dilly Anumba MD, MRCOG  Senior Lecturer/Consultant Obstetrician & 
Gynaecologist 
Dr S El Gelany MBBS    Honorary Clinical Research Associate 
 
 
 
 
 
 
 
           Please 
initial box 
 
1. I confirm that I have read and understand the information sheet dated June 2006 
   
 for the above study and have had the opportunity to ask questions. 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
   
 without giving any reason, without my medical care or legal rights being affected. 
 
 
 
3. I agree to take part in the above study.      
  
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature   
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature  
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 
Researcher Date Signature  
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Volunteer Information sheet – Normal pregnant controls  
 
Changes in serum relaxin levels and maternal and fetal blood flow in 
pregnant women with or without a history of recurrent miscarriage. 
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully. Talk 
to others about the study if you wish. Ask us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. You may obtain more information regarding the 
conduct of clinical research from the CERES web site at www.ceres.org.uk 
 
1. What is the purpose of the study? 
Pregnancy to women who have a history of more than 3 consecutive 
miscarriages (called “recurrent miscarriage”) may be more complicated than 
pregnancy to women who do not have this history. “Relaxin” is a protein 
found in blood which plays a role in normal pregnancy and fetal growth. In 
this study, we want to find out whether we can use the blood levels of 
“relaxin” during pregnancy to predict those women who will develop 
complications. We will compare relaxin levels in women with a history of 
recurrent miscarriage to those who have no such history. Using ultrasound, 
we will also check the growth of the baby, and the flow of blood through the 
womb and through the baby. We will then determine whether relaxin has any 
relationship with the blood flow results that we obtain, and whether these 
results can help us predict pregnancy problems in order to prevent them.  
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2. Why have I been chosen? 
You have never had recurrent miscarriage and we would like to compare 
your group to another group of women who have had recurrent miscarriage. 
 
3. Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  You are free to 
decline to take part, or to withdraw at any time after you have agreed to take 
part, without your decision affecting your care or that of your baby in any 
way. You can simply tell us by telephone or in writing that you no longer wish 
to take part. 
 
4. What will happen to me if I take part? 
You will be given this information sheet to keep, and asked to sign a consent 
form. The study will involve taking a small sample of blood from your vein 
several times during your pregnancy in addition to several scans to assess 
blood flow through your womb and your baby. Both procedures are safe and 
carry no risks to you or your baby. The study will involve a total of 4 visits to 
the hospital during which you will receive your normal antenatal checks. You 
will be reimbursed your travel expenses for attending to take part in this 
research study. 
 
5. What do I have to do? 
You simply need to attend your antenatal clinic appointments when, in 
addition to your routine check, a blood sample will be taken and a scan 
performed. These hospital visits will fall in with when you would normally 
attend for an antenatal check-up and when you would normally require a 
blood test or a scan for your care.  
 
6. What are the side effects of any treatment received when taking part? 
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You will receive no medication as part of the study. There are no side effects. 
Scans are safe throughout pregnancy, and the blood tests pose no risks to 
you additional to the slight pain and inconvenience that you normally 
experience when you have a blood test.  
 
7. What are the benefits of taking part? 
The study will not be able to prevent miscarriage. However, there is the 
possibility that the extra scans and visits may help us keep a closer eye on 
your pregnancy, and identify any problems early enough to treat them. 
 
8. What will happen when the research study stops? 
We hope to determine whether any of our observations during this study may 
predict problems or assist carers look after women whose pregnancies may 
be at risk of complications or impaired fetal growth. This study will in part be 
presented as a thesis for an educational qualification. We will also publish 
our results in medical journals and present our findings at conferences. You 
will not be identified in any report/publication. We will not send you the 
results of the study unless you ask us to. 
 
9. Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept 
confidential. The data that we obtain from you in relation to this study is kept 
anonymised so that no one can trace the information to any individual study 
participant. 
10. What will happen if I do not want to carry on with the study? 
If you withdraw from the study, we will destroy all your identifiable samples, 
but we will need to use the data collected up to your withdrawal. Any stored 
blood samples that can still be identified as yours will be destroyed if you 
wish. You will receive the same quality of clinical care even if you withdrew 
from the study.  
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11. What if relevant new information becomes available? 
Sometimes during the course of a research project, new information 
becomes available about the treatment/drug that is being studied.  If this 
happens, your research doctor will tell you about it and discuss whether you 
want to or should continue in the study.  If you decide not to carry on, your 
research doctor will arrange for your care to continue.  On receiving new 
information, your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He/she will explain the reasons 
and arrange for your care to continue. If the study is discontinued for any 
other reason, you will be told why and your continuing care will be arranged. 
. 
12. Who has reviewed the study?  
This study was given a favourable ethical opinion for conduct in the NHS by 
the South Sheffield Research Ethics Committee. 
 
13. What if there is a problem? 
No problem is envisaged from your taking part in this study. If you are 
harmed by your participation in the study, there are no special compensation 
arrangements. You can decide to take legal action. You are covered in the 
same way as for your ordinary treatment. If you have a concern about any 
aspect of this study, you should ask to speak with or write the researchers 
who will do their best to answer your questions. The Principal Investigator is 
Mr Anumba, Consultant Obstetrician, Jessop Wing, Sheffield on telephone 
number 0114 2268172. If you wish to complain formally, you may address 
any complaints to Professor Chris Welsh, Medical Director, Sheffield 
Teaching Hospitals NHS Foundation Trust, 8 Beech Hill Road, Sheffield.    
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Patient Information sheet - history of recurrent miscarriage 
 
Changes in serum relaxin levels and maternal and fetal blood flow in 
pregnant women with or without a history of recurrent miscarriage. 
 
You are being invited to take part in a research study.  Before you decide it is 
important for you to understand why the research is being done and what it 
will involve.  Please take time to read the following information carefully. Talk 
to others about the study if you wish. Ask us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or 
not you wish to take part. You may obtain more information regarding the 
conduct of clinical research from the CERES web site at www.ceres.org.uk 
 
1. What is the purpose of the study? 
Pregnancy to women who have a history of more than 3 consecutive 
miscarriages (called “recurrent miscarriage”) may be more complicated than 
pregnancy to women who do not have this history. “Relaxin” is a protein 
found in blood which plays a role in normal pregnancy and fetal growth. In 
this study, we want to find out whether we can use the blood levels of 
“relaxin” during pregnancy to predict those women who will develop 
complications. We will compare relaxin levels in women with a history of 
recurrent miscarriage to those who have no such history. Using ultrasound, 
we will also check the growth of the baby, and the flow of blood through the 
womb and through the baby. We will then determine whether relaxin has any 
relationship with the blood flow results that we obtain, and whether these 
results can help us predict pregnancy problems in order to prevent them.  
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2. Why have I been chosen? 
You have had recurrent miscarriage and we would like to compare your 
group to another group of women who have never had recurrent miscarriage. 
 
3. Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  You are free to 
decline to take part, or to withdraw at any time after you have agreed to take 
part, without your decision affecting your care or that of your baby in any 
way. You can simply tell us by telephone or in writing that you no longer wish 
to take part. 
 
4. What will happen to me if I take part? 
You will be given this information sheet to keep, and asked to sign a consent 
form. The study will involve taking a small sample of blood from your vein 
several times during your pregnancy in addition to several scans to assess 
blood flow through your womb and your baby. Both procedures are safe and 
carry no risks to you or your baby. The study will involve a total of 4 visits to 
the hospital during which you will receive your normal antenatal checks. You 
will be reimbursed your travel expenses for attending to take part in this 
research study. 
 
5. What do I have to do? 
You simply need to attend your antenatal clinic appointments when, in 
addition to your routine check, a blood sample will be taken and a scan 
performed. These hospital visits will fall in with when you would normally 
attend for an antenatal check-up and when you would normally require a 
blood test or a scan for your care.  
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6. What are the side effects of any treatment received when taking part? 
You will receive no medication as part of the study. There are no side effects. 
Scans are safe throughout pregnancy, and the blood tests pose no risks to 
you additional to the slight pain and inconvenience that you normally 
experience when you have a blood test.  
 
7. What are the benefits of taking part? 
The study will not be able to prevent miscarriage. However, there is the 
possibility that the extra scans and visits may help us keep a closer eye on 
your pregnancy, and identify any problems early enough to treat them. 
 
8. What will happen when the research study stops? 
We hope to determine whether any of our observations during this study may 
predict problems or assist carers look after women whose pregnancies may 
be at risk of complications or impaired fetal growth. This study will in part be 
presented as a thesis for an educational qualification. We will also publish 
our results in medical journals and present our findings at conferences. You 
will not be identified in any report/publication. We will not send you the 
results of the study unless you ask us to. 
 
9. Will my taking part in the study be kept confidential? 
Yes. All the information about your participation in this study will be kept 
confidential. The data that we obtain from you in relation to this study is kept 
anonymised so that no one can trace the information to any individual study 
participant. 
10. What will happen if I do not want to carry on with the study? 
If you withdraw from the study, we will destroy all your identifiable samples, 
but we will need to use the data collected up to your withdrawal. Any stored 
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blood samples that can still be identified as yours will be destroyed if you 
wish. You will receive the same quality of clinical care even if you withdrew 
from the study.  
11. What if relevant new information becomes available? 
Sometimes during the course of a research project, new information 
becomes available about the treatment/drug that is being studied.  If this 
happens, your research doctor will tell you about it and discuss whether you 
want to or should continue in the study.  If you decide not to carry on, your 
research doctor will arrange for your care to continue.  On receiving new 
information, your research doctor might consider it to be in your best 
interests to withdraw you from the study.  He/she will explain the reasons 
and arrange for your care to continue. If the study is discontinued for any 
other reason, you will be told why and your continuing care will be arranged. 
. 
12. Who has reviewed the study?  
This study was given a favourable ethical opinion for conduct in the NHS by 
the South Sheffield Research Ethics Committee. 
 
13. What if there is a problem? 
No problem is envisaged from your taking part in this study. If you are 
harmed by your participation in the study, there are no special compensation 
arrangements. You can decide to take legal action. You are covered in the 
same way as for your ordinary treatment. If you have a concern about any 
aspect of this study, you should ask to speak with or write the researchers 
who will do their best to answer your questions. The Principal Investigator is 
Mr Anumba, Consultant Obstetrician, Jessop Wing, Sheffield on telephone 
number 0114 2268172. If you wish to complain formally, you may address 
any complaints to Professor Chris Welsh, Medical Director, Sheffield 
Teaching Hospitals NHS Foundation Trust, 8 Beech Hill Road, Sheffield.    
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